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ABSTRACT 
The physicochemical properties and surface chemistry of orally inhaled active 
pharmaceutical ingredients (API) are critical to the quality attributes of dry 
powder inhaler (DPI) formulations. The requirement to reduce the particle size 
distribution of the APIs to a respirable range, largely performed through air-jet 
micronisation, imparts large amounts of energy to the drug particles, which 
together with particle fracture and size reduction, it is accompanied by the 
generation of structural defects and, at the limit, the formation of amorphous 
regions. This is known as mechanical activation, which may cause instability in 
the physicochemical properties and interfacial chemistry at the particle surface 
as it undergoes structural relaxation. During the thermodynamically driven 
relaxation process, differing drug properties may lead to DPI formulations with 
unpredictable formulation structure and product functionality. A fundamental 
understanding of the structural relaxation dynamics is therefore essential in the 
development and commercialisation of a quality-by-design led inhalation 
product.  
This thesis investigated the structural relaxation dynamics of micronised 
fluticasone propionate (FP), salmeterol xinafoate (SX) and glycopyrrolate 
bromide (GLY). Physicochemical properties and surface interfacial chemistry, 
via cohesive-adhesive balance (CAB) measurements, of micronised drug are 
assessed as a function of environmental stressed laagering over well-defined 
periods of time and in situ conditioning in hydrofluoroalkane (HFA). The 
influence of these dynamics upon DPI performance was also examined in both 
binary (FP, SX, GLY) and tertiary formulations (FP-SX). The results indicated 
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how structural relaxation of hydrophobic and hydrophilic APIs trigger off 
different stress relaxation pathways with different sensitivities to laagering 
conditions. These data suggested that the introduction of a post-micronisation 
conditioning step may expedite structural relaxation of hydrophobic APIs. 
Whilst the physical properties of hydrophobic APIs are largely unaffected by 
mechanical activation, surface interfacial chemistry governing inter-particulate 
forces between API and the lactose carrier is directly affected by 
environmental conditions of temperature and relative humidity during structural 
relaxation. The study also showed the potential use of post-micronisation 
conditioning to tailor the surface chemistry properties of APIs. For hydrophilic 
APIs, data suggested that post-micronisation conditioning is essential in 
enabling physical and chemical stability of  inhaled formulations. Furthermore, 
in vitro aerosolisation studies suggested that the aerodynamic particle size 
distribution and fine particle mass were directly affected by post-micronisation 
laagering conditions.  
The importance of generating a well defined, understood and controlled design 
space throughout product development dictates the need for more robust API 
processing prior to DPI formulation. This work highlights how a tailored post-
micronisation laagering strategy can have a significant effect on 
physicochemical and interfacial properties as well as product performance of 
binary and tertiary carrier based DPI formulations.        
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1 Introduction 
1.1 Respiratory Medicine 
Respiratory diseases are a major concern in the medical field due to alarming 
statistics observed over the past decades regarding death rates and other 
health economic trends (Royal College of Physicians, 2014; Rea, Scragg et 
al., 1986). Asthma and chronic obstructive pulmonary disease (COPD) cost 
governments billions of pounds and are one of the highest causes of death 
worldwide. This highlights the importance of a more efficient and effective 
development of aerosolised drugs as a pharmacotherapy response to evolving 
respiratory diseases (Harrison, Stephenson et al., 2005; Anagnostou, Harrison 
et al., 2012, Bucknall, Slack et al., 1999).  
 
The use of aerosol inhalation as a method of drug delivery to the respiratory 
tract has numerous advantages. Having the active drug being delivered 
directly to the tracheobronchial tree leads to a rapid and predictable onset of 
action, hence, avoiding first-pass effect and degradation within the 
gastrointestinal tract. This allows lower dosages to be administered as 
opposed to the oral route, ensuring side effects are kept to a minimum. 
Another major advantage of aerosol inhalation as a method of drug delivery 
lies in the fact that having an alternative route for delivery avoids drug-drug 
interaction when more than one medication is being administered concurrently 
(Timsina, Martin et al., 2003; Patton, 1996). 
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Figure 1.1 illustrates the constituents of the respiratory tract as a series of 
branching airways. The first passageway is the trachea and assumes the 
respiration role of leading inspired air to the gas exchanging regions of the 
lung. The pharynx and larynx connect it to the oral and nasal cavities. The 
trachea divides into two main bronchi, which in turn bifurcate into narrower and 
shorter bronchi and bronchioles. These together with the trachea are known as 
the conducting airways (Patton, 1996). The dichotomous branching of the 
airways from the bronchi to the bronchioles undergoes over 32 bifurcations 
(Gurney, 1991). The bronchioles bifurcate further leading to the deepest part in 
the lung where the respiratory bronchioles and alveoli are found. This area is 
known as the peripheral airways. 
 
Figure 1.1: Structure of the Human Lung (adapted from Griesenbach 
et al., 2004) 
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The respiratory tract offers two target sites for drugs delivered by inhalation. 
The conducting airways are the ideal site for drug deposits in order to cure 
respiratory diseases since these are generally diseases of the conducting 
airways themselves (Pritchard, 2006). To utilise the lung as a portal entry for 
systemic delivery, the peripheral airways need to be targeted with the excellent 
blood flow found in these regions and therefore enables a high drug absorption 
into the systemic circulation (Timsina, Martin et al., 2003).  
 
1.2 Particle Deposition in the Lungs 
In order to achieve the desired pharmacological effect, a drug particle 
designed for inhalation must deposit at the site of action (Byron and Patton, 
1994). The region and method with which the drug particles deposit are highly 
dependent on aerodynamic particle size and the three main deposition 
mechanisms, namely; inertial impaction, sedimentation and diffusion. 
Interception and electrostatic precipitation other deposition mechanism by 
which drug particles may deposit in the lungs (Heyder, Gebhart et al., 1986; 
Lalor and Hickey, 1996). As described in the following sub-sections, there are 
a variety of variables which influence the mechanism or mechanisms by which 
a drug particle deposits (Martonen and Katz, 1993)). 
 
1.2.1 Inertial Impaction 
Inertial impaction is the mechanism which dominates particle deposition in the 
lungs, and occurs mainly in the conducting airways (Asgharian and Anjilvel, 
1994). As an inhaled airstream changes direction on passing through the 
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repeated bifurcations and bends of the respiratory tract, a particle suspended 
in the airflow may not lose its inertia and relax into the new direction of the 
airflow, thereby impacting on the respiration surface (Martonen, Katz et al., 
1992). Deposition by inertial impaction is highly dependent on the material 
density and size of the suspended particles. The probability of impaction for a 
particle travelling in an airway is related to its Stokes' number (Stk), a 
dimensionless parameter that can be calculated using Equation 1.1. 
 
     Equation 1.1 
where  is the particle density,  is the particle diameter,   is the air 
velocity,  is the air viscosity and  is the airway radius. From this equation, 
the higher the value of Stokes’ number, the more readily particles will deposit 
by inertial impaction (Morrison, 1974; Martonen and Katz, 1993; Crowder, 
Rosati et al., 2002).  
 
1.2.2 Sedimentation 
The influence of gravity of the deposition of drug particles suspended in 
respiratory tract is referred to as sedimentation (Clark and Egan, 1994). For 
particles between 1 and 40 µm diameter in a laminar airstream, the terminal 
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    Equation 1.2 
 
where  is the particle density,  is the density of air,  is the particle 
diameter,  is acceleration due to gravity and  is the air viscosity. Particles 
<1 µm tend to settle with a faster terminal velocity than that predicted by 
Equation 1.2, whilst particles >40 µm diameter tend to settle at a slower 
terminal velocity (Nowak, Kakade et al., 2003).  
 
Sedimentation is a time-dependant process, as particles must have sufficient 
residence time in the airway to settle from their inertial position to deposit on 
the respiratory surface (Taulbee and Yu, 1975). It is therefore the dominant 
mechanism of deposition in the smaller airways and alveoli, due to the small 
airway dimensions and low air flow velocities found in these regions (Heyder, 
Gebhart et al., 1986; Tsuda, Butler et al., 1994a; Lalor and Hickey, 1996). 
 
1.2.3 Brownian Motion 
As the diameter of a suspended particle falls below 1 µm, the influence of 
gravity on its motion decreases, whilst the influence of Brownian motion 
caused by the random bombardment of the particle by gas molecules 
becomes greater (McMurry and Rader, 1985). By its very nature, Brownian 
motion results in particles following a random and variable path, but for those < 
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than sedimentation and so be the primary mechanism of deposition (McMurry 
and Rader, 1985; Tsuda, Butler et al., 1994a). Nevertheless, due to the 
relative magnitudes of the displacement caused by sedimentation and 
Brownian motion, particles > 2 µm are more likely to deposit in the airways 
than those < 0.5 µm diameter (Tsuda, Butler et al., 1994b). 
 
1.2.4 Interception 
Interception occurs when a particle moving within the airstream makes contact 
with the respiratory surface (Taulbee and Yu, 1975). Elongated particles are 
most likely to deposit in this manner. However, as the typical size of drug 
particles used in respiratory drug delivery is much smaller than that of the 
airways, this mechanism of deposition is relatively unimportant in most cases 
(Martonen and Katz, 1993). 
 
1.2.5 Electrostatic Precipitation 
Drug particles may become electrostatically charged during aerosolisation 
(Yeomans, Rogers et al., 1949), which, in theory, might influence deposition, 
either through the induction of an image charge on the respiratory surface and 
subsequent electrostatic attraction, or via the repulsion between positively 
charged aerosol particles directing them towards the airway walls (Balashazy 
and Hofmann, 1993).  
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1.2.6 Effect of Particle Size on Deposition in the Respiratory Tract 
Equations 1.1 and 1.2 show how aerodynamic particle size is a major variable 
in controlling particle deposition in the lung (Taulbee and Yu, 1975; Park and 
Lee, 2000). Inhalation formulations must therefore produce an aerosol of 
appropriately sized drug particles, to ensure an adequate dose reaches the  
site of action (Tismina, Martin et al., 1994; Virchow, Crompton et al., 2008). 
Even before an aerosol enters the trachea, it must negotiate a 90◦ bend 
between the oral cavity and the pharynx without impacting on the back of the 
throat (Taulbee and Yu, 1975). At each bifurcation, the cross-sectional area of 
an individual airway decreases, providing an ever more convoluted path for a 
particle to negotiate without impaction (Balashazy and Hofmann, 1993). Drug 
particles with an aerodynamic diameter larger than 10 µm will tend to impact in 
the throat and upper airways, whereas particles with an aerodynamic diameter 
less than 0.5 µm will tend to be exhaled (Hofmann, Sturm et al., 2003). The 
majority of particles with aerodynamic diameters between 2.5 µm and 6 µm will 
tend to deposit in the conducting airways, whereas particles with an 
aerodynamic diameter less than 2.5 µm will tend to deposit in the peripheral 
airways (Tsuda, Butler et al., 1994a; Tsuda, Butler et al., 1994b). It is therefore 
generally accepted that the target drug aerosol aerodynamic diameter for 
inhalation formulations is between 1 µm and 5 µm, depending on the desired 
target site of action (Heyder, Gebhart et al., 1986). 
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1.3 Treatment of Asthma and COPD  
Airflow limitations and chronic inflammation are main characteristics of both 
asthma and Chronic Obstructive Pulmonary Diseases (COPD). The most 
efficacious treatment is administering of medication which acts to reduce and 
prevent airway constriction and inflammation. The first-line treatments in both 
asthma and COPD are bronchodilators (short and long acting β2-agonists) and 
anti-inflammatory therapy (inhaled corticosteroids), which are employed to aid 
bronchodilation and reduce inflammation respectively (Greening, Ind et al., 
1994; Emmett et al., 2001).  
 
1.3.1 Bronchodilators  
Bronchodilator drugs are used to relieve symptoms of bronchoconstriction 
(Barnes, 2002). These drug agents are typically β2-agonists, which stimulate β-
adrenoceptors in the smooth-muscle of the airway, producing smooth-muscle 
relaxation and bronchodilation (Holgate and Polosao, 2008). The short-acting 
β2-agonists (SABA) include salbutamol and terbutaline, which have a duration 
of action of 3-4 hours with an onset of action of 15 minutes (Biddiscombe, 
Melchor et al., 1987). In contrast, the long-acting β2-agonists, including 
salmeterol xinafoate (SX) and formoterol fumarate dihydrate (FFD), have a 
duration of action of more than 12 hours and are helpful in controlling  chronic 
asthma (Cazzola, Testi et al., 2002).  
 
Anticholinergic quaternary ammonium compounds are a relatively novel class 
of bronchodilators (Barnes, 2004). The first use of anti-muscarinic agents in 
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the treatment of respiratory diseases was through short-acting agents 
(ipratropium and oxitropium). Once-daily treatment using long-acting 
compounds (tiotropium and glycopyrronium) have recently been introduced 
(Buhl and Banerji, 2012). Anticholinergic drugs work by competitive blockage 
of muscarinic cholinergic receptors, inhibiting bronchoconstriction and 
bronchial hypersecretion leading to airway dilation (Buhl and Banerji, 2012).  
 
1.3.2 Anti-Inflammatory Drugs 
The use of inhaled corticosteroids (ICS) is widespread in the treatment of 
asthma and COPD. ICS such as budesonide and fluticasone propionate (FP) 
reduce airway inflammation which is the underlying pathophysiological process 
in both diseases (Barnes, 2002). The responsiveness of ICS therapy is usually 
high in asthma. Corticosteroids suppress inflammation by inducing the 
recruitment of nuclear enzyme histone deacetylase 2 (HDAC2), which 
suppresses the expression of genes of various inflammatory mediators 
(Barnes, 2004).  
 
On the other hand, the use of ICS therapy in COPD treatment fails to suppress 
inflammation leading to a poor patient response. This has been reported to be 
related to the decrease of activity and expression of HDAC2 in the 
inflammatory cells and peripheral lungs of COPD patients (Barnes, 2008).  
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1.3.3 Combination Therapy 
Several studies have shown how a long-acting β2-agonist in combination with 
an ICS leads to superior results in controlling asthma (Matz, Emmett et al., 
2001). Data have shown that when FP and SX are combined, there is an 
increased clinical benefit when compared to individual drug components used 
separately (Nelson, Chapman et al., 2003). For patients with more severe 
COPD, the study suggested that using a combination of budesonide and FFD 
improves the overall exacerbation rate when compared to β2-agonist alone 
(Campbell and Szafranski, 2002). In addition, a 3-year retrospective study of 
COPD patients managed in primary care concluded that regular use of FP in 
combination with SX is associated with significantly higher rates of survival of 
COPD patients (Calverley, Pauwels et al., 2003).  
 
The superior clinical performance of combined therapy as opposed to the 
administering of individual drugs has been related to complementary efficacy 
of both long-acting β2-agonists and ICS when co-administered (Zetterstrom, 
Buhl et al., 2001). Another explanation to this superior clinical efficacy of co-
administration may be the synergistic interactions if ICS and long-acting β2-
agonists are co-deposited at the receptor, molecular and cellular level (Nelson, 
Chapman et al., 2003). 
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1.4 Current Respiratory Drug Delivery Devices 
There are currently three main drug delivery devises used to delivery 
medication to the lungs; nebulisers, pressurised metered dose inhalers 
(pMDIs), and dry powder inhalers (DPIs) (Hickey and Dunbar, 1997). These 
three devices are all used to treat respiratory conditions such as asthma and 
COPD (Lalor and Hickey, 1996). 
1.4.1 Nebulisers 
Nebulisers are devices which employ either compressed gas or ultrasonic 
energy to aerosolise aqueous drug solutions or suspensions for patient 
inhalation (Clarke, 1995). Unlike other devices, they do not require the use of 
complex breathing manoeuvre and by extending the time of operation, they 
can be used to deliver large doses (up to 1g) (de Boer, Hagedoorn et al., 
2003). The use of nebulisers is limited, however, by the length of time taken to 
deliver the required dose (10-15 minutes), their bulky size and high cost, which 
usually limits their use to hospitals and non-ambulatory patients (Garcia-
Contreras and Hickey, 2003). Recent developments in nebuliser technology 
are beginning to overcome some of these problems, allowing accurate 
metering of doses and increasing their portability (Dalby, Spallek et al., 2004). 
 
1.4.2 Pressurised Metered Dose Inhalers  
Pressurised metered dose inhalers (pMDIs) have been the drug delivery 
device of choice for respiratory diseases since 1956, as a result of their 
portability, robustness and cheap to manufacture (Hickey and Dunbar, 1997). 
Traditionally, these devices consist of a solution or suspension of fine drug 
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particles in a chlorofluorocarbon (CFC) propellant sealed in a canister at high 
pressure (Biddiscombe, Melchor et al., 1987). Actuation of the inhaler results in 
the release of a metered volume of this solution or suspension, which, driven 
by the pressure within the canister, emerges at high speed through a narrow 
orifice (Smyth, Hickey et al., 2006). This process, combined with evaporation 
of the propellant, results in an aerosol of drug particles in the inhalable size 
range (Berry, Kline at al., 2003). Notwithstanding the fact that pMDIs are the 
most frequently prescribed inhalation dosage form, most patients are unable to 
use them correctly (Virchow, Crompton et al., 2008). This is due to the high 
speed aerosol plume generated by the device, which requires the patient to 
use accurate co-ordination of inspiration and inhaler activation to ensure 
correct inhalation and deposition of the drug in the lungs (Virchow, Crompton 
et al., 2008). Even with the correct inhalation technique, pMDIs are inefficient 
often delivering less than a third of the emitted dose to the lungs (Virchow, 
Crompton et al., 2008). In addition to these problems, the introduction of the 
Montreal Protocol resulted in the phase out of CFC propellant gas in all 
aerosol-based products, including pMDIs. As a result, all pharmaceutical CFC-
based pMDI products were re-formulated using hydrofluoroalkanes (HFA) 
propellant (Richards, Hirst et al., 2001). The difficulties and expense incurred 
in re-formulating pMDI products and long term issues regarding the 
greenhouse gas properties of HFA-based propellants, have prevented, more 
recently, companies from launching new drugs as pMDI formulations 
(McDonald and Martin, 2000). 
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1.4.3 Dry Powder Inhalers 
Dry powder inhalers (DPIs) allow an accurate dose of drug to be delivered to 
the respiratory airways as a dry powder aerosol (Tismina, Martin et al., 1994). 
Interest in DPIs for inhalation therapy grew strongly due to their potential to 
offer CFC-free alternatives to pMDIs (McDonald and Martin, 2000). Currently, 
the spectrum of applications for DPIs has become much broader, due to the 
high lung deposition that can be attained and their suitability for pulmonary 
delivery of therapeutic peptide and proteins both for local and systemic 
conditions (Byron and Patton, 1994). DPIs are breath-actuated drug delivery 
systems, which enable a respirable cloud to be generated in response to the 
patient's inspiratory effort (Tismina, Martin et al., 1994). DPIs may therefore 
have many advantages over pMDIs (Hannemann, 1999; Newman and Busse, 
2002; Virchow, Cromptom et al., 2008). Firstly, DPIs do not need a propellant, 
which has been the driving force behind the introduction of a large number of 
novel DPI devices in recent years (Tismina, Martin et al., 1994). The second 
benefit is that DPIs eliminate the need for patient co-ordination of actuation 
and inhalation (Newman and Busse, 2002). Finally, in DPIs, the particles are 
travelling at a slower rate, therefore, an excessive drug loss due to impaction 
in the throat is avoided (Pauwels, Newman et al., 1997). 
 
Having particles with a mass median aerodynamic diameter (MMAD) less than 
5 µm is critical in achieving lung deposition of the said drug particles (Heyder, 
Gebhart et al., 1986; Tismina, Martin et al., 1994; Prime, Atkins et al., 1997). 
Controlling this variable is usually obtained by high-energy micronisation 
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techniques (Thibert and Tawashi, 1999), although numerous other 
technologies such as spray drying (Li, Seville et al., 2005), and supercritical 
fluid technologies (Shekunov, Feeley et al., 2003) have been evaluated. 
However, respirable sized particles exhibit high surface energies, which lead to 
particle aggregation, poor flow and entrainment properties, and therefore make 
re-dispersion of the drug a difficult process (Feeley, York et al., 1998). These 
problems relate to the cohesive nature of the powder. To overcome particle-
particle cohesion, the drug is mixed with with a coarse excipient, traditionally 
lactose monohydrate (Bell, Hartley, 1971). The micronised drug is blended with 
carrier particles of a much larger size range (20-100 µm), whereby the drug 
particles form an interactive mixture with the surfaces of the coarse lactose 
particles (Ganderton, 1992). The turbulent airflow generated within the device 
upon forced inspiration should be sufficient to fluidise the formulation from the 
device and to de-aggregate the drug particles from the carrier particles (Telko 
and Kickey, 2005; Shur, Harris et al., 2008). The drug particles are then 
entrained into the airstream, which enables the drug particle to enter the lung 
(Shur, Harris et al., 2008).  
 
DPIs are currently available in three different types; the single-dose, the multi-
dose and the reservoir-based dose (Prime, Atkins et al., 1997; Malcolmson 
and Embleton, 1998; Smith and Parry-Billings, 2003). Every DPI device 
exhibits an internal resistance which determines the inhaled flow rate that a 
patient can achieve when using the device (Harris, 2007). As flow rate will 
inevitably be linked with inhaler performance, it is essential that such factors 
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are considered in any in vitro comparative testing of DPIs (Harris, 2007). 
Successful development of DPI systems requires development on two 
integrated fronts; device engineering and powder formulation engineering 
(Tismina, Martin et al., 1994). 
  
1.5 Interparticulate Forces 
Having highlighted the importance of interparticulate interactions on the 
performance and behaviour of DPI formulations, the following section will look 
into the origins which determine these highly influential interparticulate forces. 
Interactions between particles forming a powder interact with each other 
through a composite of physical forces (Johnson, 1996). Although these forces 
are relatively weak, never exceeding 40 kJ.mol-1 as opposed to the typical 300-
700 kJ.mol-1 for covalent bonds (Johnson, 1996), their influence on powder 
behaviour is significant on particles having a diameter below 10 µm, as the 
force of gravity becomes relatively insignificant (Johnson, 1996). Such 
interactions may be classified as being either cohesive (interactions between 
particles of the same chemical structure and similar particle size), or adhesive 
(interactions between particles with different chemical structures and size) 
(Johnson, 1996). The physical forces which dominate the cohesive and 
adhesive properties of respirable drug particles are van der Waals, capillary 
and electrostatic forces (Johnson, 1996).  
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1.5.1 Van der Waals Forces 
Van der Waals forces account for the major force of interaction between 
uncharged particles in a dry environment (Lifshitz, 1955). These forces are the 
summation of the attractions between molecules that are temporarily dipolar, 
due to random fluctuations in their surrounding electron cloud, which may also 
induce the corresponding polarity in another molecule in close proximity 
(Lifshitz, 1955). 
The van der Waals forces ( VDWF ) between two ideally smooth spheres in a 
















FVDW   Equation 1.3 
where H  is the Hamaker constant (Equation 1.4), s  is the separation distance 
between the spheres and 1d  and 2d  are the diameters of the two spheres. The 
Hamaker constant is given by: 
dvvH 2,121
2    Equation 1.4 
where 1v  and 2v  are the number of atoms per unit volumes of particle 1 and 2 
and 
d





hFad      Equation 1.5 
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where h  is Planck’s constant, F  is the vibration frequency of the interacting 
electronic oscillators and a  is the polarisability of the molecules. 
The adhesive force between a sphere (diameter 1d ) and a plane composed of 






FVDW     Equation 1.6 
whereas the adhesion between a sphere (diameter 1d ) and a plane composed 
of different materials and separated by distance s  is expressed by: 
   






FVDW     Equation 1.7 
where 11H  and 22H  are the Hamaker constant for the particle and the plane 
surface, respectively.  
Equations 1.3, 1.6 and 1.7 demonstrate the importance of the separation 
distance, s , in determining the van der Waals forces between two solid 
objects. It is clear that these will retard rapidly with increasing separation 
distance, so it is not surprising that van der Waals forces exert their influence 
only over a narrow range of approximately 10 nm (Hamaker, 1937). 
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1.5.2 Capillary Forces 
When relative humidities exceed 50 %, water may condensate onto particle 
surfaces and may lead to the formation of liquid bridges between contiguous 
particles (McFarlane and Tabor, 1950; Hiestand, 1966). Such structures will 
lead to an increase in adhesive forces between particles due to the surface 
tension of water and the formation of a meniscus creating a capillary force of 
interaction (McFarlane and Tabor, 1950). The magnitude of this capillary force 
( cF ) between two identical smooth spheres (radius r ) can be calculated as:  
 
 cos2 rF wc     Equation 1.8 
 
where w  is a surface tension of water and   is a contact angle between 
water and the spheres. In the case of a sphere (radius r ) adhering to a 
surface, the capillary force resulting from the condensation of water in the 
interface can be calculated as: 
)cos(cos2   rF wc   Equation 1.9 
where   and   are the contact angles of the water with the surface and 
particle, respectively. 
When the relative humidity is in excess of 65 %, capillary forces may become 
the dominant force of interaction (Hiestand, 1966; Price, Young et al., 2002).  
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1.5.3 Electrostatic Forces 
Particles may become charged during powder handling by contact or friction 
with other particles or surfaces. This process is known as triboelectrification 
(Staniforth and Rees, 1982). If charged particles are brought into proximity of 
one another, a long-range electrostatic force (either attractive or repulsive, 
depending whether the particles are like or oppositely charged) will be 







   Equation 1.10 
 
where ELF  is the electrostatic force,  1q  and 2q  are the electrical charges on 
the two particles,   is the permittivity and s  is the separation distance 
between the particles. 
Furthermore, an uncharged particle may become charged if an image charge 
is induced upon it by the approach of a charged particle (Onsager and 






















   Equation 1.11 
where s  is the separation distance between charged and uncharged particles. 
This equation may be modified to describe the adhesion of a charged particle 
Chapter ONE                                                                                       46 
 
to a flat earthed conducting surface via the formation of an image charge by 







    Equation 1.12 
Contact between two uncharged particles with different work functions may 
also result in the flow of electrons from the particle with the lower work function 
to the particle with the higher work function until an equilibrium is established 
(Tabor, 1976). This is known as contact electrification and the resultant force of 







     Equation 1.13 
where r  is the radius of the particles and U  is the potential difference arising 
from the difference in work functions. 
Electrostatic forces are largely dependent on the electrical properties of the 
particles involved and the separation distance between them. Under normal 
environmental conditions, electrostatic forces are at least ten times smaller 
than van der Waals forces (Tabor, 1976). This leads to the dominance of the 
omni-present van der Waals forces, which is largely responsible for the 
strength of the adhesion, especially if the build-up of electrostatic charges can 
be mitigated (Johnson, 1996). 
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1.5.4 Mechanical Interlocking 
The typical micronised drug particle has a microscopically rough surface 
topography, which may result in the interlocking of contacting asperities and 
may thus increase interparticulate interactions (Jayasing, Pilpel et al., 1970; 
Adolfsson, Olsson et al., 1997). If the roughness causes particle-particle 
contact to only occur over a small surface area, the interparticulate forces 
acting on this small area will produce an extremely high pressure (Fuller and 
Tabor, 1975). This may exceed the yield value of the material, resulting in 
increased mechanical interlocking and van der Waals forces.  
 
1.6 Factors Affecting Interparticulate Forces 
Previous sections have indicated a range of factors may influence the 
adhesion force between particles. The following section reviews, in more 
detail, the specific influence of the physical and interfacial chemical 
characteristics of particles on interparticulate forces. 
 
1.6.1 Particle Size 
The van der Waals, capillary and electrostatic forces (shown in section 1.4), 
describe how these forces are directly proportional to particle diameter, with 
gravitational forces being proportional to diameter cubed ( 3d ). These 
relationships suggest as particle size is reduced, the physical forces 
experienced by a particle become more and more significant when compared 
to the gravitational forces (Visser, 1995). Depending on a material density, for 
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particles smaller than approximately 10-20 µm, the physical forces dominate 
gravitational forces, which explain the cohesiveness and poor flowability of 
very fine powders. 
1.6.2 Particle Shape 
The way in which particle shape influences adhesion is very difficult to quantify 
and control on a macroscopic scale. The equations describing particle 
adhesion make the assumption that particles are spherical in shape and 
smooth, an assumption which hardly ever mirrors reality.   
The short-range van der Waals and the long-range electrostatic forces both 
decrease as a function of the square of the separation distance between 
particles (Equations 1.3, 1.6, 1.7 and 1.10 to 1.12). Hence, an increase in 
separation distance between contacting particles would reduce particulate 
interaction. The range over which the latter exerts an influence on the van der 
Waals force is between 10-100 nm. Thus, any effect of particle shape on 
interparticulate distance may significantly influence particle interactive forces 
(Johnson, Kendall et al., 1971). For instance, small, non-interlocking surface 
asperities which increase the separation distance between particles will reduce 
the force of adhesion upon contact (Johnson, Kendall et al., 1971). When the 
asperities are of the order of 1 µm, the separation distance will be large, 
thereby limiting the van der Waals attractions to almost zero (Castellanos, 
2005). Alternatively, smooth, flat elongated particles which pack as shown in 
Figure 1.2A will experience increased interparticulate adhesion due to their 
reduced separation distance and increased interparticulate contact area. The 
packing of such particles would also depends on their process history. In the 
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absence of significant compaction, they tend to be loosely packed together 
(Figure 1.2), giving rise to higher separation distance and reduced area of 
contact leading to a reduction in their adhesive interactions (Valverde, Ramos 
et al., 1998).  
 
Figure 1.2: Packing arrangements for flat elongated particle (Zeng, 
Martin et al. 2001): (A) Closely packed orientation, typically found 
after powder handling. (B) Loosely packed orientation 
 




1.6.3 Surface Roughness of Particles 
As with particle shape, surface roughness will directly influence contact 
geometry and interparticulate forces on a mesoscopic scale (Fuller and Tabor, 
1975). Figure 1.3 shows how, if the roughness of a substrate is of a smaller 
scale than the adhering particle, the contact area between the particle and the 
surface will be decreased and the separation distance increased when 
compared to adhesion to a flat surface (Figure 1.3B), resulting in decreased 
interparticulate forces (Johnson, Kendall et al., 1971; Fuller and Tabor, 1975; 
Johnson, 1996). When the roughness of substrate is on a larger scale than the 
adhering particle, the situation is reversed (Figure 1.3C). In addition, when 
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mechanical interlocking occurs between asperities, a signifcant increase in 
interparticulate forces can be generated. 
Figure 1.3: The effects of roughness on particle-surface adhesion. (A) 
Surface roughness on a smaller scale the particle size. (B) A smooth 
surface. (C) Surface roughness on a larger scale than particle size 
                
 
One must note that in most instances, particle adhesion in pharmaceutical 
powders occurs between two rough particles or a rough particle and a smooth 
surface, therefore the examples shown in Figure 1.3 tends to simplify the 
actual situation (Zeng, Martin et al., 2001). 
 
1.6.4 Particle Deformation 
Local deformation of adhering particle surface may also influence 
interparticulate forces by decreasing particle-particle separation and increasing 
contact area, leading to a greater van der Waals force of interaction (Krishnan, 
Busnaina et al., 1994). The extent of any deformation is dependent on the 
elastic/plastic properties of the particles, the pressure generated between two 
contacting asperities, the magnitude of the attractive forces and the magnitude 
and duration of any external forces applied to the particles (Johnson, 1996). 
For certain materials such as polymer-like materials, the duration of contact is 
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also important as deformation will increase with time resulting in increased 
adhesion, a phenomenon known as aging (Krupp, 1967). 
 
1.6.5 Surface Free Energy 
The surface free energy from a solid material is described as the energy 
required to produce a unit area of surface and is analogous to the surface 
tension of a liquid (Johnson, Kendall et al., 1971). Unlike liquids, the molecules 
of a solid are not free to move, therefore, surface free energy is not uniform 
over a surface and depends on the history of the material (Johnson, 1998). 
The quantity of work required to separate two surfaces of two materials is 
called the work of adhesion ( aW ) and is related to the surface free energy of 
the surfaces by the following equation: 
 
)( CDDCsa AW     Equation 1.14 
where sA  is the area of surface produced by the separation, 
C  and 
D are 
the free energies per unit surface area of solids C and D in air, respectively; 
and 
CD  is the  free energy of the C-D interface per unit area. Therefore, the 
work of cohesion ( cW ) (i.e. the work requires to separate two surfaces of the 
same material) is shown by: 
C
sc AW 2     Equation 1.15 
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In addition to the physical contact geometry, interparticulate cohesion and 
adhesion will, in part, be determined by the surface free energies of the 
interacting particles and their work of adhesion (Johnson, Kendall et al., 1971). 
 
1.6.6 Environmental Factors (Relative Humidity) 
There are two mechanisms by which relative humidity may affect 
interparticulate forces. Firstly, relative humidity increases particulate interaction 
via capillary forces when a sufficient amount of water is condensed on the 
surfaces of the interacting system (McFarlane and Tabor, 1950; Price, Young 
et al., 2002). Secondly, the conductivity of both interactive particles will be 
increased and will accelerate the dissipation of electrostatic charges on the 
particles (Byron, Peart et al., 1997). Hence, water at high relative humidity can 
condensate at the contact points between particles, resulting in the formation 
of the liquid bridges and the formation of a dominant capillary force (Price, 
Young et al., 2002; Young, Price et al., 2003). 
 
1.7 Analytical Tools used in the investigation of interfacial properties 
via surface characterisation  
 
The importance of interfacial chemistry on the performance of DPI formulations 
has led to the necessity of analytical tools that enable direct and/or indirect 
measurements of surface energetics and particle-particle interactions. A 
number of different techniques have previously been used to quantify particle-
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particle or particle-surface adhesion in air, including centrifugal detachment, 
aerodynamic detachment, impact separation, vibration, and microbalance 
techniques. In addition to these techniques, a number of other tools have been 
recently investigated to determine the relationship between particle surface 
interfacial properties and dry powder inhaler (DPI) formulation performance, for 
example, centrifugal methods and colloid probe atomic force microscopy 
(AFM). The following section introduces some of these techniques and their 
application for investigating surface interfacial properties of pharmaceutical 
materials. 
 
1.7.1 Centrifugal Methods 
Centrifugal methods examine the forces between particles and flat surfaces. 
The equipment consists of a centrifuge, which has been modified by the 
introduction of specially manufactured adapters, in which disks of material, with 
particles added onto the top, can be placed. A typical centrifuge experiment 
begins with the disks being placed inside the adapters, with the particles 
placed facing the centre of the centrifuge rotor (Kulvanich and Stewart 1987). 
This allows a press-on force to be applied. Following this, the number of 
particles on the disk is counted and the disk is then placed in the centrifuge 
again, although this time the disk is facing outwards. The removal force is then 
applied (Podczeck and Newton, 1995). The detachment force (Fdet) applied is 
directed through the centre of gravity of the particle, outwards from the centre 
of rotation (Kulvanich and Stewart 1987) and is described by equation 1.16: 
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2
det .. rMF p           Equation 1.16 
where Mp is the particle’s mass, r is the distance from the axis of rotation to the 
particle and ω is the angular velocity (Booth and Newton, 1987). The 
centrifuge system has been used to study a number of different 
pharmaceutical systems. Lam and Newton (1993) used it to examine the effect 
of time on the press-on force of particles of PEG 4000 and Starch 1500 
against a steel surface, whereas Podczeck, et al. (1997) used it to compare 
the effects of particle on compressed disk of material to particle-on-particle 
experiments. The centrifuge and impaction approaches to particle 
measurements have many advantages. They provide data regarding the bulk, 
integrated effects of physical and environmental variation of particle adhesion, 
are of low cost, and are simple and accessible. However, the main 
disadvantage is that due to the large-scale nature of the measurements, it 
provides limited information on individual particle interactions (Podczeck and 
Newton 1995).  
 
1.7.2 Scanning Probe Microscopy 
The ability to generate data regarding single particle events has been 
facilitated by the advent of the scanning probe microscope, particularly the 
introduction of the colloid probe atomic force microscope (AFM) technique 
(Ducker, et al., 1991). 
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Scanning probe microscopy (SPM) is the name given to a range of techniques 
which involves the formation of images and acquisition of surface property 
data from a range of physical, optical and chemical interactions between a 
sharp proximal probe and a surface (Shao, et al. 1996; Vansteenkiste, et al. 
1998). Scanning tunnelling microscopy (STM) was the first in a series of high-
resolution SPM techniques (Hansma and Pietrasanta, 1998). STM relies on 
the use of an atomically fine tip that is brought into very close proximity to a 
conducting or semi-conducting surface (Yip, 2001). A bias potential is applied 
across the gap and a tunnelling current measured. The tip is then rastered 
over the surface to build a map showing the local density of states, commonly 
giving a topography image. Binnig and Rohrer received the Nobel Prize for 
Physics after inventing STM instrument in 1982, where they showed an 
atomically-resolved gold surface (Binnig, et al. 1986). A fundamental 
disadvantage with STM is the inability to image insulating specimens, such as 
biological materials and polymers. Atomic Force Microscopy (AFM) 
circumvented the need for conducting surfaces by measuring forces, rather 
than tunnelling currents, between the probe and the surface (Binnig, et al. 
1986). AFM has quickly become a routine microscopy technique, offering 
many advantages, such as minimal sample preparation, the non-requirement 
for high-energy electron beams or high vacuum conditions. 
 
1.7.2.1 Atomic Force Microscopy 
In the AFM, a sharp, pyramidal tip mounted on a cantilever, which is brought 
into close contact to the surface where the intermolecular forces acting 
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between the tip and the surface cause the cantilever to bend (Yip 2001). 
Topographical images of the surface are obtained by recording the cantilever 
deflections, as detected by a laser beam focused on the top of the cantilever 
tip, as the sample is scanned beneath. The AFM can be operated in air or 
liquid environment, which has been made possible by the development of AFM 
wet cells (Traini, et al. 2005). The AFM has three main parts: cantilever, 
scanner and optical deflection system consisting of a laser diode and 
photodetector (Figure 1.4). 
 
 
Figure 1.4 Schematic Diagram of an Atomic Force Microscope 
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The cantilever is microfabricated from silicon nitride (sometimes silicon, for 
stiffer levels) with typical dimensions that are 100 – 300 m in length, 10 – 30 
m in width and 0.5 – 3 m in thickness (Figure 1.5). 
 
Figure 1.5 Dimensions of the Tip and Cantilever of an Atomic Force 
Microscope 
 
Very small deflections of the cantilever are amplified by a laser beam that 
reflects off the end of the cantilever onto the photodetector, which senses the 
changes in the position of the laser beam (Yip 2001). A four-quadrant 
photodetector gives the opportunity to measure both normal bending and 
torsion of the cantilever, corresponding to normal and lateral forces (Young, et 
al. 2003). 
The sample is mounted via a sample holder on to the AFM scanner, which 
consist of piezoelectric ceramics that move the sample relative to the 
cantilever in three dimensions (x, y and z directions). In the contact mode of 
operation, the tip and sample are placed in contact and the tip is rastered 
across the surface resulting in a topographical image of the surface. The 
scanning is done under feedback control where the sample is moved towards 
or away from the cantilever during the scan to maintain constant force on the 
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sample surface. Hence, the scanner retracts if the tip moves over a high 
feature or towards the cantilever over low features. This up and down motion 
of the sample is therefore a record of the sample topography (Hansma and 
Pietrasanta 1998). 
1.7.2.2 Colloid Probe Atomic Force Microscopy  
Soon after the invention of the AFM, the colloid probe technique was 
developed for mapping the interaction forces of colloid probes in air and liquid 
environments (Ducker, et al. 1991). Data from the force-distance curves 
generated have been utilised to study interfacial particle interactions and to 
characterise material properties such as elasticity and the coefficient of friction. 
The principle of the colloid probe technique is the same as standard AFM as 
outlined above, except that the sharp tip is replaced with a colloid probe 
attached to the end of a tipless cantilever. In force measurement mode, the 
sample is moved up and down, by applying a voltage to the piezoelectric 
translator, onto which the sample is mounted, while recording the cantilever 
deflection. The deflection of the cantilever is normally measured using the 
optical lever technique. A beam from a laser diode is focused onto the end of 
the cantilever and the position of the reflected beam is monitored by a position 
sensitive detector. The backside of the cantilever is usually covered with a thin 
gold layer to enhance its reflectivity. 
Analysis of a typical force measurement consists of the following: 
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1. Initially, the probe and substrate have a large separation distance 
and there is no interaction, so no displacement of the cantilever 
is recorded. 
2. As the substrate approaches the probe, the presence of long-
range electrostatic forces can be evaluated. In the example 
shown, there is an electrostatic repulsion between the probe and 
substrate leading to the cantilever being deflected away from the 
surface. 
3. As the separation between the probe and substrate decreases, 
the short-range, attractive van der Waals forces overcome the 
repulsion and the probe jumps into contact with the substrate. 
4. The probe and substrate are pressed together with a pre-set 
compressive loading. 
5. The substrate is subsequently withdrawn from the probe until 
they are pulled apart. The point at which this happens 
corresponds to the adhesive force and the area between the 
curve and the zero interaction level can be integrated to give the 
energy of adhesion. 
 
The direct result of such a force measurement is the detector signal in volts, 
ΔV, versus the position of the piezo Δzp, normal to the surface. To obtain a 
force-versus-distance curve ΔV and Δzp are converted into force and distance. 
Chapter ONE                                                                                       60 
 
To calculate the cantilever deflection from the detector signal, the 
corresponding conversion factor is needed, which can be obtained from a 
linear fit of the constant compliance region. The tip-sample separation is then 
obtained by adding the cantilever deflection to the piezo position. 
The force acting on the cantilever, F, is obtained by Hooke’s law, which relates 
the stiffness of the cantilever (k, the spring constant) and deflection of the 
cantilever (x): 
    kxF      Equation 1.17 
 
In order to make a quantitative measurement, it is necessary to know the 
spring constant of the cantilever, which can either be taken from the 
manufacturer’s literature or, more accurately, determined for individual 
cantilevers using a variety of methods. 
Force-distance curves can be generated singly, but in order to obtain a 
statistically relevant set of data in a single operation, force-volume mode can 
be employed. In this mode, the AFM raster scans the substrate under the 
colloidal probe to produce a series of force-distance curves, each from a well-
defined interval in the x and y direction, and a low-resolution topographical 
image. These data can be processed to calculate the force of adhesion from 
each individual force curve, which can be displayed as a force map, showing 
variation in adhesion over the surface. 
Given the importance of inter-particle adhesion to the performance of DPI 
formulations, it is not surprising that the colloidal probe technique has been 
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applied to this area of research (Louey, et al. 2001; Price, et al. 2002; 
Tsukada, et al. 2004; Hooton, et al. 2008). The naturally irregular morphology 
of the particles in DPI formulations, however, was found to produce great 
variability in the results of colloid probe adhesion measurements between 
formulation components, as it led to significant variation in the contact area 
between the colloidal probe and substrate, to which adhesion is directly 
proportional. As a result, the use of colloidal probe AFM in the study of 
inhalation formulations was largely qualitative. Recently, however, a number of 
techniques have been developed to overcome this limitation. One such 
technique employs a grid of extremely sharp spikes over which the colloidal 
probe is scanned, resulting in an image of its interacting region from which the 
morphology and the contact area can be calculated. It is then possible to 
normalise adhesion measurements by the contact area and so calculate the 
work of adhesion between the substrate and particle. 
Another technique that to some extent, overcomes the limitation of contact 
area and which has been used to explain the behaviour of DPI systems is 
known as the cohesive-adhesive balance (CAB) procedure (Begat, et al. 
2004a, b). This employs specially grown molecularly smooth crystals as 
substrates to ensure that the contact area between a given colloidal probe and 
various substrates is uniform and constant. 
A number of colloidal probes of each material under investigation are prepared 
and the adhesive force between each probe and a crystalline substrate of each 
material under investigation is measured in force-volume mode. This data is 
used to produce a CAB graph, by plotting the mean force of cohesion for each 
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probe (the adhesive force between a probe and a substrate of the same 
material) against the mean force of adhesion between that probe and a 
substrate of another material. When data for a number of probes of the same 
material interacting with the same substrate are plotted on the same axes, a 
straight line is formed allowing linear regression analysis of these data. 
Although the contact area of each probe may vary significantly, the contact 
area of an individual probe is the same for both the cohesive and adhesive 
measurements and thus the ratio between cohesion and adhesion remains 
consistent between different probes. This ratio, known as the CAB ratio, can 
be measured from the analysis of the gradient of the CAB plot. 
 
The CAB procedure is able to produce data that are independent of the 
contact area between the colloidal probe and substrate and which are, 
therefore, quantitative. The approach has been shown to predict the force 
balance and behaviour and possibly the in vitro performance of simple powder 
formulations of binary DPI systems. 
 
1.8 Optimising Pharmaceutical Engineering of DPIs 
 
The fundamentals of DPI formulation engineering is firstly the milling (air-jet 
micronisation) of large, primary crystalline drug particles to produce fine 
particles with a median geometric diameter of 1-5 µm (Telko and Hickey, 
2005). Secondly, the blending of these particles with large carrier particles, 
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traditionally lactose monohydrate, to improve powder fluidisation (Dunbar, 
Morgan et al., 2000). Due to the influential interparticulate cohesive and 
adhesive forces noted with fine drug particles and the large carrier particles, 
lung delivery efficiencies of just 10-30 % of the nominal dose are typically 
observed (Dunbar, Morgan et al., 2000). This highlights the dependence of 
particle entrainment and drug deposition in the airways, on the balance of 
interfacial forces between components of DPI formulations (Jones, Harris et 
al., 2008). Hence, the control and understanding of the interfacial properties of 
DPI formulations are critical in enabling the formation of DPI products with 
defined quality and functionality (Edge, Muller et al., 2008). 
 
The primary design concept in drug particle manufacturing is particle size, 
notwithstanding the common knowledge that surface properties will drastically 
alter DPI product performance. However, our limited understanding of the 
effects of processing on drug surface properties, has limited adequate control 
of product performance.  
 
1.8.1 Micronisation and Mechanical Activation  
To reduce the particle size of a primary drug crystal, a destructive, highly 
energetic processing techniques, such as air-jet micronisation, are commonly 
employed (Malcolmson and Embleton, 1998). During comminution, mechanical 
loading of the crystalline solid is known to cause distortion and disordering of 
the crystal lattice leading to structural and thermodynamic modifications of the 
processed material. The thermodynamically activated state of the micronised 
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material is commonly described as “mechanical activation” (Huttenrauch, 
Fricke et al., 1985). A graphical illustration of the relationship between 
mechanical activation and the free energy state of a material during 
micronisation and its relaxation post processing is shown in Figure 1.6.  
 
 
Figure 1.6 Schematic representation of the process of mechanical 
activation and relaxation process of micronised particles. A = Low 
surface free energy of crystalline unprocessed material, B = Brittle -
ductile transition, at which point particle fragmentation is not 
probable, C = Mechanically activated stated, D = Relaxation behaviour 
of the mechanically activated material over time and E = Relaxation of 
the mechanically activated state by post-processing conditioning. 
  
During micronisation the high degree of particle-particle collisions leads to 
significant crystal fracturing and particle size reduction. At a critical particle 
size, the material reaches its brittle-ductile transition (Figure 1.6B), at which 
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point the material becomes less likely to undergo fracture. At this transition, 
materials under mechanical loading will experience a dramatic increase in 
elastic strain energy as the tensile strength and boundary surface tension of 
the material are overcome. The loading may be sufficient to plasticise the 
material and the corresponding elastic strain energy within the crystalline 
lattice is stored in the form of structural defects, dislocations and surface 
amorphicity. It has been reported that lattice defects introduced upon 
mechanical activation is a surface led phenomena and penetrates into the 
lattice to depths of 10-6 to 10-8 m (Huttenrauch, Fricke et al., 1985). The elastic 
energy that remains upon mechanical treatment is the source of excess 
enthalpy and Gibbs free energy. Structural changes directly influence the 
thermodynamic properties of a substance, for example, surface free energy, 
reactivity, conductivity and true density. Hence, the process of mechanical 
activation of micronised solids may directly influence the surface free energy of 
the material that will affect adhesion between the processed API and carrier 
particles, which in turn, will have a critical affect on DPI drug product quality 
and performance.  
 
Since the mechanically activated system is thermodynamically unstable, the 
process is reversible, whereby there is an energy loss and energy output of the 
system. For mechanically activated solids, the reverse process is driven 
towards equilibrium but never reaches a state free of structural defects, 
leading to some residual activity. The rate of structural relaxation depends on 
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environmental conditions and material properties and is thought to range 
between a few milliseconds to several months. The kinetics of relaxation 
depends primarily on the structural nature of the material and environmental 
conditions (temperature and relative humidity), which may influence the degree 
of molecular mobility within the material. However, the relaxation of these 
structural modifications may never reach the initial low surface energy state of 
the crystalline material and thereby a residual activity will remain (Huttenrauch, 
Fricke et al., 1985). The time dependant re-crystallisation of amorphous 
regions and relaxation of process induced defects may result in irreversible 
agglomeration (caking) of micronised materials, and thereby rendering the 
drug product unusable (Ahlneck and Zografi, 1990). During this process of 
relaxation the surface free energy of the material may also significantly change 
over-time as indicated in Figure 1.6D. This may have a corresponding effect on 
particle adhesion, which will affect the surface interfacial force balance within a 
DPI formulation and therefore, product performance. Hence, active ingredient 
processing conditions must be controlled to produce materials that have 
suitable physicochemical and surface energetic properties. However, as there 
are many difficulties associated with controlling micronisation processing of 
materials, this can result in variations in the surface properties of equivalent 
drug batches and therefore adhesion, which can lead to significant batch-to-
batch variability in drug product performance (Feeley, York et al., 1998).   
1.8.2 Environmental Laagering  
One of the methods employed to improve the physicochemical stability of 
micronised API and, hence, reduce or eliminate batch to batch variability, is 
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the introduction of a post-micronisation conditioning step (Trofast, Trofast et 
al., 1992; Pfeiffer-Brodka, Haeusler et al., 2003). During this process, the 
structural relaxation of a material is expedited under conditions that are 
controlled with respect to relative humidity and temperature (Pfeiffer-Brodka, 
Haeusler et al., 2003). Furthermore, the conditioning of hydrophobic materials 
using organic vapours such as ethanol have also been investigated (Trofast, 
Trofast et al., 1992; Jones, Young et al., 2008). Since the activated state of the 
micronised material is thermodynamically unstable (Huttenrauch, Fricke et al., 
1985), accelerated conditioning aims at dissipating much of the stored 
mechanical energy, induce re-crystallisation of amorphous domains in 
reducing the free energy of the material, as indicated in Figure 1.6. Previous 
studies have shown that conditioning of micronised drug actives results in 
significant reduction in surface amorphous content, allowing greater control of 
batch-to-batch variations of material physicochemical properties (Pfeiffer-
Brodka, Haeusler et al., 2003). The importance of post-micronisation 
conditioning within the industry is indicated through the registration of a 
number of patents documenting the use of several conditioning steps involving 
humidity and temperature (Morton, Shott et al., 2008; Jakupovic and Trofast, 
1998; Brodka-Pfeiffer, Grass et al., 2004; Trofast, 2000). 
 
1.8.3 In-situ conditioning with supercritical fluid technologies and HFA 
The requirement for consistent and reliable manufacture of drug compounds 
with controlled and stable physical properties has driven the advance of 
supercritical fluid (SCF) technology to make giant leaps over the past decade 
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(Muhammad et al., 2010; Pathak, Meziani et al., 2005). A widely published use 
of SCFs in the manufacture of particles for inhalation via the solution enhanced 
dispersion by supercritical fluids (York, Hanna et al., 1998). This process uses 
CO2 to extract the solvent within which the drug crystals are dissolved, using 
temperature and pressure to control the properties of the drug particles (York, 
Hanna et al., 1998). The use of similar technologies have shown the potential 
of controlled key particle parameters such as particle size, shape and 
morphology, rendering the application desirable for use in pulmonary delivery 
(Muhammad et al., 2010). Whilst the use of CO2 as a SCF in the manufacture 
or particles intended for delivery to the lungs consistently yields particles with 
desirable properties, the delivery of particles to the lungs once formulated have 
generally shown an inferior efficiency to other more traditional manufacturing 
processes (Vervaet and Byron, 1999).  
In recent years, the use of 1,1,1,2-tetrafluoroethane (HFA 134a) has been 
investigated as a replacement for CO2 in organic chemistry. It has been shown 
to be effective as a reaction medium for a variety of reaction mechanisms 
(Tallon and Catchpole, 2008). HFA is a gas at atmospheric pressure with a 
boiling point of -26.3◦C and a molecular formula of CH2FCF3. HFA is widely 
used as a liquefied propellant, including MDIs as discussed previously. It has a 
distinctively low interfacial tension value (Vervaet and Byron, 1999) giving HFA 
good dispersive properties. 
 
Chapter ONE                                                                                       69 
 
1.9 Thesis Overview  
Structural relaxation kinetics has been shown to be strongly dependent on 
environmental conditions (temperature and relative humidity), which may 
influence the degree of molecular mobility within the material, and the period of 
exposure to such conditions. The laagering or quarantine period required for 
materials to undergo structural relaxation may vary significantly from minutes, 
hours to months and appears to be highly dependent on their 
hydrophilic/hydrophobic nature. However, there remain lapses in published 
knowledge relating to the influence of processing history on the dynamics of 
particles’ properties and their subsequent in vitro performance. 
 
1.9.1 Aims of this Thesis 
This study aims at enhancing the knowledge of how processing histories relate 
to critical drug surface properties including interfacial behavior. A number of 
studies will be undertaken to study trends in the post-micronisation behaviour 
of various drug compounds through physicochemical and interfacial properties, 
together with their corresponding in vitro performance. This study will also 
evaluate the potential of HFA as a post-micronisation process for in situ 
conditioning of a mechanically activated drug. The studies will seek to gain a 
better understanding of the dynamics through which micronised particles 
regain stable properties and will also assess the potential of stress conditions 
in accelerating the mechanical relaxation profile of a drug. This work aims at 
increasing the understanding in the relation between manufacturing cycle 
times and drug product critical quality attributes. The outcome of this work will 
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assist in the complex interaction between technical requirements driven by the 
nature of the active pharmaceutical ingredient and the needs of quality 
attributes specifically fine particle mass of the aerosolised dose to be within 
registered specification. This work will potentially allow for the 
shortening/removal of post-micronisation ‘waiting’ periods by introducing 
conditioning steps which expedite the stress relaxation of micronized drug 
ensuring the physicochemical properties leading to robust and stable critical 
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2 The Influence of Post-Micronisation Conditioning on the Interfacial 
Properties and the In Vitro Performance of Fluticasone Propionate 
 
2.1 INTRODUCTION 
Tailoring an active pharmaceutical ingredient (API) to respirable sized particles 
through jet-milling micronisation is a highly energetic, poorly controlled process 
(Malcolmson and Embleton, 1998). The lack of control throughout this process 
leads to energy levels exceeding the particle fracture energy threshold, hence 
inducing an increased Gibbs free energy to the drug surfaces, which may 
cause plastic deformation (Colombo, Grassi et al., 2009). The altered chemical 
and physical properties of the newly created surfaces are highly unstable and 
require an undetermined period of stress relaxation during which surface 
properties can shift towards their more stable, lower energy, state (Florence 
and Salole, 1976; Sekiguchi, Shirotani et al., 1980; Buckton, Choulorton et al., 
1988; Otsuka and Kaneniwa, 1990; Saleki-Gerhardt, Ahlneck et al., 1994; 
Briggner, Buckton et al., 1994). This process induced structural disorder 
(PISD) may directly influence the physicochemical properties of a substance, 
including surface free energy, reactivity, conductivity and true density. For 
respirable drug particles, mechanically activated particles directly influence the 
interfacial free energy, which may directly affect particle interactions between 
the processed API and carrier particles. This instability may translate into an 
unacceptable degree of variability in the drug/formulation stability and in vitro 
performance as interfacial forces are instrumental to the aerosolisation of 
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powders (Frijlink and de Boer, 2004; Ganderton and Kassem, 1992). One of 
the approaches utilised to circumvent this problem is the introduction of post-
micronisation conditioning (Trofast et al., 1992; Brodka-Pfeiffer, Haeusler et al., 
2003). During this conditioning step, the rate of structural relaxation is critically 
dependant on the relative humidity and temperature during laagering (Brodka-
Pfeiffer, Haeusler et al., 2003). This process aims to dissipate the stored 
structural elastic strain energy and thereby aid relaxation of the micronised 
material. Accelerated stability conditions (temperature and relative humidity) 
have also been shown to expedite the dissipation of much of the stored 
mechanical energy and to stabilize particulate surfaces upon secondary 
processing (Liu, Rigsbee et al., 2002). Studies have shown that conditioning of 
micronised drug actives results in significant reduction in surface amorphous 
content, allowing greater control of batch-to-batch variations of material 
physicochemical properties (Brodka-Pfeiffer, Haeusler et al., 2003). The 
importance of post-micronisation conditioning is evidenced in the registration 
of a number of patents documenting the use of several conditioning steps 
involving humidity and temperature (Morton, Shott et al., 2008; Jakupovic and 
Trofast, 1998; Brodka-Pfeiffer, Grass et al., 2004; Trofast, 2000). 
Fluticasone propionate (FP) has an extremely low aqueous solubility (>100ng 
mL-1) (Davies and Feddah, 2003) due to its hydrophobic molecular nature 
(Magee, French et al., 2003). The hydrophobic nature of FP may hinder the re-
crystallisation of amorphous regions created upon micronisation. The aims of 
this study are therefore to study the dynamics by which FP undergoes stress 
relaxation as a function of elevated temperature and humidity. This study 
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investigates the changes in the cohesion and adhesion balance (CAB) of 
micronised FP particles and the impact that the new interfacial chemistry has 
on the in vitro performance. This work also assesses the use of a liquefied 
propellant, hydrofluoroalkane-134a (HFA), as a novel method of in situ post-
micronisation conditioning by suspending the drug particles in HFA in an 
attempt to expedite the stress relaxation for micronised FP particles.  
 
2.2 MATERIALS AND METHODS 
2.2.1 MATERIALS 
Freshly micronised FP (FP) was supplied by Chemagis (Bnei Brak, India). FP 
is a synthetic corticosteroid. It is chemically described as S-(fluoromethyl)6a,9-
difluoro-11b,17-dihydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17b-
carbothioate,17-Propionate. FP has a molecular mass of 500.57 and a 
molecular formula of C25H31F3O5S. A milled grade of lactose, ML001, was used 
throughout this study, supplied by DFE Pharma (Vehgel, Netherlands). All 
solvents used were of HPLC grade (Fisher Chemicals, Loughborough, UK). 
Ultra pure water was produced by reverse osmosis (MilliQ, Millipore, 
Molsheim, France).  
Hydrofluoroalkane 134a (HFA 134a) is an inert gas with a chemical name of 
1,1,1,2-Tetrafluoroethane. It has a molecular mass of 102.03 and a molecular 
formula of CH2FCF3. HFA 134a is a non-polar propellant widely used in 
aerosol products. HFA 134a was purchased from Mexichem, Cheshire, UK 
(Batch number 003215). 
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2.2.2 METHODS 
An initial 2 gram aliquot was taken from the freshly micronised FP for full 
physicochemical characterisation, formulation and testing for in vitro 
performance. In parallel to this, the remaining micronised FP was split into two 
ex situ post-micronisation conditioning arms. In one arm, the micronised FP 
was conditioned at a relative humidity of 75 % relative humidity and a 
temperature of 40◦C. At day 7 and 14, drug aliquots of 2 grams each, referred 
to hereunder as HT7 and HT14 were removed for characterisation, formulation 
and testing. In another conditioning arm, FP was conditioned at 60◦C and 
ambient relative humidity (33 %). After 48 and 72 hours, 2 gram drug samples, 
referred to as T48 and T72 were once again taken for characterisation, 
formulation and testing.  
In situ conditioning of the freshly micronised FP was conducted in parallel by 
placing 3 grams of FP in 90 grams of HFA 134a (Mexichem Fluor, Cheshire, 
UK). The HFA was controllably filled into a pressurised vessel and kept under 
pressure for 7 days. The vessel was subsequently de-pressurised at a rate of 
0.1 bar per minute. The HFA conditioned FP was dried in controlled ambient 
conditions (25◦C, 33 % RH) for 12 hours. All FP samples were sieved through 
a 500 µm mesh sieve prior to use. The study protocol for this study is tabulated 
in table 2.1. 
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Day 0 Initial 
FP Binary 
FP/SX Combination 
40◦C/75 % RH 
7 Days HT7 FP Binary & FP/SX  
14 Days HT14 FP Binary & FP/SX 
60◦C, 44 % RH 
48 Hours T48 FP Binary & FP/SX 
72 Hours T72 FP Binary & FP/SX 




2.2.2.1 Particle Size Analysis of FP 
Particle size distributions of all FP samples were measured in the wet state 
using a Sympatec HELOS and CUVETTE (Sympatec GmbH, Clausthal-
Zellerfeld, Germany) laser diffraction system using an R3 lens (0.5-175 μm). 
Approximately 10 mg of FP was suspended in HPLC grade cyclohexane 
containing 0.5 % w/v lecithin (Acros Organics, Geel, Belgium) and sonicated 
for 5 minutes and immediately transferred into a 50 mL cuvette to produce an 
appropriate optical concentration (8-12 %). Each measurement was performed 
in triplicate and particle size analysis was performed using WINDOX 5.0 
software (Sympatec GmbH, Clausthal-Zellerfeld, Germany).  
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2.2.2.2 Scanning Electron Microscopy of FP samples 
Particle morphology of all FP samples was investigated using scanning 
electron microscopy (SEM). Sample aliquots were fixed onto sticky carbon 
tabs (Agar Scientific, Cambridge, UK) followed by removal of excess powder 
using pressurised air.  Samples were subsequently sputter coated with gold 
(Edwards Sputter Coater S150B, Edwards High Vacuum, Sussex, UK) to 
achieve a thickness of approximately 20 nm. Imaging was performed using a 
scanning electron microscope (JEOL JSM6480LV, Tokyo, Japan) using 15 kV 
accelerating voltage. 
 
2.2.2.3 X-ray powder diffraction (XRPD) analysis of FP samples 
The X-ray powder diffraction (XRPD) patterns of FP samples were analysed on 
a Bruker Powder Diffractometer (D8; Bruker AXS Inc., Madison, USA) using 
CuKα radiation (λ=1.54 Å). The data were collected over a single 2θ sweep 
with range 2θ = 5 - 30° and a step size of 0.025°/step with a step time of 1.5 s. 
 
2.2.2.4 Differential Scanning Calorimetry of FP samples 
The thermal properties of all samples were investigated using a differential 
scanning calorimeter (DSC 2920, TA Instruments, Surrey, UK), calibrated with 
an indium standard. Approximately 3 mg of sample were accurately weighted 
into an aluminium pan and crimped with a lid to form a hermetic seal. The 
sample and reference pan were heated at a rate of 10◦C/min from 30◦C to 
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350◦C. The calorimeter head was continuously flushed with dry nitrogen gas at 
0.2 L/min during all measurements.  
 
2.2.2.5 Methodology of the CAB approach to colloid probe AFM 
2.2.2.5.1  Crystallisation of substrates 
To perform quantitative binary and combination AFM-CAB analysis of 
secondary processed FP samples, smooth single crystal surfaces of FP, 
salmeterol xinafoate (SX) and lactose monohydrate were produced. Briefly, 
saturated solutions of FP in 2 ml of acetone were prepared and sonicated prior 
to filtration via a 0.22-µm PTFE membrane filter (Whatman Inc., Clifton, NJ, 
USA). FP was crystallised using water as the anti-solvent. Briefly, a 
microscope cover slip (12 mm x 12 mm) was supported on a vertical post in a 
crystallisation dish that contained the anti-solvent. A droplet of the saturated 
solution of the API was then placed on the coverslip using a syringe attached 
to the 0.22-µm-membrane filter. The system was sealed by inverting a glass lid 
in the crystallisation dish to allow vapour phases of the miscible solvents to 
come into equilibrium resulting in heterogeneous nucleation and crystal growth 
within the droplet. The glass cover slip was then attached to a magnetic AFM 
stub.  
Lactose and SX were crystallized upon introduction of saturated droplets 
between two glass cover slips. Smooth lactose crystals were generated upon 
preparing a solution of lactose (1 gm-1) in double-distilled water, which was 
heated to 100 °C with constant stirring. The heated saturated droplet of the 
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solution was filtered through a 0.2 μm PTFE membrane filter (Whatman Inc., 
Clifton, NJ, USA) and placed on to the centre of a clean cover slip, which was 
then sandwiched by placing another cover slip over the droplet. Similarly, a 
solution of SX (0.75 gm-1) was prepared in methanol following sonication for 30 
mins, following which the solution was filtered through a 0.2 μm PTFE 
membrane filter and a droplet of this solution was then sandwiched between 
two coverslips. The resulting crystals of lactose or SX were then isolated upon 
cleaving the coverslips apart and attaching each coverslip to a magnetic AFM 
stub.  
2.2.2.5.2  Colloidal probe force measurements 
Prior to colloidal force measurements, individual particles from each sample of 
FP were attached onto standard V-shaped tipless cantilevers with pre-defined 
spring constants (DNP-020, DI, CA, USA) using an epoxy resin glue (Araldite, 
Cambridge, UK). Five probes were prepared for the as received, LH, HH and 
HT conditioned FP samples at each pre-defined laagering stage. All probes 
were examined with an optical microscope (magnification 50x) to ensure the 
integrity of the attached particle, before allowing the thin layer of glue to cure 
and dry.  
Single crystal substrates were loaded onto an AFM scanner stage, which was 
enclosed in a custom-built environmental chamber, in which the ambient 
conditions were maintained at a constant temperature of 25 °C (± 1.5 °C) and 
relative humidity of 35 % RH (± 3 %). The interaction forces were measured by 
recording the deflection of the AFM cantilever as a function of the substrate 
displacement (z) by applying Hooke’s Law. Individual force curves (n = 1024) 
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were conducted over a 10 µm x 10 µm area at a scan rate of 4 Hz and a 
compressive load of 40 nN.  
A custom-built software was developed to extract data contained within each 
force-volume dataset. These data was analyzed to ensure normal distribution, 
indicating uniform contact area between the drug probe and the smooth 
substrate surfaces. Arithmetic mean and standard deviation were measured to 
produce CAB plots for the interactions of the different batches of FP with both 
lactose monohydrate and SX.  
2.2.2.6 Preparation of powder formulations 
Binary formulation blends (1.0 % w/w) were manufactured using the initial FP 
aliquot and each of the conditioned FP samples (HT7, HT14, T48 and T72). 
These blends were manufactured by the sequential addition of the drug to the 
milled lactose (ML001) followed by low shear blending using a T2F Turbula® 
mixer (Wily A Bachofen AG, Basel, Switzerland) for 45 minutes at 46 rpm. 
Combination formulations containing FP (1.0 % w/w) and SX (0.2 % 
w/w) (Merck 
Generics, Potters Bar, UK) were also manufactured using the same method for 
each of the FP samples; Initial, HT7, HT14, T48 and T72.  
A fill weight of 25 ± 1 mg of each blend was loaded into size 3 
hydroxypropylmethyl cellulose (HPMC, Shionogi Qualicaps, Madrid, Spain) 
capsules. The loaded dose for the FP binary formulations was 250µg of FP per 
25 mg fill weight. For the FP SX combination formulations, the loaded doses 
were 250 µg of FP and 50 µg of SX per 25 mg fill weight. The capsules were 
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stored at 44 % RH for 24 hours prior to in vitro testing to ensure the dissipation 
of any electrostatic charges introduced during processing. 
2.2.2.7 In vitro aerosolisation studies 
In vitro testing was performed using a Next Generation Impactor (NGI, Copley 
Scientific, Nottingham, UK) with a pre-separator, connected to two vacuum 
pumps to create sonic flow (GE Motors). The pre-separator contained 15 ml of 
mobile phase. The NGI cups were coated with 1 % v/v silicone oil in hexane to 
eliminate any particle bounce. For each experiment, two individual 25 mg 
capsules of the same blend were discharged into the NGI at 55 L/min for 4.4 s, 
equivalent to a total volume of 4 L, from a Rotahaler® DPI device (Cipla, 
Mumbai, India). Before each test, the flow rate was verified with a flow meter 
(DFM 2000, Copley Scientific, Nottingham, UK). The amount of API deposited 
on each part of the NGI was determined by high pressure liquid 
chromatography (HPLC). This testing protocol was repeated three times for 
each blend, following which, the mass median aerodynamic diameter (MMAD) 
geometric standard deviation (GSD), fine particle dose less than 5.0 μm (FPD) 
and fine particle fraction (FPF) were determined.  
 
2.2.2.8 HPLC analysis of FP and SX 
The drug content was detected and quantified using HPLC. For the 
determination of drug content in FP binary formulations, the HPLC method 
consisted of a pump coupled to an auto-sampler and multi-wavelength UV 
detector (Agilent 1200, Wokingham, UK) set at 235 nm. The pump flow rate 
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was set to 1.5 mL/min through a Hypersil ODS-C18 column (Fisher Scientific, 
Loughborough, UK, column length 250 mm, internal diameter 4.6 mm, and 
particle size of the packing material 5 m), which was placed in a column oven 
(Agilent, Wokingham, UK) set to 40°C. The mobile phase consisted of 
methanol, acetonitrile and water (45:35:20 % v/v). The elution time for the FP 
peak using this method was 3.4 minutes. For the drug content determination of 
FP SX combination formulations, the HPLC method used a flow rate of 1.0 
mL/min through a Hypersil BDS-C18 column (Fisher Scientific, Loughborough, 
UK, column length 250 mm, internal diameter 4.0 mm, and particle size of the 
packing material 5 m) placed in a column oven set at 40°C. The mobile phase 
consisted of 75:25 % v/v methanol:0.6 % aqueous ammonium acetate.   
For both methods, linear regression analysis was used for the assessment of 
the HPLC calibration. Quantiﬁcation was carried out by an external standard 
method, and linearity was verified between 0.05 and 50 g/mL. The limit of 
detection was 0.02 g/mL and 0.03 g/mL for both FP and SX respectively.   
 
2.2.2.9 Statistical analysis 
Linear regression analysis was used for the assessment of HPLC calibration. 
Statistical analysis between different populations carried out using one-way 
analysis of variance. Comparison of the mean values was performed by 
Tukey’s multiple comparison. All statistical analyses were performed using 
GraphPad Prism software (GraphPad Software Inc, California, USA). Error 
bars in graphical representations of data show ± standard deviation (s.d.) in all 
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cases. 
   
2.3 RESULTS AND DISCUSSION 
In order to investigate the influence of post-micronisation conditioning on the 
dynamics of the mechanical stress relaxation of micronised FP, conditioned 
samples were analysed for physicochemical changes. Measurements of the 
functional influence of conditioning on the surface interfacial properties of 
conditioned FP samples with both lactose and SX substrate surfaces were 
recorded by colloidal probe CAB-AFM. The in vitro performance of 
formulations manufactured using the different FP samples was studied in 
relation to the CAB values.  
 
2.3.1 Physicochemical characterisation for FP sample 
The XRPD profiles for the initial, HT14 and T72 FP samples are shown in 
Figure 2.1. The comparison of these patterns shows the presence of distinct 
peaks throughout the diffractograms, suggesting that all FP samples were of 
the same polymorphic form. This suggests that the polymorphic form for FP 
samples is not affected by the post-micronisation conditioning used within this 
study.  
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Figure 2.1    X-ray powder diffraction profiles for the Initial, HT14 and 
T72 FP samples 
 
Representative DSC thermographs of the initial, HT14 and T72 FP, shown in 
Figure 2.2, also suggested the insensitivity of polymorphic form to conditioning. 
Thermal analysis of all conditioned samples (intermediate time points data not 
shown) indicated that all samples had an onset of melt at approximately 295 
°C, which was related to the melting of polymorphic form I of FP 
(Pitchayajittipong, Shur et al.). The initial FP sample does exhibits an 
exothermic response in a region preceding the melting phase, which may 
suggest the presence of amorphous content in the FP sample. This response 
is visibly reduced in the HT14 and T72 samples, suggesting that both ex situ 
post-micronisation conditioning may reduce the amorphous content present in 
the FP sample to some degree.  
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Figure 2.2   Differential Scanning Calorimetry thermographs for the 
Initial, HT14 and T72 FP samples 
 
Particle size distribution analyses of all the FP samples handled throughout 
this study are tabulated in Table 2.2. The d10, d50 and d90 values show a high 
degree of physical stability upon post-micronisation conditioning. All particle 
size results suggest suitability for DPI formulations (Frijlink and de Boer, 2004). 
Inspection of SEM images shown in Figure 2.3 confirms that all FP samples 
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 d10 (µm) d50 (µm) d90 (µm) 
Initial 0.74 ±0.02 1.79 ±0.03 3.67 ±0.01 
T48 0.74 ±0.01 1.81 ±0.02 3.68 ±0.01 
T72 0.73 ±0.03 1.81 ±0.01 3.66 ±0.02 
HT7 0.74 ±0.01 1.79 ±0.01 3.64 ±0.02 
HT14 0.73 ±0.02 1.77 ±0.03 3.61 ±0.02 
 
Table 2.2   Particle Size Distribution data for the micronised and subsequently 
conditioned FP determined by laser diffraction 
 
 
Figure 2.3   Scanning Electron Micrographs for the initial FP aliquot 
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2.3.2 Surface Interfacial Properties of FP Samples 
Table 2.3 tabulates the influence that post-micronisation conditioning has on 
the surface interfacial chemistry of the FP samples. Figures 2.4 and 2.5 show 
the linear regression analysis of the CAB plots with respect to lactose and SX 
respectively. The CAB ratios were determined from the gradient of each plot.  
The balance of the interaction forces between FP and lactose particles are 
described in Table 2.3 as the CAB values with respect to lactose. The initial FP 
sample shows a slightly cohesive nature, indicating a preference for the FP 
particles to adhere to themselves rather than to the lactose particles. The 
conditioning of this sample failed to impose highly significant shifts to the 
nature of its interfacial chemistry, however, an opposing trend emerged from 
the different conditioning environments. Whilst the post-micronisation 
conditioning of FP samples in an environment set at 40◦C and 75 % RH 
showed no significant changes in terms of interfacial chemistry, conditioning at 
60◦C provoked a significant (p<0.05) trend towards a less cohesive behaviour 
of the FP particles. There was no significant difference after conditioning for 48 
hours (T48), however the T72 sample exhibited a significantly less cohesive 
behaviour than all the other samples. Figure 2.4A and 2.4B show the CAB 
plots with respect to lactose for the HT(7, 14) and T(48, 72) FP samples. 
These figures show how besides the adhesive-driven trend described 
previously, the samples conditioned at 60◦C seem to exhibit higher adhesive 
and cohesive forces.  
The CAB values for FP particles with respect to SX (Table 2.3) show a higher 
sensitivity to conditioning. The initial FP sample exhibited a slightly adhesive 
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nature, suggesting that the FP particles are slightly more inclined to interact 
with the SX particles. Conditioning at 60◦C magnified this adhesive nature by 
imposing a very significant (p<0.02) adhesive-driven trend. After 72 hours of 
conditioning the FP samples at 60◦C, the possibilities of FP particles interacting 
with SX particles are 1.54 times higher than that of an FP-FP interaction 
occurring. The HT samples on the other hand demonstrate a slight cohesive-
driven trend. Both HT7 and HT14 exhibit a predominantly cohesive behaviour. 
This significant (p<0.02) shift suggests that the FP particles were more likely to 
interact with themselves rather than with SX particles. The linear regression 
CAB plots (Figure 2.5A and 2.5B) with respect to SX for the conditioned FP 
particles illustrate the significantly (p<0.001) higher forces of adhesion for the 
T48 and T72 samples. Over a period of 72 hours, the forces of adhesion 
between the Initial and T72 FP samples have tripled. These drastic changes in 
adhesion forces are possibly due to surface changes to the FP particles which, 
in turn, influence the manner in which the FP particles interact with surrounding 
particles.    
Table 2.3   Cohesive-Adhesive Balance (CAB) values with respect to Lactose 
and SX for all FP samples 
  CAB w.r.t Lactose CAB w.r.t SX 
Freshly Micronised Initial 1.18 ±0.02 0.95 ±0.02 
60◦C 
T48 1.15 ±0.03 0.82 ±0.02 
T72 1.05 ±0.04 0.65 ±0.03 
40◦C / 75 % RH 
HT7 1.21 ±0.02 1.05 ±0.01 
HT14 1.20 ±0.03 1.10 ±0.04 
 





Figure 2.4   (A) Cohesive-Adhesive Balance (CAB) plot of initial,  T48 
and T72 FP samples with respect to lactose, (B) CAB plot of initial, 
HT7 and HT14 FP samples with respect to lactose  
 
  
Figure 2.5   (A) Cohesive-Adhesive Balance (CAB) plot of initial, T48 
and T72 FP samples with respect to SX, (B) CAB plot of initial, HT7 
and HT14 FP samples with respect to SX 
 
The sensitivity of the interfacial chemistry to post-micronisation conditioning is 
illustrated in Figure 2.6 both in terms of both FP-SX and FP-lactose 
A B 
A B 
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interactions. Whilst particulate interactions between FP and SX particles varies 
between a slightly cohesively-led system (1.10 ±0.04) and a highly dominant 
adhesive one (0.65 ±0.03), the interfacial chemistry describing the interactions 
between FP and lactose suggests a very low sensitivity towards conditioning. 
The lower sensitivity of FP-lactose interactions towards conditioning is 
probably due to the size difference between the particles in question. This 
suggests that surface chemistry changes to the FP particles materialise into 
functional changes more readily when present in a system containing particles 
of similar size. 
 
 
Figure 2.6   CAB values plotted against conditioning parameters T72 
(72 hours at 60 ◦C), T48 (48 hours at 60 ◦C), Initial (freshly micronised), 
HT7 (7 days at 40 ◦C/75 % RH), and HT14 (14 days at 40 ◦C/75 % RH) 
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2.3.3 In vitro performance of FP samples in a binary formulation 
The in vitro performance of the FP samples in a binary formulation is 
summarised in Table 2.4. There is a significant (p<0.02) and constant drop in 
the FPF for the T48 and T72 formulations. This dip in performance is 
consistent with the adhesive-driven trend seen in the CAB results for these 
samples with respect to lactose. The increasing affinity of the FP particles to 
adhere to the lactose carrier impedes the aerosolisation efficiency of the FP 
particles. The overall FPF increase in the HT formulation is statistically 
insignificant. However, qualitatively, these increases can be attributed to an 
increase in the cohesive nature of the FP particles, a cohesive-driven trend 
which although statistically insignificant, has been observed previously in CAB 
values. 
 
 RD (µg) ED (µg) FPM (µg) FPF (%RD) MMAD (µm) GSD (µm) 
Initial 224.27 ±6.04 133.47 ±3.90 34.58 ±0.62 15.42 ±0.14 3.9 ±0.00 2.1 ±0.00 
T48 230.18 ±12.99 147.2 ±17.69 30.56 ±1.09 13.28 ±0.12 4.43 ±0.06 2.1 ±0.00 
T72 256.55 ±16.47 136.58 ±19.49 31.76 ±0.97 12.38 ±0.16 4.3 ±0.17 2.27 ±0.06 
HT7 241.19 ±6.53 168.04 ±3.98 41.16 ±2.68 17.06 ±0.24 4.2 ±0.00 2.0 ±0.00 
HT14 223.47 ±5.54 156.3 ±3.35 36.43 ±7.99 16.19 ±2.50 4.27 ±0.06 2.1 ±0.00 
 
Table 2.4   In vitro aerosolisation performance for FP formulations produced 
using initial, T48, T72, HT7 and HT14 FP. Results are described by the recovered 
dose (RD), emitted dose (ED), fine particle mass (FPM), fine particle fraction 
(FPF) expressed as a percentage of the recovered dose, mass median 
aerodynamic diameter (MMAD) and geometric standard deviation (GSD) 
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Figure 2.7    Fine Particle Fraction (FPF) of FP binary formulations 
expressed as a percentage of the Recovered Dose (RD) plotted 
against the CAB of FP particles with respect to lactose 
 
Figure 2.7 illustrates the relationship between drug-carrier CAB ratios and the 
performance of the FP formulations. The opposite trends that the T and HT 
formulations follow have been discussed previously. What emerges from 
Figure 2.7 is that notwithstanding the significant (p<0.02) trend seen in the 
FPF of the FP formulations, the extent to which the in vitro performance of the 
FP relates to the changes in the forces of interactions between the FP particles 
and the carrier is limited. This clustered data set may suggest the presence of 
a buffer zone when the balance of cohesive and adhesive forces for FP and 
lactose is one that indicates a slightly cohesive nature. 
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Figure 2.8   Stage by stage deposition profile expressed as the 
percentage of drug deposited per stage for FP in binary formulations; 
initial, T48 and T72 
 
 
Figure 2.9   Stage by stage deposition profile expressed as the 
percentage of drug deposited per stage for FP in binary formulations; 
initial, HT7 and HT14 
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2.3.4 In vitro performance of FP samples in a combination formulation 
with SX 
Table 2.5 tabulates the in vitro performance results for the FP samples in 
combination based formulations with SX. For all conditioning samples there is 
a significant (p<0.02) drop in FPF with respect to the Initial formulation. 
Furthermore, the significant (p<0.02) increase in MMAD values suggests that 
drug-drug agglomeration is taking place. The possible presence of these 
agglomerates together with the drop in the FPF for the formulations 
manufactured using conditioned FP samples could be interpreted in context of 
the balance between the cohesive and adhesive forces governing the 
interactions between the FP and SX particles.  
 
 RD (µg) ED (µg) FPM (µg) FPF (%RD) MMAD (µm) GSD (µm) 
Initial 236.02 ±8.48 160.17 ±5.29 42.3 ±0.37 17.94 ±0.74 3.93 ±0.15 2.03 ±0.12 
T48 276.11 ±16.14 192.14 ±5.84 41.98 ±0.76 15.2 ±0.23 4.5 ±0.10 2.17 ±0.06 
T72 326.12 ±14.01 183.42 ±4.14 43.78 ±1.51 13.43 ±0.53 4.23 ±0.12 1.97 ±0.06 
HT7 305.76 ±1.13 169.47 ±1.13 45.04 ±1.05 14.73 ±0.18 4.07 ±0.12 2.07 ±0.06 
HT14 326.8 ±1.03 179.87 ±0.60 41.99 ±1.44 12.85 ±0.53 4.43 ±0.06 1.93 ±0.06 
 
Table 2.5   In vitro aerosolisation performance for FP in combination 
formulations with SX produced using initial, T48, T72, HT7 and HT14 FP. Results 
are described by the recovered dose (RD), emitted dose (ED), fine particle mass 
(FPM), fine particle fraction (FPF) expressed as a percentage of the recovered 
dose, mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) 
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Figure 2.10    Fine Particle Fraction (FPF) of FP in combination 
formulation with SX expressed as a percentage of the Recovered Dose 
(RD) plotted against the CAB of FP particles with respect to SX 
 
Figure 2.10 illustrates the correlation between the drop in FPF for FP and the 
CAB values for the conditioned FP particles and their corresponding 
formulations. The steady increase in the adhesive nature of the FP particles 
conditioned in an environment set at 60◦C points towards an increasing affinity 
between the FP and SX particles. This increase may lead to the formation of 
FP-SX agglomerates, resulting in drug agglomerates which are unable to 
gather the required inertial force to leave the capsule and device. This is 
evidenced by the significant (p<0.001) increase in the percentage of drug 
deposits seen for the T72 formulation on these very stages (figure 2.11). The 
HT FP particles on the other hand, exhibited a cohesive-driven trend in their 
interfacial chemistry, suggesting an increase in the FP-FP interactions over 
FP-SX. The shift, from an overall adhesive system to a system dominated by 
cohesive forces, suggested the presence of an increased amount of FP-FP 
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agglomerates. These agglomerates once again contributed to a drop in the 
FPF. This drop is evidenced in the significant increase of drug deposits in the 
capsule-holding device for both HT7 and HT14 formulations seen in the stage 
by stage analysis (figure 2.12). 
 
 
Figure 2.11   Stage by stage deposition profile expressed as the 
percentage of drug deposited per stage for FP in combination 
formulations with SX; initial, T48 and T72 
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Figure 2.12   Stage by stage deposition profile expressed as the 
percentage of drug deposited per stage for FP in combination 
formulations with SX; initial, HT7 and HT14 
 
2.3.5 In vitro performance of SX in a combination formulation with FP 
samples 
The aerosolisation performance results for a single sourced batch of SX in 
combination formulations with the FP samples used throughout this study are 
tabulated in table 2.6. Figure 2.13 shows the correlation of the FPF for SX with 
the CAB values of the FP particles used in the manufacture of these 
formulations with respect to SX. The FPF for SX in these combination 
formulations with the FP samples follow opposing trends for the two different 
environments used to condition the FP samples following micronisation. T48 
and T72 formulations aerosolise significantly (p<0.02) more efficiently than the 
initial FP sample formulation. Interestingly, there is no significant difference 
between the FPF for T48 and T72. The HT samples on the other hand 
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followed an inverted trend, with the FPF for SX dropping significantly for both 
HT7 and HT14.  
 RD (µg) ED (µg) FPM (µg) FPF (%RD) MMAD (µm) GSD (µm) 
Initial 97.53 ±3.99 81.21 ±5.04 16.92 ±0.58 17.36 ±0.39 2.27 ±0.06 2.0 ±0.17 
T48 93.44 ±10.38 73.43 ±10.69 17.99 ±0.81 19.24 ±0.56 2.6 ±0.00 2.2 ±0.10 
T72 85.96 ±10.08 56.91 ±12.09 17.06 ±0.15 19.88 ±1.02 2.43 ±0.06 2.07 ±0.06 
HT7 103.91 ±2.50 55.49 ±1.32 14.4 ±0.35 13.87 ±0.28 2.5 ±0.17 2.37 ±0.06 
HT14 112.76 ±2.49 64.33 ±0.80 14.47 ±1.92 12.79 ±0.94 2.7 ±0.10 2.1 ±0.00 
 
Table 2.6   In vitro aerosolisation performance for SX in combination 
formulations with FP produced using initial, T48, T72, HT7 and HT14 FP. Results 
are described by the recovered dose (RD), emitted dose (ED), fine particle mass 
(FPM), fine particle fraction (FPF) expressed as a percentage of the recovered 




Figure 2.13    Fine Particle Fraction (FPF) of SX in combination 
formulation with FP expressed as a percentage of the Recovered Dose 
(RD) plotted against the CAB of FP particles with respect to SX 
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Figure 2.13 illustrates these opposing FPF trends for SX with the CAB values 
for FP with respect to SX. The relation between the HT samples and the CAB 
values is consistent with the agglomeration theory discussed previously for the 
performance of FP in combination with SX. The FPF for SX drops as the 
interfacial chemistry of the formulation becomes cohesive, suggesting that SX 
may prefer an adhesive tendency to the FP, as suggested by Jones et al. 
(2008).  
The increasing adhesive nature of the FP particles conditioned at 60◦C with SX 
suggests the formation of stable FP-SX agglomerates. Whilst these 
agglomerates can impede capsule and device emptying as evidenced by the 
increasing amount of SX deposits in the device (figure 2.14), an increase in the 
affinity of the two APIs significantly improved the aerosolisation of the lower 
dose of SX from the lactose carrier significantly (p<0.02) as evidenced by the 
significant decrease in the amount of SX deposited in the pre-separator (figure 
2.14).     
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Figure 2.14   Stage by stage deposition profile expressed as the 
percentage of drug deposited per stage for SX in combination 
formulations with FP; initial, T48 and T72 
 
 
Figure 2.15   Stage by stage deposition profile expressed as the 
percentage of drug deposited per stage for SX in combination 
formulations with FP; initial, HT7 and HT14 
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2.3.6 Assessment of the FP sample following post-micronisation in situ 
conditioning using HFA-134a 
2.3.6.1 Physicochemical Characterisation 
Figure 2.16 shows the XRPD profiles for the initial and HFA-conditioned FP 
samples. The distnctive peaks present suggested that the polymorphic form for 
the FP sample conditioned in situ with HFA-134a remained unchanged.  
 
Figure 2.16    X-ray powder diffraction profiles for the Initial and HFA 
FP samples 
 
The representative DSC thermographs for the initial and HFA-conditioned 
samples are shown in figure 2.17. The thermal analysis showed both FP 
samples having a melting onset of 295 °C, which was related to the melting of 
polymorphic form I of FP (Pitchayajittipong, Shur et al.). The isotherm for the 
initial FP sample shows an endotherm in the crystallisation region preceding 
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the melting phase, which suggests the presence of amorphous content in the 
FP sample. The absence of this endotherm in the thermal analysis of the HFA 
sample suggests that the in situ conditioning may have re-crystallised any 
process induced structural disorder in the initial FP sample.  
 
Figure 2.17   Differential Scanning Calorimetry thermographs for the 
Initial and HFA FP samples 
 
Table 2.7 shows the particle size distribution for the initial and the HFA 
conditioned FP samples. The d10, d50 and d90 values suggest a significant 
(p<0.02) increase in the particle size of the FP particles upon in situ 
conditioning with HFA. This increase may relate to the low solubility of FP  
within HFA-134a (approx. 9.6 µg/ml) which may cause the fine fraction of FP 
particles to dissolve. However, with a d90 value of 4.45 µm, the FP drug 
particles conditioned using HFA are nonetheless suitable for DPI formulations 
(Frijlink and de Boer, 2004). The SEM images shown in Figure 2.18 suggest 
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similar shape and sized particles between initial and HFA samples. However, 
in situ conditioning appeared to reduce the degree of surface roughness of the 
micronised particles, which may relate to the slight dissolution of FP in HFA-
134a.  
  d10 (µm) d50 (µm) d90 (µm) 
Initial 0.74 ±0.02 1.79 ±0.03 3.67 ±0.01 
HFA 0.92 ±0.02 2.24 ±0.04 4.45 ±0.03 
 
Table 2.7   Particle Size Distribution data for the freshly micronised and HFA 








Figure 2.18   Scanning Electron Micrographs for the initial FP aliquot 
(A, B) and the HFA conditioned sample (C, D) 
A B 
C D 
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2.3.6.2 Surface Interfacial Properties of FP Samples 
Table 2.8 tabulates the cohesive and adhesive balance following in situ 
conditioning of FP with HFA. Figures 2.19A and 2.19B show the linear 
regression analysis of the CAB plots with respect to lactose and SX 
respectively. The CAB ratios were determined from the gradient of each plot.  
The CAB values shown in table 2.8 suggest that HFA conditioning did not alter 
the interfacial properties of the FP particles. The CAB results for the initial FP 
sample with respect to lactose suggest an interfacial chemistry with a slightly 
cohesive nature (1.18 ±0.02). Following in situ conditioning with HFA for 7 
days, the FP particles seem to maintain an unchanged balance between the 
cohesive and adhesive forces (1.15 ±0.04), showing no statistical difference 
from the initial FP sample. Figure 2.19A however, shows a significant (p<0.05) 
decrease in the forces constituting these CAB values. This decrease in the 
magnitude of forces, whilst maintaining a cohesive balance, suggests physical 
changes to the particle surfaces may occur. 
  CAB w.r.t Lactose CAB w.r.t SX 
Freshly Micronised Initial 1.18 ±0.02 0.95 ±0.02 
HFA HFA 1.15 ±0.04 0.90 ±0.04 
 
Table 2.8   Cohesive-Adhesive Balance (CAB) values with respect to Lactose 
and SX for the initial and HFA conditioned FP samples   
 
The CAB values for the initial FP particles with respect to SX suggested an 
interfacial chemistry dominated by adhesive forces (0.95 ±0.02). Once again, 
the HFA FP sample showed no significant differences from the initial sample 
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(0.90 ±0.04), retaining a slight adhesively-led interfacial system. Figure 2.19B 




Figure 2.19   (A) Cohesive-Adhesive Balance (CAB) plot of initial and 
HFA FP samples with respect to lactose, (B) CAB plot of initial and 
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2.3.6.3 In vitro performance of FP samples following in situ HFA conditioning 
 
 RD (µg) ED (µg) FPM (µg) FPF (%RD) MMAD (µm) GSD (µm) 
FP Binary 
Initial 224.27 ±6.04 133.47 ±3.90 34.58 ±0.62 15.42 ±0.14 3.9 ±0.00 2.1 ±0.00 
HFA 319.92 ±11.45 199.79 ±10.68 49.67 ±2.43 15.44 ±0.93 4.03 ±0.31 2.07 ±0.15 
FP in Combination with SX 
Initial 236.02 ±8.48 160.17 ±5.29 42.3 ±0.37 17.94 ±0.74 3.93 ±0.15 2.03 ±0.12 
HFA 230.59 ±10.16 187.3 ±14.18 40.42 ±2.78 17.56 ±1.35 4.43 ±0.21 2.0 ±0.17 
SX in Combination with FP 
Initial 97.53 ±3.99 81.21 ±5.04 16.92 ±0.58 17.36 ±0.39 2.27 ±0.06 2.0 ±0.17 
HFA 86.34 ±9.01 73.65 ±9.17 15.6 ±0.91 18.08 ±0.31 2.63 ±0.25 2.1 ±0.20 
 
Table 2.9   In vitro aerosolisation performance for formulation manufactured using the initial and the HFA conditioned FP 
samples. Results are described by the recovered dose (RD), emitted dose (ED), fine particle mass (FPM), fine particle fraction 
(FPF) expressed as a percentage of the recovered dose, mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) 
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Table 2.9 shows the in vitro performance of binary and combination based 
formulations manufactured using FP particles conditioned using HFA. Results 
suggest that there are no statistically significant differences between the 
performances of formulations manufactured using freshly micronised FP 
(Initial) and those manufactured using HFA-conditioned FP. These data are 
consistent with the CAB results which suggest that the way in which the FP 
particles interact with the lactose and the SX particles is unchanged between 
the initial and the HFA-conditioned FP sample. Figures 2.20-2.22 show the 
FPF of the formulations manufactured using the HFA conditioned FP in 
relation to the other FP samples used in this study, showing a very close 
relation between the interfacial chemistry and the in vitro performance. 
 
Figure 2.20   Fine Particle Fraction (FPF) of FP in a binary formulation 
manufactured using HFA conditioned FP particles shown in context 
of similar formulations manufactured using freshly micronised FP 
and ex situ conditioned FP as described previously, expressed as a 
percentage of the Recovered Dose (RD) plotted against the CAB of FP 
particles with respect to lactose 
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Figure 2.21    Fine Particle Fraction (FPF) of FP in a combination 
formulation with SX manufactured using HFA conditioned FP 
particles shown in context of similar formulations manufactured 
using freshly micronised FP and ex situ conditioned FP as described 
previously, expressed as a percentage of the Recovered Dose (RD) 
plotted against the CAB of FP particles with respect to lactose 
Figure 2.22    Fine Particle Fraction (FPF) of SX in a combination 
formulation with FP manufactured using HFA conditioned FP 
particles shown in context of similar formulations manufactured 
using freshly micronised FP and ex situ conditioned FP as described 
previously, expressed as a percentage of the Recovered Dose (RD) 
plotted against the CAB of FP particles with respect to lactose 
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2.4 CONCLUSIONS 
The results shown in this study suggest that whilst ex situ and in situ post-
micronisation conditioning does not alter the polymorphic form of FP, 
conditioning appears to directly influence the physical and interfacial chemistry 
of micronised FP. It was shown that the interfacial chemistry of the FP 
particles with respect to SX changes significantly upon post-micronisation 
conditioning, with temperature imposing an adhesive-driven trend whilst 
humidity shifts the adhesive FP particles to a cohesively-led system. The in 
vitro performance of the formulations followed the relevant changes to the 
interfacial properties of FP, with the FPF of SX also being affected by the 
changing properties of the FP particles.  The similarity in the in vitro results 
seen between the initial and HFA-conditioned sample suggests that the stress 
relaxation pathway taken during in situ conditioning with HFA promotes 
interfacial stability.  The differences seen in both the interfacial properties of 
FP and the FPF of all the formulations highlight the importance for a better 
understanding and control on the stress relaxation of FP particles following 
micronisation.  
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3 THE INFLUENCE OF SECONDARY PROCESSING ON THE 




Particle size reduction of active pharmaceutical ingredients (APIs) for delivery 
to the lungs requires secondary processing of primary crystals using highly 
energetic comminution techniques, such as air-jet micronisation (Kubavat et 
al., 2012). For brittle materials, particle-particle and particle-wall collisions 
within a microniser often leads to the formation of short-lived defects formed 
along existing flaws within a crystalline lattice that can lead to crystal fracture 
(Ward and Schultz, 1995; Joshi et al., 2002). However, at the brittle-ductile 
transition, the material absorbs a significant amount of impact energy before 
undergoing any further particle reduction (Huttenrauch et al., 1985). This 
impact energy is stored as strain energy within the crystalline lattice in the 
form of structural defects, dislocations and, at the limit, can lead to localized 
amorphous regions on a particle surface (Huttenrauch et al., 1985; Brodka-
Pfeiffer et al., 2003a; Shur et al., 2013). 
 
Process induced structural disorder can lead to uncontrolled thermodynamic 
changes to the materials, and is commonly described as “mechanical 
activation” (Wildfong et al., 2006; Huttenrauch et al., 1985; Brodka-Pfeiffer et 
al., 2003a; Shur et al., 2013). Mechanical activation may directly influence the 
physicochemical properties of a substance, for example, surface free energy, 
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reactivity, conductivity and true density (Shur et al., 2013; Colombo et al., 
2009). For carrier-based dry powder inhaler (DPIs) formulations, mechanical 
activation can directly influence the interfacial free energy of the respirable 
drug particles (e.g. < 5 µm), which may increase the tendency for 
agglomeration. This may also affect the relative magnitude of the cohesive 
(drug-drug) and adhesive (drug-excipient) inter-particulate forces. Since the 
performance of adhesive mixtures is a function of the relative magnitude of 
these forces, the interfacial properties of secondary processed APIs can 
dominate blending dynamics, formulation microstructure and ultimately drug 
product quality and performance of carrier-based DPI formulations (Shur et 
al., 2013).   
 
Mechanically activated particles are thermodynamically unstable and are 
driven to undergo structural relaxation to a more stable state (Huttenrauch et 
al., 1985; Brodka-Pfeiffer et al., 2003a). Structural relaxation kinetics has been 
shown to be strongly dependent on environmental conditions (temperature 
and relative humidity), which may influence the degree of molecular mobility 
within the material, and the period of exposure to such conditions (Brodka-
Pfeiffer et al., 2003a; Shur et al., 2013). The laagering or quarantine period 
required for materials to undergo structural relaxation may vary significantly 
from minutes, hours to months and appears to be highly dependent on their 
hydrophilic/hydrophobic nature (Huttenrauch et al., 1985; Shur et al., 2013).  
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Accelerated stability conditions of both temperature and relative humidity have 
been shown to expedite the rate of structural relaxation and may aid in 
stabilization of particulate surfaces upon secondary processing (Shur et al., 
2013; Brodka-Pfeiffer et al., 2003b). Studies have also shown that post-
micronisation relaxation may significantly reduce the levels of localized 
amorphous disorder, and the tendency for micronised particles to aggregate 
(Brodka-Pfeiffer et al., 2003b). The use of post-micronisation environmental 
conditioning appears to be widely applied to hydrophilic compounds (Bender 
et al., 2004; Riebe et al., 2003; Muhrer et al., 2012). For example, micronised 
tiotropium bromide monohydrate was exposed to the conditions of 70-80 % 
RH and 25-30 C for up to 28 hours on sheet metal racks prior to formulating 
as a DPI product (Bender et al., 2004). The structural relaxation of the 
conditioned tiotropium bromide monohydrate is characterized by measuring 
the change in specific enthalpy of solution. Micronised salbutamol sulphate 
was mechanically relaxed to a low energy, crystalline form for use in 
suspension-based metered dose inhalers (MDIs) by exposing a shallow bed of 
powder to the conditions of 60 % RH and 25 C for 65 hours (Riebe et al., 
2003). Micronised glycopyrrolate bromide could be exposed to a dry 
environment at an elevated temperature between 60 and 90 C for at least six 
hours, but preferably between 24 and 50 hours, to limit the tendency of the 
particles to aggregate and/or agglomerate upon storage of the DPI formulation 
(Muhrer et al., 2012). 
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For hydrophobic drugs, there is limited literature regarding the use of 
environmental conditions for post-micronisation surface conditioning of 
materials. Among these, Joshi et al. showed an interesting observation on 
temperature-dependent stress relaxation of budesonide that led to an 
anomalous increase in specific surface area during post-micronisation storage 
(Joshi et al., 2002). The significant increase in surface area of budesonide 
upon storage was hypothesized to be related to the residual stress stored in 
the form of defects and dislocation upon micronisation, which may lead to 
crack propagation and induce secondary particle fracture with the creation of 
new surface (Joshi et al., 2002).   
 
Based on the above information, the properties of carrier-based DPI 
formulation prepared with the freshly micronised or laagered (post-
micronisation and conditioned) drug are likely to be different, particularly as its 
performance is strongly dependent on the particle size, morphology and 
interfacial chemistry of the particle surface (Shur et al., 2013). Any processing 
or storage conditions that may affect such properties need to be monitored 
and controlled to ensure formulation consistency during processing and over 
the product shelf life. Therefore, the aim of this study is to investigate the 
structural relaxation of micronised fluticasone propionate (FP) stored under 
different conditions of temperature and relative humidity and their possible 
influence on the FP physicochemical and interfacial properties. FP was 
chosen due to its hydrophobic nature and our limited understanding of the 
structural relaxation kinetics of such hydrophobic materials. The results of this 
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study are expected to provide a valuable insight into how changes to these 
material properties during relaxation affect cohesive forces (FP-FP), adhesive 
forces with another drug component such as salmeterol xinafoate (SX) and 
lactose monohydrate, and consequently the in vitro performance of carrier-




3.2 MATERIALS AND METHODS 
3.2.1 MATERIALS 
 
Micronised FP (C25H31F3O5S, Molecular weight = 500.571) was purchased 
from Chemagis (Lot no. 104364, 100 grams, Bnei Brak, Israel). The FP 
sample was shipped directly upon micronisation and supplied in very tight 
packaging and held under 10 % RH during transport. Salmeterol Xinafoate 
(C36H45NO7, molecular weight = 603.745) was sourced from Neuland 
Pharmaceuticals (Lot no. 12004, 20 grams, Mumbai, India). A milled grade 
(ML001) of lactose monohydrate (C12H24O12, molecular weight = 360.312) was 
sourced from DFE Pharma (Lot no. 10474128, Borculo, Netherlands). In vitro 
aerosolization testing of the binary and combination DPI formulations was 
performed using a Cipla Rotahaler® DPI capsule device (Cipla, Mumbai, 
India). Water used during the studies was Milli-Q reverse osmosis purified 
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(Merck Millipore, Darmstadt, Germany). Methanol and acetonitrile were of 
HPLC grade and purchased from Sigma (Gillingham, UK). 
 
3.2.2 METHODS 
A 2g sample of FP was taken from a micronised batch for full physicochemical 
characterization. The remaining drug sample was separated into three 6g 
batches and conditioned under three different environmental conditions of 
temperature and relative humidity for well-defined periods. An aged batch of 
micronised SX (>12 months) was used for tertiary DPI formulation 
preparations, and was kept under ambient conditions during the period of the 
study. The use of such aged SX batch allowed the investigation to focus on 
examining the effect of FP relaxation behavior under different storage 
conditions on the in vitro performance of the tertiary DPI formulation, as its 
physicochemical and interfacial properties were not expected to change. The 
particle size distribution of the coarse lactose monohydrate was monitored 
during the study to ensure that there was no change to particle size, since any 
change to the fine or coarse end of the particle size distribution may influence 
drug product performance.  
  
3.2.2.1 Conditioning of micronised FP 
The three conditioning environments chosen for this investigation were (1) 
ambient temperature and low humidity (LH) (25 C, 33 % RH), (2) ambient 
temperature and high humidity (HH) (25 C, 75 % RH), and (3) high 
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temperature and ambient humidity (HT) (60 C, 44 % RH). An aliquot of each 
conditioned FP sample (2 g) was taken from the LH and HH conditions upon 
being laagered for 30, 60 and 90 days. The HT sample was quarantined at a 
single time point of 14 days. All samples were sieved through a 500 µm mesh 
sieve prior to physicochemical characterization. Table 3.1 provides a summary 
of the conditioning environments and periods for micronised FP samples as 
well as their corresponding nomenclatures. 
 
 
Table 3.1    Nomenclature of post-micronised FP samples based on their 








(used as received) 
0 Days Day 0 
25 C, 33 %RH 
30 Days LH30 
60 Days LH60 
90 Days LH90 
25 C, 75 %RH 
30 Days HH30 
60 Days HH60 
90 Days HH90 
60 C, 44 %RH 14 Days HT 
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3.2.2.2 Laser Diffraction 
Particle size distributions (PSDs) of all FP samples were measured in the wet 
state. Approximately 10 mg of FP was suspended in HPLC grade cyclohexane 
containing 0.5 % w/v lecithin (Acros Organics, Geel, Belgium) and sonicated 
for 5 minutes and then immediately transferred into a 50 mL cuvette to 
produce an appropriate optical concentration (8-12 %). Each measurement 
was performed in triplicate. Particle size analysis was performed using 
WINDOX 5.0 software (Sympatec GmbH, Clausthal-Zellerfeld, Germany).  
 
3.2.2.3 Scanning Electron Microscopy (SEM) 
Particle morphology of all FP samples was investigated using scanning 
electron microscopy (SEM). Sample aliquots were fixed onto sticky carbon 
tabs (Agar Scientific, Cambridge, UK), followed by removal of excess powder 
using pressurized air. Samples were subsequently sputter coated with gold 
(Edwards Sputter Coater S150B, Edwards High Vacuum, Sussex, UK) to 
achieve a thickness of approximately 20 nm. Imaging was performed using a 
scanning electron microscope (JEOL JSM6480LV, Tokyo, Japan) using 15 kV 
accelerating voltage. 
 
3.2.2.4 X-ray powder diffraction (XRPD)  
The X-ray powder diffraction (XRPD) patterns of FP samples were analyzed 
by a Bruker Powder Diffractometer (D8; Bruker AXS Inc., Madison, USA) 
using CuKα radiation (λ=1.54 Å). The data were collected over a single 2θ 
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sweep with range 2θ = 5 - 30° and a step size of 0.025°/step with a step time 
of 1.5 s.  
 
3.2.2.5 Differential Scanning Calorimetry (DSC) 
The thermal properties of all samples were investigated using a differential 
scanning calorimeter (DSC 2920, TA Instruments, Surrey, UK). 
  
3.2.2.6 Specific Surface Area by Brunauer–Emmett–Teller (BET) 
The specific surface area (SSA) of FP samples was measured using a Gemini 
2360 surface area analyser (Micromeritics Instrument Corporation, Norcross, 
USA). A five-point BET nitrogen adsorption analysis was carried out in 
triplicate after degassing the samples for 24 hours in a FlowPrep 060 
degasser (Micromeritics Instrument Corporation, Norcross, USA). 
 
3.2.2.7 Rugosity (Ra)  
Rugosity (Ra) is a semi-quantitative measure of shape and surface texture of 
particles and can be calculated based on the ratio of the surface area 
calculated by BET (SSA) to a product of the drug density and the surface area 
by laser diffraction (Sv) (Joshi et al., 2002).  As described above, the laser 
diffraction measurement assumes that particles are smooth and spherical, and 
does not account for the surface roughness or shape of particles in its 
theoretically calculated surface area. Thus, Ra can provide an estimate of 
changes that could be attributed to surface texture and smoothness.   
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3.2.2.8 Thermal Activity Monitoring (TAM) 
 
3.2.2.8.1 Preparation of Amorphous Form 
A small-scale spray dryer with inert loop (model B-295, Büchi, Labortechnik 
AG, Flawil, Switzerland) was used for spray drying FP. The system 
incorporated a high-efficiency cyclone and was fitted with a co-axial two-fluid 
atomizer with an orifice of 0.7 mm. The nozzle was also equipped with 
automated cooling and cleaning systems. The relative humidity (RH) of the 
drying air before heating was 0 % and both the inlet and outlet air 
temperatures were monitored. Spray drying of FP was conducted upon 
spraying a 0.5 w/v solution of the drug in acetone. The resultant droplets were 
dried at 110°C inlet temperature, outlet temperature ranged between 50 – 
60°C, spray flow rate of 500 dm3. h-1 and solution feed rate of 8 cm3.min-1. 
Once the material was produced it was immediately transferred into a 
container and stored at -90°C. In doing this, the materials remained 
amorphous for up to 1 month. 
 
3.2.2.8.2 Preparation of Calibration Curve 
The amorphous samples used to construct the calibration plots were prepared 
by directly weighing proportional masses of the appropriate crystalline and 
amorphous materials into the calorimetric ampoule. Saturated solutions of 
fluticasone propionate were prepared in acetone at 21°C under continual 
stirring. The solutions were then filtered in heated labware using a 0.45 μm 
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nylon membrane filter (Whatman, Brentford, UK) and introduced to a sealed 
glass crystallisation vessel continually stirred by an overhead stainless steel 
three blade stirrer with a water-jacket temperature control maintained at 21°C 
(K20; Haake, Karlsruhe, Germany). The FP was crystallised by the addition of 
an excess amount of n-hexane to a saturated solution of FP in acetone. The 
mass of the crystalline component was kept constant in all the mixtures (50 ± 
0.01 mg) and an appropriate amount of spray-dried material was added to 
make 1, 3, 5 and 10 % amorphous samples. The mixtures were made 
homogenous in the calorimetric ampoule by geometric mixing of the spray 
dried and amorphous forms of the drug in the ampoule before loading onto the 
perfusion apparatus. The mixing was conducted at low humidity to prevent 
physicochemical changes occurring in the bulk. Calibration curves were then 
constructed for each of the drug samples by plotting the measured heat of 
crystallization versus the known amorphous content. 
 
3.2.2.8.3 Isothermal Microcalorimetry (TAM) 
Calorimetric data were recorded using a 2277 Thermal Activity Monitor (TAM, 
Thermometric AB, Jarfalla, Sweden) at 25 °C equipped with a gas perfusion 
unit. Briefly, the unit controls the relative humidity (RH) of a carrier gas flowing 
over the sample by proportional mixing of two gas lines (0 and 100 % RH) 
using mass-flow controllers. In addition, the unit enables the introduction of 
0.9 partial pressure of ethanol vapour pressure when used as a plasticizer. 
Similarly, to the humidity set-up, partial pressure of solvent can be returned to 
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0. This allows freshly loaded samples to be held under a dry atmosphere, 
preventing the onset of crystallisation and allowing the apparatus to reach 
thermal equilibrium before the commencement of data capture. Data were 
recorded every 10 s with an amplifier range of 3000 μW using the dedicated 
software package Digitam 4.1. Data were recorded in triplicate. Peak analysis 
was performed using Origin (Microcal Software Inc., USA). In the analysis of 
fluticasone propionate ethanol vapour was used to aid re-crystallization. For 
this the programme started under dry nitrogen, switched to 0.9 partial 
pressure and returned to 0. In both cases, upon returning the system to the 
dry state after crystallization, the drying response was subtracted from the 
wetting response. 
 
3.2.2.8.4 Physicochemical Analysis of Spray Dried FP 
The scanning electron micrographs of spray dried FP are shown in Figure 3.1. 
The particle of spray dried FP appeared spherical and possessed a smooth 
morphology. Furthermore, the particles of the material were extensively 
agglomerated. The X-ray powder diffractogram of spray dried FP is shown in 
Figure 3.2. The absence of any distinct peaks in the diffraction pattern 
suggests that the material was amorphous with very little crystallinity. Hence, 
these data suggest that the spray drying process was successful in generating 
an amorphous sample of FP for this study.  
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Figure 3.1 Scanning Electron Micrographs of spray dried FP at a 
magnification factor of (A) at 3,000 and (B) 7,000  
 
 
Figure 3.2 X-ray powder diffractogram of spray dried FP 
 
3.2.2.8.5 Isothermal Calorific Responses for FP 
A common approach to crystallise amorphous samples in an isothermal 
calorimeter is to use either elevated RH or organic vapour (maintained 
through the use of a mini hygrostat located in the sample ampoule). The 
sample absorbs humidity or vapour, which plasticises the material and, after a 
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time period that varies in proportion to the amorphous content, results in the 
crystallization of the material. While such experiments are relatively is simple 
to run, it is very difficult to de-convolute the many events that occur during 
crystallization. Two of the principal problems of the mini-hygrostat method are 
that hydration is initiated externally from the calorimeter, therefore, the initial 
wetting, and possibly some crystallisation, data are lost and that there are 
imbalances in the rate of solvent evaporation and condensation. The use of a 
perfusion unit to initiate crystallisation circumvents this problem. However, a 
different approach to data analysis is required. This is required, because as 
the humidity or vapour are elevated, all the internal surfaces of the ampoule, 
as well as the sample, are wetted, which produces a large exothermic heat 
signal that often occurs over a time-period that is longer than the time required 
for the sample to crystallise. In effect, the crystallisation signal is obscured by 
the wetting response. Hence, in order to determine the enthalpy of re-
crystallization from these data it is imperative to return the system to 0 % RH 
after crystallisation and subtract the drying response from the wetting 
response. The responses of spray dried FP and mixtures of 
crystalline/amorphous samples are shown in Figure 3.3. The spray dried FP 
had a greater response than the mixtures containing either 3 % or 5 % spray 
dried material mixed with crystalline samples of the respective materials. 
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Figure 3.3  The wetting and drying calorimetric response of (A) spray 
dried FP, (B) 5% spray-dried FP with crystalline FP and (C) 3% spray-
dried FP with crystalline FP 
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3.2.2.8.6 Construction of a Calibration Curve for the Amorphous 
Quantification of FP 
 
The enthalpy of re-crystallization of the calibration standards of FP from the 
calorimetric data was calculated by subtracting the drying response from the 
wetting response. These data are shown in Figure 3.4. The LOD of this 
calibration curve was 0.16 % and the LOQ was 0.50 %. 
 
 
Figure 3.4  Calibration curves for FP and the lines shown are linear 
regression fits. Equation of line: y=1.85x – 0.16, R2=0.99. 
 
The amorphous content of micronised FP samples was determined using the 
TAM and the constructed calibration curves.  
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3.2.2.9 Cohesive-Adhesive Balance (CAB) 
 
3.2.2.9.1 Preparation of crystal substrates 
To perform quantitative scanning probe microscopy (SPM) measurements of 
the cohesive-adhesive balance (CAB) of the FP samples, smooth single 
crystal surfaces of FP, SX and lactose monohydrate were prepared (Begat et 
al., 2004; Kubavat et al., 2012). The procedure for these preparations is briefly 
summarized below. 
A saturated solution of FP in 2 mL of acetone was prepared and sonicated 
prior to filtration via a 0.22 µm polytetrafluoroethylene (PTFE) membrane filter 
(Whatman Inc., Clifton, NJ, USA). FP was crystallized using water as an anti-
solvent. Specifically, a microscope cover slip (12 mm x 12 mm) was supported 
on a vertical post in a crystallization dish that contained the anti-solvent. A 
droplet of the FP saturated solution was placed on the coverslip using a 
syringe attached to the 0.22-µm-membrane filter. The system was sealed by 
inverting a glass lid in the crystallisation dish to allow vapor phases of the 
miscible solvents to come into equilibrium, resulting in heterogeneous 
nucleation and crystal growth within the solution droplet. A similar approach 
was used for the preparation of smooth crystal substrates of lactose 
monohydrate and SX and a detailed method is published elsewhere (Kubavat 
et al., 2012). 
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3.2.2.9.2 Interaction force measurements 
Prior to force measurements, individual particles from each sample of FP were 
attached onto standard V-shaped tipless cantilevers with pre-defined spring 
constants (DNP-020, DI, CA, USA) using an epoxy resin glue (Araldite, 
Cambridge, UK). Five probes were prepared for the initial, LH, HH and HT 
conditioned FP samples at each pre-defined laagering period. All probes were 
examined with an optical microscope (magnification 50x) to ensure the 
integrity of the attached particle, before allowing the thin layer of glue to cure 
and dry.  
Single crystal substrates were loaded onto the scanner stage of a multi-mode 
scanning probe microscope (SPM) (Bruker, Santa Babara, CA, USA), which 
was enclosed in a custom-built environmental chamber, in which the ambient 
conditions were maintained at a constant temperature of 25 °C (± 1.5 °C) and 
relative humidity of 44 % RH (± 3 %). The interaction forces were measured 
by recording the deflection of a cantilever as a function of the substrate 
displacement (z) by applying Hooke’s Law. Individual force curves (n = 1024) 
were conducted over a 10 µm x 10 µm area at a scan rate of 4 Hz and a 
compressive load of 40 nN.  
 
A custom-built software was developed to extract data contained within each 
force-volume dataset. These data were analyzed to ensure normal 
distribution, indicating uniform contact area between the drug probe and the 
smooth substrate surfaces. Arithmetic mean and standard deviation were 
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measured to produce CAB plots for the interactions of the different batches of 
FP with both lactose monohydrate and SX.  
 
3.2.2.10 Preparation of powder formulations 
Binary powder blends (4 g) were manufactured using lactose monohydrate 
and 1.0 % w/w FP (day 0, LH, HH, or HT). A pre-weighed amount of lactose 
monohydrate (3.96 g) was initially passed through an 850 µm aperture sieve 
to break any large agglomerates which may have formed during storage. A 
quarter of the mass of the lactose monohydrate required was transferred to a 
stainless steel cylindrical vessel with an internal diameter of 100 mm and a 
height of 150 mm, and all the FP (40 mg) was sandwiched with another 
quarter of the sieved lactose monohydrate. This was mixed in a T2F Turbula® 
mixer (Wily A Bachofen AG, Basel, Switzerland) for 10 minutes at 46 rpm. The 
remaining half of the lactose monohydrate was then added and mixed for a 
further 45 minutes at 46 rpm. Upon blending, formulations were passed 
through a 250 µm sieve and stored at 20 ± 2 °C and 44 % RH for at least 48 
hours before the content uniformity of the blends was assayed. Tertiary 
powder blends containing FP (1.0 % w/w), SX (0.2 % w/w SX base) and 
lactose monohydrate were similarly prepared by sandwiching 40 mg of FP and 
8 mg of SX between ½ of the lactose monohydrate then mixed for 10 min at 
46 rpm and then the remaining ½ of the lactose added and mixed for a further 
45 minutes at 46 rpm. 
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Following content uniformity testing, 25 ± 1 mg of the formulated blend was 
loaded into size 3 hydroxypropylmethyl cellulose (HPMC, Shionogi Qualicaps, 
Madrid, Spain) capsules. The targeted dose of the binary formulations was 
250 µg of FP per 25 mg fill weight. For the tertiary formulations, the targeted 
dose of FP and SX were 250 µg and 50 µg, respectively, per 25 mg fill weight. 
The filled capsules were stored at 20 ± 2 °C and 44 %RH for 24 hours prior to 
in vitro testing to ensure dissipation of any electrostatic charges that may have 
been introduced during processing. 
 
3.2.2.11 HPLC analysis of Fluticasone Propionate and Salmeterol                                                                                                                                                                                                                                               
Xinafoate 
The drug content was quantified using HPLC. For the determination of drug 
content in FP binary formulations, the HPLC method consisted of a pump 
coupled to an auto-sampler and multi-wavelength UV detector (Agilent 1200, 
Wokingham, UK) with a wavelength set at 235 nm. The pump flow rate was 
set to 1.5 mL/min through a Hypersil ODS-C18 column (Fisher Scientific, 
Loughborough, UK, column length of 250 mm, internal diameter of 4.6 mm, 
and particle size of the packing material of 5 m), which was placed in a 
column oven (Agilent, Wokingham, UK) set to 40°C. The mobile phase 
consisted of methanol, acetonitrile and water (45:35:20 % v/v). The elution 
time for the FP peak using this method was 3.4 mins. For the drug content 
determination of FP and SX in combination formulations, the HPLC method 
used a flow rate of 1.0 mL/min through a Hypersil BDS-C18 column (Fisher 
Chapter THREE                                                                                 130 
 
Scientific, Loughborough, UK, column length of 250 mm, internal diameter of 
4.0 mm, and particle size of the packing material of 5 m) placed in a column 
oven at 40 °C. The mobile phase consisted of 75:25 % v/v methanol: 0.6 % 
w/v aqueous ammonium acetate.   
For both methods, a linear regression analysis was used for the assessment 
of the HPLC calibration. Quantiﬁcation was carried out by an external 
standard method, and linearity was verified between 0.05 and 50 g/mL. The 
limit of detection was 0.02 g/mL and 0.03 g/mL for both FP and SX 
respectively.   
3.2.2.12 Content Uniformity  
Ten random samples of 25 ± 1 mg, from different areas of the powder bed 
were weighed and dissolved in 50 mL of mobile phase. The amount of drug in 
each sample was obtained from HPLC assay and the content uniformity was 
expressed as a relative standard deviation (%RSD).  
 
3.2.2.13 In Vitro Aerosolization Analysis 
Analysis was performed using a Next Generation Impactor (NGI, Copley 
Scientific, Nottingham, UK) with a pre-separator, which was connected to two 
vacuum pumps (Copley Scientific, Nottingham, UK) to create critical (sonic) 
flow. The pre-separator contained 15 mL of mobile phase. The NGI cups were 
coated with 1 % v/v silicone oil in hexane to eliminate any particle bounce. For 
each experiment, two capsules of the same blend were discharged into the 
NGI at 55 L/min for 4.4 s, equivalent to a total volume of 4 L. Prior to each 
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test, the flow rate was verified using a digital flow meter (DFM 2000, Copley 
Scientific, Nottingham, UK). The amount of API deposited on each part of the 
NGI was determined by HPLC. This protocol was repeated three times for 
each formulation. The mass median aerodynamic diameter (MMAD), 
geometric standard deviation (GSD), fine particle dose (FPD) and impactor 
stage mass (ISM) were determined for each case. In all cascade impactor 
tests conducted, the mass balance was within ±15 % of the total recovered 
dose.  
 
3.2.2.14 Statistical Analysis 
Statistical analysis between different populations carried out using one-way 
analysis of variance. Comparison of the mean values was performed by 
Tukey’s multiple comparison. All statistical analyses were performed using 
GraphPad Prism software (GraphPad Software Inc, California, USA). Error 
bars in graphical representations of data show ± standard deviation (SD) in all 
cases. 
 
3.3 Results and Discussion 
To investigate the effect of controlled environmental laagering on the 
structural relaxation behavior of micronised FP, a range of physicochemical 
properties were systematically evaluated under different storage conditions 
and over pre-defined time periods. Colloidal probe CAB-SPM was then utilized 
to provide a more functional measurement of the influence of these 
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physicochemical properties on the surface interfacial interaction of conditioned 
FP samples with FP, SX and lactose monohydrate substrate surfaces. These 
data were further compared to the in vitro performance of binary and tertiary 
DPI formulations containing the micronised (used as received) and laagered 
FP samples. 
 
3.3.1 Physicochemical Characterization  
Representative XRPD profiles of the Day 0, LH90, HH90 and HT FP samples 
are shown in Figure 3.5 (other time point traces are not shown). The presence 
of distinct peaks in the XRPD profiles between 10° and 40° angle 2θ for all 
samples suggested that all FP samples were of the same polymorphic form 
and that conditioning of FP samples under the environments and periods 
chosen in this study did not alter the crystalline form (Kubavat et al., 2012). 
There was, however, a broad diffuse peak below 10° angle 2θ for both the 
LH90 and HH90 samples. The origin of this peak was not fully understood but 
might suggest either incorporation of greater randomness within the crystalline 
structure or possible changes in preferred orientation of the crystallites upon 
packing into the instrument caused by extended exposure to low and high 
relative humidity. 
Chapter THREE                                                                                 133 
 
 
Figure 3.5: X-ray powder diffraction profiles for Day 0, LH90, HH90 
and HT FP samples 
 
Representative DSC thermographs of the Day 0, LH90, HH90 and HT FP 
samples are shown in Figure 3.6. Thermal analysis of all samples (other time 
point traces not shown) indicated that all materials had an onset of melting at 
approximately 295 °C, which was related to the melting point for form I of FP 
(Pitchayajittipont et al., 2009). Again, the DSC data further supported the 
same polymorphic form of all FP samples. 
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Figure 3.6: Differential scanning calorimetry (DSC) thermographs for 
the Day 0, LH90, HH90 and HT FP samples 
 
PSD of Day 0 and all laagered FP samples are summarized in Table 3.2. 
These data showed that while the PSD was relatively insensitive to laagering 
at HT, laagering of FP under controlled humidity conditions led to some 
observable changes in the PSD of laagered FP samples. For example, upon 
exposure to LH, the d50 of FP showed an increase at 30 days (2.74 µm), 
followed by a decrease at 60 days (2.18 µm) and an increase at 90 day (2.68 
µm) where the d50 remained below the initial value (2.41 µm). A similar 
qualitative trend was observed for HH samples. 
 
The corresponding surface areas measured by laser diffraction and BET, as 
well as the Ra of the FP samples are tabulated in Table 3.2. The SSA 
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measurements followed, in most cases, a similar qualitative trend to that 
observed in the particle size and Sv measurements by laser diffraction. For 
example, upon exposure to 33 % RH, there were noticeable increase and 
subsequent decrease in the SSA at 60 and 90 days, respectively, with respect 
to SSA at 30 days.  
 
However, an anomalous finding was observed for the HH90 FP sample. 
Unlike the particle size and Sv data of HH 30 and HH 60, the HH90 FP sample 
showed a significant decrease in the SSA accompanied by a noticeably 
smaller value of Ra with respect to all other FP samples. This observation 
indicated a marked reduction in the surface roughness of the HH90 FP 
sample. These data suggested that the morphology of the HH90 FP sample 
differed considerable from the other laagered FP samples.  
 
Representative SEM images of the Day 0, HT, LH90 and HH90 FP samples 
are shown in Figure 3.7. With the limited spatial resolution of the SEM, it is 
difficult to quantitatively discern morphological and surface roughness 
differences of the Day 0 FP sample from the HT and LH90 FP samples. 
However, it appeared that laagering under high humidity conditions (HH90) 
created a noticeable change in morphology, resulting in increased surface 
smoothening (Figure 3.7) consistent with the decrease observed in the SSA 
and Ra measurements. However, these topographical changes were not 
apparent for HH30 and HH60 FP samples (data not shown). The surface 
transformation of the HH90 FP samples suggested that laagering at high 
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humidity (>75 % RH) for an extended period of time (60 < t < 90 days) may 
provide the conditions to overcome the activation energy required for the 










Figure 3.7: Scanning Electron Micrographs for the Day 0 (A), HT (B), 
LH90 (C) and HH90 (D) FP samples 
A B 
C D 
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Day 0 1.12 ±0.01 2.41 ±0.02 4.37 ±0.02 2.29 7.54 ±0.27 3.30 5.05 ±0.20 1.09 ±0.01 2.00 ±0.03 
LH30 1.28 ±0.02 2.74 ±0.01 4.99 ±0.03 2.01 7.43 ±0.31 3.70 4.89 ±0.18 1.04 ±0.02 1.83 ±0.01 
LH60 0.96 ±0.01 2.18 ±0.01 4.03 ±0.01 2.55 7.98 ±0.18 3.13 4.34 ±0.21 0.92 ±0.01 0.80 ±0.02 
LH90 1.29 ±0.01 2.68 ±0.03 4.86 ±0.01 2.02 7.40 ±0.22 3.66 1.12 ±0.20 0.88 ±0.02 0.52 ±0.02 
HH30 1.19 ±0.03 2.57 ±0.01 4.72 ±0.02 2.14 7.88 ±0.11 3.68 2.77 ±0.18 0.76 ±0.03 1.44 ±0.02 
HH60 0.99 ±0.03 2.22 ±0.02 4.09 ±0.02 2.49 7.49 ±0.21 3.01 1.88 ±0.21 0.93 ±0.02 0.85 ±0.03 
HH90 1.08 ±0.01 2.33 ±0.02 4.22 ±0.02 2.36 4.90 ±0.17 2.07 1.29 ±0.20 1.15 ±0.02 0.64 ±0.01 
HT 1.14 ±0.02 2.40 ±0.01 4.28 ±0.03 2.27 7.01 ±0.33 3.08 <LOQ 0.74 ±0.01 1.17 ±0.02 
aAC = amorphous content
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3.3.2 Post-micronisation conditioning effects on amorphous content of 
FP samples 
The amorphous contents by TAM for the FP samples are summarized in Table 
3.2. These data indicated that all laagering conditions led to a lowering in the 
amorphous content. Laagering under high temperature (i.e., HT FP sample) 
reduced the amorphous content to below the limit of quantification (LOQ) of 
the analytical method. Under ambient temperatures, the partial water vapour 
pressure surrounding the FP powder and the period of exposure also had a 
direct effect on the amorphous content. Under high humidity conditions, there 
was a sharp decrease in the amorphous content of the HH30 and HH60 FP 
samples. In contrast, under low humidity, there was only a minor decrease in 
the amorphous content of the LH30 and LH60 FP samples. However, the 
amorphous contents of the LH90 and HH90 samples were low. Interestingly, 
while the relaxation pathway of the amorphous disorder was different for FP 
conditioning under 33 % RH and 75 % RH, as suggested in the previous 
physiochemical and SEM data, the amorphous content at 90 days was similar 
for the both conditions, which was around 1.0 %.  
 
3.3.3 Post-micronisation Conditioning Effects on Interfacial Forces  
The influence of different laagering conditions on the surface interfacial forces 
of the micronised and laagered FP samples was investigated by CAB analysis. 
The individual CAB plots of the FP samples with respect to both lactose 
monohydrate and SX are shown in figures 3.8-3.10.  A summary plot of the 
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Figure 3.8: (A) Cohesion (Fcoh (FP-FP)) versus adhesion (Fcoh (FP-
LAC)) plots of the micronised FP sample (Day 0) and samples 
conditioned at low humidity (LH30, LH60, LH90) with respect to 
lactose monohydrate, (B) Cohesion (Fcoh (FP-FP)) versus adhesion 
(Fcoh (FP-SX)) plots of the micronised FP sample (Day 0) and samples 
conditioned at low humidity (LH30, LH60, LH90) with respect to SX. 
A 
B 





Figure 3.9: (A) Cohesion (Fcoh (FP-FP)) versus adhesion (Fcoh (FP-
LAC)) of the micronised FP sample (Day 0) and samples conditioned 
at high humidity (HH30, HH60, HH90) with respect to lactose 
monohydrate, (B) Cohesion (Fcoh (FP-FP)) versus adhesion (Fcoh (FP-
SX)) of the micronised FP sample (Day 0) and samples laagered at 
high humidity (HH30, HH60, HH90) with respect to SX.  
A 
B 





Figure 3.10: (A) Cohesion (Fcoh (FP-FP)) versus adhesion (Fcoh (FP-
LAC)) of the micronised FP sample (Day 0) and samples conditioned 
at 60◦C (HT) with respect to lactose monohydrate, (B) Cohesion (Fcoh 
(FP-FP)) versus adhesion (Fcoh (FP-SX)) of the micronised FP sample 
(Day 0) and samples laagered at 60 ◦C (HT) with respect to SX. 
A 
B 
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Figure 3.11: Variations in the CAB ratios with respect to lactose 
monohydrate and SX of micronised FP particles laagered under low 
and high relative humidity at 30, 60 and 90 day time points.  
 
The CAB ratios with respect to lactose monohydrate for the low humidity 
laagering conditions indicated a shift from a slightly cohesive-led interaction 
(FP-FP, CAB ratio > 1.0) for the micronised FP to an adhesive-led system (FP-
Lactose, CAB ratio < 1.0) In other words, these data suggested that the 
adhesion of FP to lactose monohydrate increased upon extended exposure of 
FP to low humidity conditions. The CAB ratios of the low humidity laagered FP 
samples with SX (Table 3.2), also indicated that a significant change in the 
interfacial forces between FP and SX substrates occurred upon laagering. The 
cohesive nature of the Day 0 FP sample, which was two-fold greater than its 
affinity to SX, only slightly decreased for the LH30 sample. However, upon 
laagering at low humidity for 60 days the CAB measurements demonstrated a 
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significant (p<0.02) shift from a highly cohesive-led system to an adhesive-led 
(FP-SX > FP-FP) system. This shift to an adhesive (FP-SX)-led system 
continued for the LH90 FP sample, with the 90 day laagered FP sample 
shifting the balance of forces to an approximately two-fold greater adhesive 
(FP-SX) interaction than its cohesive (FP-FP) interaction. These data indicated 
that laagering micronised FP sample for 90 days at 33 % RH, increased the 
adhesive interaction to the SX by about four-fold with respect to the as 
received micronised FP.  
 
The low sensitivity of the FP-lactose CAB interactions and the highly sensitive 
nature of the FP-SX CAB to surface chemistry of the secondary processed FP 
have been observed previously by Kubavat et. al. (2012). They also showed 
that different solvent and anti-solvent conditions during primary crystallization 
conditions could directly affect the interfacial surface chemistry of the 
secondary processed FP.  
 
A similar trend in the FP-SX CAB measurements was observed upon laagering 
under high humidity conditions. However, the FP-lactose CAB measurements 
did not follow a similar trend as the low humidity laagered FP samples. As 
reflected in the CAB ratios relisted in Table 3.2, initial exposure to elevated 
humidity increased the adhesive tendency of FP to lactose monohydrate 
(HH30), to a greater extent than 90-day exposure at 33 % RH (i.e., LH90 FP 
sample). However, both 60 and 90 day exposure to 75 % RH subsequently 
reduced the adhesive tendency of the laagered FP samples to lactose 
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monohydrate. As a result, the HH90 sample exhibited a greater cohesive 
tendency than its interaction with lactose monohydrate. Such findings have 
been previously seen between a partially and fully mechanically relaxed new 
chemical entity (Shur et al., 2007). It should also be noted that in Table 3.2 the 
HH90 FP sample showed both the greatest cohesive tendency with respect to 
lactose monohydrate and a relatively high adhesive tendency to SX. This 
unique combination of changes in the interactive force measurements is most 
likely due to the structural reconstruction of the FP surface as indicated by the 
marked decrease in SSA and rugosity values of the HH90 FP. 
 
High temperature conditioning of FP at 60°C led to the greatest increase in the 
adhesive tendency of the FP to lactose monohydrate, with respect to the 
cohesive interaction (Table 3.2). However, for the FP-SX CAB measurements, 
while exhibiting a significant (p<0.05) decrease in cohesiveness (Fig. 6B), the 
HT sample failed to shift the dominant force to an adhesive led system that 
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Table 3.3: In vitro formulation performance, as measured by the mass balance 
(MB), impactor stage mass (ISM), mass median aerodynamic diameter (MMAD), 
geometric standard deviation (GSD) and fine particle mass (FPM<5µm), from the 
aerosolization of binary and tertiary DPI formulations of freshly micronised and 
laagered FP samples (n=3). Note that the large SDs in some APSD data below 








(µg ± S.D) 
MMAD 
(µm ± S.D) 
GSD 
(µm ± S.D) 
FPM 
(µg ± S.D) 
Binary wrt 
FP 
Day 0 1.3 92.6 32.07 ± 0.90 3.80 ± 0.03 2.01 ± 0.00 29.02 ± 0.80 
LH30 0.9 103.8 35.39 ± 8.14 3.65 ± 0.04 2.04 ± 0.02 31.60 ± 7.57  
LH60 1.0 91.1 48.58 ± 0.73 4.22 ± 0.01 2.03 ± 0.00 46.74 ± 0.40 
LH90 1.8 105.4 57.68 ± 0.50 4.24 ± 0.01 2.05 ± 0.01 55.67 ± 0.37 
HH30 1.0 97.0 29.01 ± 0.39 4.28 ± 0.01 2.15 ± 0.02 28.82 ± 0.34 
HH60 1.6 92.4 36.50 ± 1.38 4.08 ± 0.13 2.00 ± 0.02 34.06 ± 0.58 
HH90 2.2 98.8 47.16 ± 0.67 3.92 ± 0.01 2.01 ± 0.00 43.27 ± 0.57 








(µg ± S.D) 
MMAD 
(µm ± S.D) 
GSD 
(µm ± S.D) 
FPM 
(µg ± S.D) 
Day 0 3.0 90.6 36.18 ± 3.77 4.76 ± 0.26 2.04 ± 0.01 37.19 ± 2.57 
LH30 1.6 98.4 46.03 ± 8.13 4.37 ± 0.32 2.01 ± 0.07 43.89 ± 9.86  
LH60 1.4 92.0 40.61 ± 2.17 4.54 ± 0.09 1.93 ± 0.04 39.59 ± 1.02 
LH90 2.2 93.2 60.48 ± 0.30 3.90 ± 0.02 2.01 ± 0.02 55.50 ± 0.04 
HH30 1.0 99.1 32.75 ± 0.36 4.28 ± 0.02 1.91 ± 0.02 30.84 ± 0.16 
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HH60 1.3 90.6 43.70 ± 6.20 3.62 ± 0.03 1.91 ± 0.02 37.70 ± 5.29 
HH90 1.9 97.0 52.79 ± 0.65 3.53 ± 0.01 1.94 ± 0.00 45.44 ± 0.57 








(µg ± S.D) 
MMAD 
(µm ± S.D) 
GSD 
(µm ± S.D) 
FPM 
(µg ± S.D) 
Day 0 5.5 91.3 8.09 ± 0.57 3.77 ± 0.05 2.18 ± 0.06 7.60 ± 0.38 
LH30 2.8 97.1 11.02 ± 1.66 3.24 ± 0.17 2.15 ± 0.01 9.64 ± 1.60  
LH60 1.9 95.2 11.43 ± 0.11 3.00 ± 0.12 2.75 ± 0.33 10.56 ± 0.46 
LH90 2.1 97.4 11.87 ± 0.19 3.02 ± 0.07 2.47 ± 0.04 10.72 ± 0.12 
HH30 2.7 91.7 10.07 ± 1.36 2.97 ± 0.05 2.06 ± 0.01 8.32 ± 0.38 
HH60 2.5 96.5 10.71 ± 0.19 2.71 ± 0.19 2.48 ± 0.05 9.07 ± 0.42 
HH90 2.6 97.4 14.57 ± 0.63 2.29 ± 0.10 2.80 ± 0.06 12.32 ± 0.40 
HT 1.6 96.8 8.53 ± 0.57 2.80 ± 0.06 2.57 ± 0.14 6.63 ± 0.37 
 
3.3.4 Drug content uniformity 
The relative standard deviation (RSD) measurements of the drug content for 
binary and tertiary DPI formulations containing micronised and laagered FP 
are shown in Table 3.3. For all binary DPI formulations, the RSDs were ≤ 2.5 
%, indicating homogeneity of the prepared mixtures. In the tertiary DPI 
formulations, the RSDs for FP were ≤ 3 %, while for SX were ≤5.5 %, which 
suggested a homogeneous distribution of the two active ingredients in the 
formulated mixtures. 
Chapter THREE                                                                                  147 
 
3.3.5 In vitro aerosolization performance of binary DPI formulations  
The in vitro APSD characterization of binary DPI formulations containing 
lactose monohydrate and micronised or laagered FP sample are summarized 
in Table 3.3. The MMAD and FPM are also plotted as a function of LH and HH 
laagering conditions in Figure 3.12, together with a plot of their respective FP-
lactose CAB values.  For the HT FP sample, there was a significant (p<0.05) 
increase in the FPM and MMAD with respect to the Day 0 FP sample. 
Similarly, there was also a significant (p<0.05) increase in MMAD and FPM of 
the LH FP samples over 60 and 90 days, with respect to the Day 0 and LH30 
samples.  
These differences in APSD of the HT and LH FP samples did not appear to be 
directly related to changes in the material physical properties (e.g. particle size 
and surface area). The CAB measurements, however, suggested that the 
balance of forces for the LH FP samples shifted from being cohesive at Day 0 
and 30 day exposure to being adhesive following laagering for 60 and 90 days. 
This was also observed from the Day 0 to HT FP sample.  Such a shift in the 
nature of interaction force corresponds with an increase in MMAD of the 
formulations, which might be related to formation of API/fines agglomerates 
owing to the higher adhesive affinity of LH60 and LH90 FP samples to lactose 
monohydrate fines. It should be noted that with the high levels of intrinsic 
lactose monohydrate fines (< 4.5 µm) present in the ML001 grade of lactose 
(ca. 10-15 % w/w), a shift in the balance of forces between FP and lactose 
monohydrate has been previously shown to lead to a greater elutriation and 
deaggregation efficiency of FP from the coarse carrier surfaces due to stable 
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agglomerate formation with lactose monohydrate fines (Jones et al., 2008a; 
Shur et al., 2008). This mechanism of agglomerate formation, suggested by 
Jones et. al., indicated that a greater adhesive affinity between API and 
lactose monohydrate led to a significant increase in MMAD and fine particle 






























Figure 3.12: In vitro aerosolization performance of FP in binary DPI 
formulations upon laagering a batch of micronised FP under low and 
high relative humidity for 30, 60 and 90 days. The corresponding CAB 
ratios with respect to lactose monohydrate under such conditions are 
also plotted.   
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Laagering FP samples under high humidity conditions for 30, 60 and 90 days 
also had a significant effect on APSD of the carrier-based DPI formulations 
(Figure 3.12, Table 3.2). Laagering for 30 days under high humidity conditions 
led to an increase in the MMAD but no significant change in FPM. The 
increase in MMAD is in agreement with the slight changes in PSD and SSA 
measurements, and the relative increase in adhesion to the lactose 
monohydrate, as measured by CAB, which may aid formation of API/lactose 
monohydrate fines agglomerates (Begat et al., 2004; Jones et al., 2008a). 
Increasing the period of laagering at the high humidity condition led to an 
increase in FPM accompanied by a decrease in MMAD (close to but slightly 
higher than that of the Day 0 FP sample) over 90 days. It was not evident that 
a single parameter was responsible for or could be used to explain this unique 
change in formulation performance. Nevertheless, the trends observed here 
might be related to the combined effect of changes in the physical shape, 
morphology and interfacial properties of the HH FP particles that may affect 
the formulation microstructure during processing and formulation performance. 
Further research is warranted to better understand the fundamental factors 
and possibly their interactions that influence the performance of binary DPI 
formulation containing HH30 and HH90 FP samples.  
 
3.3.6 In vitro aerosolization performance of tertiary DPI formulations 
The in vitro APSD characterization of tertiary DPI formulations containing 
lactose monohydrate, SX and micronised or laagered FP samples are 
summarized in Table 3.3. The MMAD and FPM of SX are plotted together with 
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the FP-SX CAB values in Figure 3.13. As mentioned above, an aged batch of 
micronised SX (> 12 months) was used. Cohesive-adhesive balance (CAB) 
measurements indicated that there was no noticeable difference in the 
interfacial properties of the SX during the duration of the study (The average 
CAB ratio of SX with respect to lactose monohydrate over the different time 































Figure 3.13: In vitro aerosolisation performance of SX in combination 
with FP in tertiary formulations upon laagering a batch of micronised 
FP under low and high relative humidity for 30, 60 and 90 days. The 
corresponding CAB ratios with respect to SX under such conditions 
are also plotted.   
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The aerosolization performance of FP were not significantly (p>0.05) affected 
by laagering at low humidity over 60 days. However, extended laagering (60 < 
t < 90 days) led to a significant (p<0.05) increase in FPM and a smaller MMAD. 
Laagering under high humidity, similar to the binary DPI formulations, 
extended laagering appeared to progressively affect the aerosolization 
performance of the FP component in the tertiary formulations. However, 
increasing laagering increased the FPM but decreased the MMAD of the FP 
component in the presence of SX, whereas for the binary formulation extended 
laagering showed an initial marked increase followed by a gradual decrease in 
FP MMAD and a consistent increase in FP FPM. For the SX component, 
increasing the period of laagering led to an increase in FPM recovery of SX 
and a decrease in MMAD of the SX component for LH and HH FP samples. 
The aerosolization performance of the tertiary DPI formulations (particularly 
with respect to the SX component) appeared to be sensitive to shift in the 
balance of forces between FP and SX upon FP laagering. As has been 
indicated in a number of studies, the greater the adhesive tendency between 
FP and SX, the more significant is the improvement in aerosolization 
performance of SX (Kubavat et al., 2012; Jones et al., 2008a; Jones et al., 
2008b). These studies proposed that higher deaggregation efficiency of the SX 
occurred as a result of the greater propensity of FP and SX to form fine particle 
agglomerates during blending. Similar observations have also been reported 
for suspension MDI formulations comprising of FP and SX (Rogueda et al., 
2011). However, additional studies will be needed to fully understand the 
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complex relationships between the interfacial properties and aerosolization 
performance for such tertiary systems.        
3.4 CONCLUSIONS   
The ability to understand and predict interparticulate forces of secondary 
processing of APIs in DPI systems is critical in our ability to predict and 
optimize DPI product performance. The relative magnitudes of the cohesive 
(drug-drug) and adhesive (drug-excipient, drug 1-drug 2 such as FP-SX) forces 
and how primary and secondary processing of drug materials may directly 
impact these interparticulate forces is a major research objective. This study 
shows that the relative magnitudes of cohesive-to-adhesive forces of 
secondary processed FP are a direct function of the conditioning environment 
and duration. While the time to re-equilibrate the FP particles from their 
unstable amorphous state to the thermodynamically stable crystalline state can 
be expedited, laagering is an essential parameter requiring controlled 
conditions of temperature and relative humidity. Unlike high temperature, 
humidity based conditioning failed to completely eliminate amorphous related 
disorders and significantly affected the relative balance of the adhesive and 
cohesive forces during storage. A significant morphological and topographical 
change was seen following the conditioning of FP under high humidity for 90 
days, suggesting a surface reconstruction event. This study clearly shows that 
the different post-micronisation laagering conditions translated into different 
interfacial behavior, accompanied by significant changes in product 
performance characterized by APSD measurements by cascade impaction. 
However, the fundamental factor(s) and mechanism(s) responsible for the 
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observed differences in product performance are not fully understood for the 
complex formulations in DPIs investigated here. Therefore, the present study 
clearly indicates the critical importance and need for more research in 
understanding the physical, chemical and interfacial properties of secondary 
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4 The Stress Relaxation Dynamics of Micronised Salmeterol Xinafoate 
4.1 INTRODUCTION 
The importance of developing a product with stable critical quality attributes 
dictates the necessity of having thermodynamically stable active 
pharmaceutical ingredients. This allows for drug products to not only meet 
release specifications, but to also remain compliant throughout their shelf-life. 
This is only possible if post-micronisation kinetics are fully understood as a 
function of both time and storage conditions. There is a limited amount of 
published data regarding the influence of relative humidity on the dispersibility 
of salmeterol xinafoate (SX) powder blends (Das et al., 2009; Adi et al., 2006; 
Adi et al., 2008). These studies have provided only a limited understanding of 
the between post-micronisation relaxation kinetics and subsequent 
aerosolisation performance. 
This study investigates the kinetics with which SX reverts back to its more 
stable crystalline state following micronisation. Conditioning is employed to 
understand the potential of expediting the stress relaxation profile for 
micronised SX. This work will look into understanding the physical, chemical 
and interfacial trends followed during the stress relaxation period, and also 
relates these trends to in vitro aerosolisation performance.  
Salmeterol is a long acting β2 (2)-adrenoceptor agonist (LABA) prescribed for 
the treatment of asthma and COPD. β2 (2)-receptor stimulation leads to the 
relaxation of bronchial smooth muscle, bronchodilation and increased 
bronchial airflow (Chowdhury and Pan, 2010). SX has a molecular weight of 
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603.75 and is chemically described as C25H37NO4.C11H8O3. It is sparingly 
soluble in water and has a partition coefficient (logP) of 4.2, reflecting its highly 
hydrophobic nature. Capillary actions between SX and water are quantified in 
a contact angle of 67.7◦. (Das et al., 2009)      
 
4.2 MATERIALS AND METHODS 
4.2.1 MATERIALS 
Salmeterol Xinafoate (SX) was purchased from Merck Generics (Potters Bar, 
UK) and was shipped immediately after being micronised. The sample was 
packed at low humidity and transported over dry ice. Hydrofluoroalkane 134a 
(HFA 134a) is an inert gas with a chemical name of 1,1,1,2-Tetrafluoroethane. 
It has a molecular mass of 102.03 and a molecular formula of CH2FCF3. HFA 
134a is a non-polar propellant widely used in aerosol products. HFA 134a was 
purchased from Mexichem, Cheshire, UK (Batch number 003215). 
 
4.2.2 METHODS 
4 grams of micronised SX were sampled upon delivery for full physicochemical 
characterisation. The remaining SX was separated into the four samples of 5 
grams each. Three of these samples were put in their respective chambers for 
environmental conditioning as tabulated in table 4.1. The other sample was 
conditioned with HFA-134a. 
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4.2.2.1 Environmental Conditioning 
The environmental conditions used for this study were as follows; low humidity 
at ambient temperature (LH) (25C, 33 % RH), high humidity at ambient 
temperature (HH) (25C, 75 % RH), and ambient humidity at a high temperature 
(T) (60◦C, 44 %RH). 2 grams were taken from each conditioning chamber at 30 
and 60 days for full characterisation and formulation. Samples were sieved 
through a 500 µm mesh sieve prior to characterisation.    
 
4.2.2.2 In situ conditioning 
Freshly micronised SX was in-situ conditioned in HFA by the addition of 5 
grams of SX in 80 grams of HFA 134a in a pressurised vessel (Mexichem 
Fluor, Cheshire, UK). The HFA was directly inserted into a pressurised vessel 
and kept under pressure for 21 days. The vessel was then de-pressurised at a 
rate of 0.1 bar per minute. The conditioned SX was then dried in controlled 
ambient conditions (25C, 33 % RH) for 12 hours and sieved through a 500 µm 
mesh sieve prior to characterisation and formulation. 
Table 4.1 describes the conditioning and sampling protocol used throughout 











Freshly Micronised Day 0 Initial 
25°C, 33 %RH 
30 Days LH30 
60 Days LH60 
25°C, 75 %RH 
30 Days HH30 
60 Days HH60 





HFA 21 Days HFA 
 
Table 4.1    Summary of SX samples studied throughout this work 
 
4.2.2.3 Particle Size Analysis of SX 
The particle size distribution (PSD) for all samples was determined in the wet 
state using a Sympatec HELOS and CUVETTE (Sympatec GmbH, Clausthal-
Zellerfeld, Germany). Each measurement was performed in triplicate and 
particle size analysis was performed using WINDOX 5.0 software (Sympatec 
GmbH, Clausthal-Zellerfeld, Germany).  
 
4.2.2.4 Scanning Electron Microscopy of SX samples 
The morphology of the SX samples was investigated using scanning electron 
microscopy (SEM). Sample aliquots were fixed onto sticky carbon tabs (Agar 
Scientific, Cambridge, UK) followed by removal of excess powder using 
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pressurised air. Samples were subsequently sputter coated with gold (Edwards 
Sputter Coater S150B, Edwards High Vacuum, Sussex, UK) to achieve a 
thickness of approximately 20 nm. Imaging was performed using a scanning 
electron microscope (JEOL JSM6480LV, Tokyo, Japan) using 15 kV 
accelerating voltage. 
 
4.2.2.5 X-ray powder diffraction (XRPD) analysis of SX samples 
The X-ray powder diffraction (XRPD) patterns of SX samples were analysed 
on a Bruker Powder Diffractometer (D8; Bruker AXS Inc., Madison, USA) using 
CuKα radiation (λ=1.54 Å). The data were collected over a single 2θ sweep 
with range 2θ = 5 - 30° and a step size of 0.025°/step with a step time of 1.5 s. 
 
4.2.2.6 Differential Scanning Calorimetry of SX samples 
The thermal properties of all samples were investigated using a differential 
scanning calorimeter (DSC 2920, TA Instruments, Surrey, UK), calibrated with 
an indium standard. Approximately 3 mg of sample were accurately weighted 
into an aluminium pan and crimped with a lid to form a hermetic seal. The 
sample and reference pan were heated at a rate of 10◦C/min from 30◦C to 
240◦C. The calorimeter head was continuously flushed with dry nitrogen gas at 
0.2 L/min during all measurements.  
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4.2.2.7 Specific Surface Area by BET of SX samples 
The specific surface area (SSA) of SX samples was measured using a Gemini 
2360 surface area analyser (Micromeritics Instrument Corporation, Norcross, 
USA). A five-point BET nitrogen adsorption analysis was carried out in 
triplicate after degassing the samples for 24 hours in a FlowPrep 060 degasser 
(Micromeritics Instrument Corporation, Norcross, USA). 
 
4.2.2.8 Rugosity Calculation 
Rugosity (Ra) is the qualitative description of the surface roughness of 
particles. It is mathematically described in Equation 5.1 (Joshi et al., 2002). It 
uses the particles’ surface volume result obtained from particle size 
measurement and the specific surface area value achieved from BET analysis. 
The validity of rugosity values for comparative reasons relies on the lack of 
change to macroscopic shape.   
 
 a  =
 easured  ET Surface Area (SSA)
Calculated Surface Area from Particle Size  easurements (Sv)
 
    Equation 5.1 
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4.2.2.9 Cohesive-Adhesive Balance Measurements  
4.2.2.9.1 Crystallisation of substrates 
To perform quantitative binary and combination AFM-CAB analysis of 
secondary processed SX samples, smooth single crystal surfaces of 
Salmeterol Xinafoate (SX), Fluticasone Propionate (FP) and lactose 
monohydrate were produced. Briefly, saturated solutions of SX in 2 ml of 
acetone were prepared and sonicated prior to filtration via a 0.22-µm PTFE 
membrane filter (Whatman Inc., Clifton, NJ, USA). SX was crystallised using 
water as the anti-solvent. Briefly, a microscope cover slip (12 mm x 12 mm) 
was supported on a vertical post in a crystallisation dish that contained the 
anti-solvent. A droplet of the saturated solution of the API was then placed on 
the coverslip using a syringe attached to the 0.22-µm-membrane filter. The 
system was sealed by inverting a glass lid in the crystallisation dish to allow 
vapour phases of the miscible solvents to come into equilibrium resulting in 
heterogeneous nucleation and crystal growth within the droplet. The glass 
cover slip was then attached to a magnetic AFM stub.  
Lactose and FP were crystallized upon introduction of saturated droplets 
between two glass cover slips. Smooth lactose crystals were generated upon 
preparing a solution of lactose in double-distilled water, which was heated to 
100 °C with constant stirring. The heated saturated droplet of the solution was 
filtered through a 0.2 μm PTFE membrane filter (Whatman Inc., Clifton, NJ, 
USA) and placed on to the centre of a clean cover slip, which was then 
sandwiched by placing another cover slip over the droplet. Similarly, a solution 
of FP (0.75 gm-1) was prepared in methanol following sonication for 30 mins, 
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following which the solution was filtered through a 0.2 μm PTFE membrane 
filter and a droplet of this solution was then sandwiched between two 
coverslips. The resulting crystals of lactose or FP were then isolated upon 
cleaving the coverslips apart and attaching each coverslip to a magnetic AFM 
stub.  
 
4.2.2.9.2 Colloidal probe force measurements 
Prior to colloidal force measurements, individual particles from each sample of 
SX were attached onto standard V-shaped tipless cantilevers with pre-defined 
spring constants (DNP-020, DI, CA, USA) using an epoxy resin glue (Araldite, 
Cambridge, UK). Five probes were prepared for the as received, LH, HH and T 
conditioned SX samples at each pre-defined laagering stage. All probes were 
examined with an optical microscope (magnification 50x) to ensure the integrity 
of the attached particle, before allowing the thin layer of glue to cure and dry.  
Single crystal substrates were loaded onto an AFM scanner stage, which was 
enclosed in a custom-built environmental chamber, in which the ambient 
conditions were maintained at a constant temperature of 25 °C (± 1.5 °C) and 
relative humidity of 35 % RH (± 3 %). The interaction forces were measured by 
recording the deflection of the AFM cantilever as a function of the substrate 
displacement (z) by applying Hooke’s Law. Individual force curves (n = 1024) 
were conducted over a 10 µm x 10 µm area at a scan rate of 4 Hz and a 
compressive load of 40 nN.  
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A custom-built software was developed to extract data contained within each 
force-volume dataset. These data was analyzed to ensure normal distribution, 
indicating uniform contact area between the drug probe and the smooth 
substrate surfaces. Arithmetic mean and standard deviation were measured to 
produce CAB plots for the interactions of the different batches of SX with both 
lactose monohydrate and FP.  
 
4.2.2.10 Preparation of powder formulations 
SX binary formulations (0.2 % w/w) were manufactured using freshly micronised 
and conditioned samples of SX (HFA, LH30, HH30, T30, LH60, HH60, T60). 
Blends were manufactured by the sequential addition of the drug to the milled 
lactose (ML001) followed by low shear blending using a T2F Turbula® mixer 
(Wily A Bachofen AG, Basel, Switzerland) for 45 minutes at 46 rpm. 
SX/FP combination formulations were also prepared for each sample 
containing FP (1.0 % w/w) (Chemagis Bnei Brak, India) and SX (0.2 % 
w/w).  
Each blend was filled into size 3 hydroxypropylmethyl cellulose (HPMC, 
Shionogi Qualicaps, Madrid, Spain) capsules with a fill weight of 25 ± 1 mg. 
The loaded dose for the SX binary formulations was 50 µg salmeterol per 25 
mg. For the FP/SX combination formulations, the loaded doses were 250 µg of 
FP and 50 µg of salmeterol per 25 mg fill weight. The capsules were stored at 
44 % RH for 24 hours prior to in vitro testing to ensure the dissipation of any 
electrostatic charges introduced during processing. 
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4.2.2.11 In vitro aerosolisation studies 
Aerosolisation performance of the formulations was tested using a next 
generation impactor (NGI, Copley Scientific, Nottingham, UK) with pre-
separator, which was connected to two vacuum pumps to create sonic flow  
(GE Motors). The pre-separator contained 15 ml of mobile phase. The NGI 
cups were coated with 1 % v/v silicone oil in hexane to eliminate any particle 
bounce. For each experiment, two individual 25 mg capsules of the same 
blend were discharged into the NGI at 55 L/min for 4.4s, equivalent to a total 
volume of 4 L, from a Rotahaler® DPI device (Cipla, Mumbai, India). Before 
each test, the flow rate was verified with a flow meter (DFM 2000, Copley 
Scientific, Nottingham, UK). The amount of API deposited on each part of the 
NGI was determined by High Pressure Liquid Chromatography (HPLC). This 
testing protocol was repeated three times for each blend, following which, the 
mass median aerodynamic diameter (MMAD) geometric standard deviation 
(GSD), fine particle mass (FPM) and fine particle fraction (FPF) were 
determined.  
 
4.2.2.12 HPLC analysis of SX and FP 
High Pressure Liquid Chromatography (HPLC) was used to quantify the drug 
content. For the determination of drug content in SX binary formulations, the 
HPLC method consisted of a pump coupled to an auto-sampler and multi-
wavelength UV detector (Agilent 1200, Wokingham, UK) set at 235 nm. The 
pump flow rate was set to 1.5 mL/min through a Hypersil ODS-C18 column 
(Fisher Scientific, Loughborough, UK, column length 250 mm, internal 
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diameter 4.6 mm, and particle size of the packing material 5 m), which was 
placed in a column oven (Agilent, Wokingham, UK) set to 40°C. The mobile 
phase consisted of methanol, acetonitrile and water (45:35:20 % v/v). The 
elution time for the SX peak using this method was 6.7 minutes. For the drug 
content determination of FP/SX combination formulations, the HPLC method 
used a flow rate of 1.0 mL/min through a Hypersil BDS-C18 column (Fisher 
Scientific, Loughborough, UK, column length 250 mm, internal diameter 
4.0 mm, and particle size of the packing material 5 m) placed in a column 
oven set at 40°C. The mobile phase consisted of 75:25 % v/v methanol:0.6 % 
aqueous ammonium acetate.  The elution times were 3.4 and 6.7 for FP and 
SX respectively.  
For both methods, linear regression analysis was used for the assessment of 
the HPLC calibration. Quantiﬁcation was carried out by an external standard 
method, and linearity was verified between 0.05 and 50 g/mL. The limit of 
detection was 0.02 g/mL and 0.03 g/mL for both FP and SX respectively.   
 
4.2.2.13 Statistical analysis 
Linear regression analysis was used for the assessment of HPLC calibration. 
Statistical analysis between different populations carried out using one-way 
analysis of variance. Comparison of the mean values was performed by 
Tukey’s multiple comparison. All statistical analyses were performed using 
GraphPad Prism software (GraphPad Software Inc, California, USA). Error 
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bars in graphical representations of data show ± standard deviation (s.d.) in all 
cases. 
4.3 RESULTS AND DISCUSSION 
A number of physicochemical properties were studied over a period of time to 
understand the effect of environmental conditioning on the relaxation kinetics 
of SX following micronisation. Colloid probe investigations through CAB-AFM 
was used to examine the response of the trended physicochemical properties 
on the interfacial chemistry between the conditioned SX, FP and inhalation 
grade lactose monohydrate.  
 
4.3.1 Physicochemical Results for Environmentally Conditioned SX 
Samples 
X-ray powder diffraction (XRPD) scans for micronised SX and SX samples 
conditioned for 60 days at 33 %RH (LH60), 75 %RH (HH60) and 60°C (T60) 
are shown in Figure 4.1. The nature of the peaks seen between 10 and 25 
angle 2θ° for all samples suggest that environmental conditioning did not alter 
the polymorphic forms of the conditioned samples. The presence of a broad 
signal between 5 and 10 angle 2θ° for the initial SX sample, together with 
more intense responses, maybe probably related to the different packing 
properties of freshly micronised material.  
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Figure 4.1    X-ray powder diffraction profiles for the Initial, LH60, 
HH60 and T60 salmeterol xinafoate samples 
 
Differential scanning calorimetry (DSC) thermograms of the SX samples 
indicated two major endothermic phase changes at approximately 125°C and 
140°C, as shown in Figure 4.2. These thermographs correspond to the two 
polymorphs of salmeterol xinafoate in an enantiotropic system (Tong et al., 
2001; Beach et al., 1999). These thermograms further suggested that 
environmental conditioning had no impact on the polymorphic state of 
micronised SX.  
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Figure 4.2   Differential Scanning Calorimetry thermographs for the 
Initial, LH60, HH60 and   T60 salmeterol xinafoate samples 
 
The particle size distribution profiles for the freshly micronised and 
environmentally conditioned SX drug samples are tabulated in Table 4.2. 
These data show that the distribution for samples conditioned at room 
temperatures using both low and high humidity remain largely unchanged. This 
suggests a stable physical system for micronised SX, upon exposure to 
elevated humidities. Conditioning micronised SX at 60°C, however, led to a 
significant (p<0.05) coarsening in particle size. All percentile (d10, d50 and d90) 
values increased consistently over the conditioning period as shown in Table 
4.2. This shift in PSD may directly influence the aerodynamic properties of the 
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SX and potentially influencing the aerosolisation performance of formulations 
manufactured using said samples.    
  d10 (µm) d50 (µm) d90 (µm) 
Initial Day 0 0.91 ±0.03 2.42 ±0.04 5.35 ±0.05 
33 % RH 
Day 30 0.83 ±0.02 2.25 ±0.06 5.31 ±0.05 
Day 60 0.86 ±0.02 2.35 ±0.01 5.37 ±0.04 
75 % RH 
Day 30 0.84 ±0.01 2.29 ±0.03 5.29 ±0.03 











Table 4.2   Particle Size Distribution of the micronised and subsequently 
conditioned salmeterol xinafoate determined by laser diffraction 
  
The influence of temperature and humidity conditioning on the specific surface 
area per unit mass (SSA) of the SX samples is shown in Fig. 5.3. The SSA 
values together with surface area per unit volume as determined from PSD 
analysis, and calculated rugosity values for each sample are also tabulated in 
Table 4.3. Conditioning at low relative humidity appeared to continually reduce 
the SSA of the SX powder. Exposure to high humidity led to an initial drop in 
SSA but did not alter significantly upon more exposure. Exposure of SX to high 
temperature led to the most significant drop in SSA and continued to decrease 
with extended period of exposure. 
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Surface rugosity has the potential of influencing the manufacturability and 
aerosolisation performance of both binary and tertiary formulations through 
increased or decreased surface interactions based on the physical properties 




Figure 4.3   Specific Surface Area for salmeterol xinafoate samples 
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Initial Day 0 3.20 5.20 ±0.24 1.63 
33 % RH 
Day 30 3.43 4.66 ±0.18 1.27 
Day 60 3.32 4.36 ±0.21 1.40 
75 % RH 
Day 30 3.39 4.75 ±0.30 1.40 











Table 4.3   Surface area per unit volume (Sv), specific surface area per unit mass 
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Morphological analysis for the SX samples was performed using SEM imaging 
as shown in Figure 4.4. The electron micrographs showed how conditioning 
led to no apparent difference in the bulk morphological properties of the 
temperature and humidity conditioned samples.  
 
Figure 4.4    Scanning Electron Micrographs for freshly micronised SX 
(A, B), and for samples conditioned for 60 days at 33%RH (C, D), 









Dynamic vapour sorption (DVS) isotherms for freshly micronised SX and for 
the samples conditioned for 60 days at 33 %RH (LH60), 75 %RH (HH60) and 
at 60°C (T60) are shown in Figures 4.5 A-D. The DVS moisture sorption 
isotherm for the freshly micronised SX sample shows a rapid moisture uptake 
of ~0.21% w/w between 30% and 90 % RH. The sorption isotherms for the 
samples conditioned at room temperature (LH60 and HH60) on the other hand 
only indicated a moisture uptake of ~0.05 % w/w. The representative sorption 
isotherm for the T60 sample illustrates an even lower moisture uptake of ~0.03 
% w/w. This decreased moisture uptake during the moisture sorption cycles of 
the conditioned samples may suggest a decrease in the level of process 
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induced structural disorder in the samples. As for the freshly micronised SX 
samples, the LH60 and HH60 samples retain ~0.05 % w/w of the moisture 
uptake. The SX sample conditioned at 60°C for 60 days (T60) retains ~0.01 % 
w/w from the sorption cycle. This seems to suggest that whilst conditioning at 
room temperature significantly decreases amorphous regions, the application 
of elevated temperatures in conditioning SX is more effective at minimising 
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Figure 4.5A   Dynamic Vapour Sorption (DVS) isotherm for freshly 
micronised SX (Initial)
 
Figure 4.5B   Dynamic Vapour Sorption (DVS) isotherm for SX 
conditioned at 33%RH for 60 days (LH60) 
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Figure 4.5C   Dynamic Vapour Sorption (DVS) isotherm for SX 
conditioned at 75%RH for 60 days (HH60)  
 
Figure 4.5D   Dynamic Vapour Sorption (DVS) isotherm for SX 
conditioned at 60°C for 60 days (T60) 
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4.3.2 Cohesive-Adhesive Balance results for environmentally 
conditioned Salmeterol Xinafoate 
 
CAB values for all SX samples are tabulated in Table 4.4. The CAB plots 
measures the interfacial chemistry of the SX particles with respect to lactose 
and FP. Figures 4.6-4.8 show the linear regression analysis of the CAB plots 
with respect to lactose and to FP.  
 
  CAB wrt Lactose CAB wrt FP 
Initial Day 0 1.83 ±0.03 1.35 ±0.02 
33 % RH 
Day 30 2.45 ±0.02 1.74 ±0.01 
Day 60 2.23 ±0.02 1.96 ±0.03 
75 % RH 
Day 30 2.35 ±0.01 1.84 ±0.03 









Table 4.4   Cohesive-Adhesive Balance (CAB) values with respect to Lactose 
and Fluticasone Propionate for freshly micronised SX and for SX samples 
conditioned environmentally  
 
CAB ratios show a general and significant trend towards a more cohesive 
interfacial system, suggesting a higher tendency for SX-SX interactions upon 
Chapter FOUR                                                                                    179 
 
conditioning. Freshly micronised SX already exhibits a cohesive tendency with 
respect to lactose monohydrate with a CAB ratio of 1.83, suggesting SX-SX 
interactions have a surface affinity 1.83 times greater than SX-Lactose 
interactions. This cohesive tendency is less pronounced with respect to FP, 
with SX-SX interactions 1.35 times greater than SX-FP interactions. These 
data suggest a predominant cohesive chemical nature for freshly micronised 
SX.  
 
Environmental conditioning seemed to drive a cohesive shift for 
environmentally conditioned SX samples. This shift seems to largely occur 
within the first 30 days of conditioning, suggesting that interfacial instability for 
micronised SX is more significant (p<0.05) during the first 30 days post-
micronisation. Whilst the cohesive shift is observed in all samples, the 
interfacial chemical nature of SX with respect to FP seems to be more 
responsive to post-micronisation conditioning. The cohesive shift for 
conditioned samples with respect to FP varies from 45 to 54 % at the 60 day 
mark. On the other hand, the cohesive shift with respect to lactose varies 
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Figure 4.6A Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and samples conditioned at low 
humidity (LH30, LH60) with respect to lactose
 
Figure 4.6B Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and samples conditioned at low 
humidity (LH30, LH60) with respect to FP 
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Figure 4.7A Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and samples conditioned at high 




Figure 4.7B Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and samples conditioned at high 
humidity (HH30, HH60) with respect to FP
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Figure 4.8A Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and samples conditioned at 60°C 




Figure 4.8B Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and samples conditioned at 60°C (T30, 
T60) with respect to FP
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4.3.3 Aerosolisation performance results for environmentally 
conditioned Salmeterol Xinafoate in binary formulations 
The aerosolization performance for binary, carrier-based DPI formulations with 
freshly micronised and conditioned SX samples are tabulated in Table 4.5. 
These data support the cohesive shift observed in the CAB analysis. The 
emitted dose (ED) dropped significantly (p<0.02) for all formulations 
manufactured using SX samples conditioned for 30 days. Thereafter, the 
emitted dose seemed to remain stable confirming interfacial instability is 
largely affected within the first 30 days post-micronisation. This initial drop in 
ED maybe directly related to the increased cohesive chemical nature of SX 
particles, leading to increase particle segregation and hindering aerosolisation 
deaggregation efficiency (Jones et al., 2008). This marked drop in emitted 
dose leads to a concomitant decrease in fine particle mass (FPM). 
Furthermore, the mass median aerodynamic diameter (MMAD) results reflect 
an increased cohesive nature of SX for all three formulations conditioned for 
30 and 60 days. These MMAD data are consistent with greater cohesion 
between SX particles which are unable to deaggregate as efficiently as the 
freshly micronised particles.  
These in vitro data support the increase in cohesive behaviour of SX upon 
conditioning and that interfacial stability is obtained within the first 30 days of 
conditioning and translates into aerosolisation performance stability.    










Table 4.5 In Vitro aerosolisation performance for SX formulations manufacture with freshly micronised and environmentally 
conditioned SX. Results are described by the recovered dose (RD), emitted dose (ED), fine particle mass (FPM), fine particle 
fraction (FPF) expressed as a percentage of the emitted dose, mass median aerodynamic diameter (MMAD) and geometric 
standard deviation (GSD) 
 
 RD (µg) ED (µg) FPM (µg) FPF (%ED) MMAD (µm) GSD (µm) 
Initial 54.58 ±3.12 32.11 ±2.55 11.69 ±1.01 36.39 ±2.34 1.98 ±0.02 2.71 ±0.02 
LH30 49.11 ±2.46 24.02 ±2.04 9.31 ±0.78 38.76 ±2.14 3.04 ±0.03 2.07 ±0.01 
LH60 47.66 ±3.01 22.70 ±1.67 8.12 ±0.92 35.78 ±1.97 3.08 ±0.02 2.14 ±0.02 
HH30 45.09 ±2.98 27.09 ±3.24 8.87 ±1.44 32.74 ±2.89 3.40 ±0.02 2.03 ±0.01 
HH60 43.61 ±3.45 28.69 ±2.01 8.96 ±0.89 31.21 ±2.43 3.66 ±0.02 2.11 ±0.02 
T30 47.12 ±4.21 24.57 ±1.78 8.84 ±1.09 35.98 ±1.79 3.46 ±0.04 1.90 ±0.02 
T60 47.02 ±4.11 23.55 ±1.12 8.25 ±0.83 35.01 ±2.13 3.94 ±0.03 2.09 ±0.01 
Chapter FOUR                                                                                    185 
 
Stage by stage deposition profiles of SX binary formulations manufactured 
using freshly micronised and environmentally conditioned SX samples are 
show in Figures 4.9 A-C. Figure 4.9A shows a significant (p<0.02) increase in 
drug deposition in the device, whilst figures 5.9B and 5.9C show significant 
decreases in stages 2-4. These deposition profiles are consistent with a 
cohesive shift in the chemical nature of the formulations.  
 
Figure 4.9A   Stage by stage deposition profile expressed as the 
percentage of emitted dose per stage for SX in binary formulations 
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Figure 4.9B   Stage by stage deposition profile expressed as the 
percentage of emitted dose per stage for SX in binary formulations 
manufactured using SX conditioned at 75%RH 
 
Figure 4.9C   Stage by stage deposition profile expressed as the 
percentage of emitted dose per stage for SX in binary formulations 
manufactured using SX conditioned at 60°C 
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4.3.4 Aerosolisation performance results for environmentally 
conditioned Salmeterol Xinafoate in ternary formulations 
 
Tables 4.6 and 4.7 tabulate the in vitro performance results SX and FP, 
respectively for freshly micronised and conditioned SX. These results describe 
the influence of SX post-micronisation relaxation kinetics on ternary 
formulations with inhalation grade lactose monohydrate and an aged and 
stable batch of FP. These data seem to be consistent with interfacial shifts 
towards to more cohesively-led chemical system. Fine Particle Mass (FPM) for 
SX drops consistently for samples conditioned at room temperatures (LH60, 
HH60). The formulations manufactured using SX conditioned at 60°C on the 
other hand seem to stabilise within the first 30 days of conditioning. There 
seems to be however a significant increase (p<0.02) in the MMAD for T60 
sample. This MMAD increase is also observed in the FP data for the T60 
sample and together with the cohesive shift in the interfacial properties of the 
SX, might be consistent with the lower rugosity and SSA values reported for 
this sample in table 4.3. Data for the aerosolisation performance of FP follow 
similar trends to SX data and suggest that FP is influenced by the changing 
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Table 4.6   In vitro aerosolisation performance for SX in ternary formulations with FP manufactured with freshly micronised and 
environmentally conditioned SX. Results are described by the recovered dose (RD), emitted dose (ED), fine particle mass (FPM), 
fine particle fraction (FPF) expressed as a percentage of the emitted dose, mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) 
 RD (µg) ED (µg) FPM (µg) FPF (%ED) MMAD (µm) GSD (µm) 
Initial 48.75 ±3.57 28.78 ±2.21 11.90 ±1.27 41.35 ±1.36 3.08 ±0.03 2.00 ±0.02 
LH30 57.89 ±5.36 30.78 ±3.01 12.63 ±1.83 41.07 ±1.87 3.07 ±0.02 2.00 ±0.02 
LH60 45.74 ±4.28 29.33 ±2.48 7.33 ±0.78 24.97 ±1.42 3.17 ±0.02 2.00 ±0.01 
HH30 47.98 ±3.48 25.96 ±3.01 9.09 ±0.38 35.02 ±1.37 2.75 ±0.01 1.89 ±0.01 
HH60 43.99 ±2.98 26.20 ±2.45 6.90 ±0.46 26.34 ±1.36 3.08 ±0.02 1.96 ±0.01 
T30 41.62 ±4.38 21.57 ±1.84 5.13 ±0.67 23.78 ±0.83 3.16 ±0.03 1.84 ±0.02 
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Table 4.7   In vitro aerosolisation performance for FP in ternary formulations with SX manufactured with freshly micronised and 
environmentally conditioned SX. Results are described by the recovered dose (RD), emitted dose (ED), fine particle mass (FPM), 
fine particle fraction (FPF) expressed as a percentage of the emitted dose, mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) 
 RD (µg) ED (µg) FPM (µg) FPF (%ED) MMAD (µm) GSD (µm) 
Initial 216.50 ±7.35 139.28 ±4.55 47.26 ±2.45 33.93 ±1.35 3.91 ±0.04 2.00 ±0.02 
LH30 231.10 ±8.35 119.34 ±3.98 40.22 ±1.38 33.70 ±1.03 4.01 ±0.03 1.98 ±0.02 
LH60 206.11 ±6.98 131.91 ±4.58 23.52 ±2.01 17.83 ±0.85 4.34 ±0.03 1.96 ±0.03 
HH30 207.49 ±5.36 111.50 ±6.02 31.40 ±1.48 28.17 ±1.23 3.72 ±0.02 1.96 ±0.01 
HH60 195.28 ±9.46 106.53 ±4.36 29.33 ±1.82 27.54 ±1.83 3.40 ±0.04 1.87 ±0.02 
T30 202.87 ±6.24 106.25 ±9.11 28.05 ±0.97 26.41 ±1.49 3.40 ±0.03 1.88 ±0.02 
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4.3.5 Physicochemical Characterisation of Post-Micronised Conditioned 
SX using HFA-134a 
Physicochemical analysis of in-situ conditioned SX with HFA-134a was 
performed to determine any possible influence on material properties.  
The XRPD diffractograms for the freshly micronised and HFA conditioned SX 
are shown in Fig. 5.10. The peaks present between 10 and 40 angle 2θ° 
suggest there is no change in the polymorphic nature of the two samples. 
There is a significant decrease in peak intensity for the HFA conditioned 
sample, however this seems to be consistent with packing differences between 
freshly micronised and aged material.  
 
 
Figure 4.10    X-ray powder diffraction profiles for the Initial and HFA 
conditioned SX samples 
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Figure 4.11 shows the DSC thermographs for the unconditioned and HFA 
conditioned SX. This thermal analysis suggests that HFA conditioning has 
either led to a complete conversion of form II into form I or possibly the 
removal of the form II seeds, which may be formed during micronisation of 
form I of SX. This is consistent with the findings documented in (Tong et al., 
2001; Beach et al., 1999) form II is less stable than form I. Fast-cooling 
crystallisation processes and particle engineering technologies are known to 
produce salmeterol xinafoate of exclusively form I (Beach et al., 1999). 
 
Figure 4.11   Differential Scanning Calorimetry thermographs for the 
Initial and HFA conditioned SX samples 
 
Chapter FOUR                                                                                    192 
 
Particle size distribution data of the initial and HFA conditioned SX is shown in 
Table 4.8. The d10 and d50 percentiles indicate that conditioning using HFA has 
limited influence on the physical size of the micronised SX. There is a slight 
increase in the d90 values which suggests a small but significant shift towards 
a coarser distribution. Whilst this shift is consistent with the use of elevated 
temperatures and the possible influence of Ostwald ripening, the overall 
particle size distribution remains largely stable.  
 
  d10 (µm) d50 (µm) d90 (µm) 
Initial Day 0 0.91 ±0.03 2.42 ±0.04 5.35 ±0.05 
HFA Day 21 0.90 ±0.03 2.45 ±0.05 5.62 ±0.07 
 
    
Table 4.8   Particle Size Distribution of the Initial and HFA conditioned SX 
samples determined by laser diffraction 
 
Figure 4.12 shows a significant drop in specific surface area (SSA) determined 
by BET analysis consistent with the drop seen for environmentally conditioned 
(LH60, HH60, T60) SX samples. With similar PSD profiles, the drop in SSA 
coincides with a significant drop in rugosity from 1.63 for the freshly micronised 
SX to 1.28 for SX conditioned in-situ with HFA. With stable physicochemical 
properties, a drop in rugosity may prove a significant factor due to the altered 
mixing pattern smoother particles may undergo. A rugosity value of 1.28 
represent the lowest value observed in this conditioning study, suggesting that 
HFA conditioning produced SX particles with the smoothest surfaces.   
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Figure 4.12   Specific Surface Area for Initial and HFA conditioned SX 





2cm3) SSA (m2/gram) Ra 
Initial Day 0 3.20 5.20 ±0.24 1.63 
HFA Day 21 3.19 4.09 ±0.16 1.28 
 
    
Table 4.9   Surface area per unit volume (Sv), specific surface area per unit mass 
(SSA), and rugosity values (Ra) for the Initial and HFA conditioned SX samples 
 








Figure 4.13    Scanning Electron Micrographs for the Initial SX sample 
(A) and for the HFA conditioned sample (C) at a magnification factor 
of 3,000, and for the Initial SX sample (B) and the HFA conditioned 
sample (D) at a magnification factor of 10,000 
 
The morphology of the HFA conditioned sample was studies using SEM 
imaging. The scans shown in Figure 4.13 do not show any significant 
differences to the bulk morphologies of the samples. Conditioning micronised 
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Figure 4.14A   Dynamic Vapour Sorption (DVS) isotherms for freshly 
micronised SX
 
Figure 4.14B   Dynamic Vapour Sorption (DVS) isotherms for SX 
conditioned in-situ with HFA for 21 days 
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Figures 4.14 A-B show the isotherms for freshly micronised and HFA 
conditioned SX respectively. The DVS moisture sorption isotherm for the 
freshly micronised SX, described previously, shows a significant moisture 
uptake (~0.21 % w/w between 30 % and 90 % RH) which is only partially 
retained following the desorption cycle. The HFA isotherm shows (Figure 
4.14B) a negative hysteresis with a net moisture loss of ~0.65 % w/w, possibly 
suggesting some moisture retention trapped in slightly amorphous regions.  
 
4.3.6 Cohesive-Adhesive Balance and Impaction results for SX 
conditioned in-situ with HFA post-micronisation 
The interfacial chemistry and aerosolisation behaviour were examined to 
further understand the influence of conditioning freshly micronised SX using 
HFA. The CAB values in Table 4.10 indicated a similar cohesive shift in the 
interfacial nature of SX as previously observed for the environmentally 
conditioned SX samples. A significant (p<0.02) cohesive shift is noted for SX 
particles with respect to both lactose and FP. As previously shown (Table 4.4), 
the cohesive shift is larger for SX with FP (~45 %) than then it is for SX with 
respect to lactose (~36 %). The linear regression analysis of the CAB plots are 
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Table 4.10   Cohesive-Adhesive Balance (CAB) values with respect to Lactose 
and Fluticasone Propionate for freshly micronised SX and for SX samples 
conditioned in-situ with HFA  
  CAB wrt Lactose CAB wrt FP 
Initial Day 0 1.83 ±0.03 1.35 ±0.02 
HFA Day 30 2.48 ±0.04 1.96 ±0.04 
   
 
   
    
Figure 4.15A Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and and SX conditioned in-situ with 
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Figure 4.15B Cohesive-Adhesive Balance (CAB) plot of the freshly 
micronised SX sample (Initial) and SX conditioned in-situ with HFA 
with respect to FP 
 
The in vitro aerosolisation data for binary and ternary formulations 
manufactured using freshly micronised and HFA conditioned SX are tabulated 
in table 4.11. As previously seen with environmentally conditioned SX 
samples, the cohesive shift observed in the CAB data leads to a decreased 
aerosolisation performance. Data shown for the binary formulation evidence a 
significant (p<0.02) increase in MMAD with concurrent significant drops 
(p<0.02) in ED and FPF. Figure 4.16 reflects this cohesive shift with a 
significant (p<0.02) increase in drug deposition recorded in the device stage 
with subsequent significant (p<0.05) decrease in deposition recorded on 
stages 1-5. 
Chapter FOUR                                                                                    199 
 
Data shown for the ternary formulation evidence how the larger cohesive shift 
observed in the SX-FP chemical system leads to a decreased aerosolisation 
performance for FP too. This is probably due to a reduction in the formation iof 
stbale FP-SX agglomerates which leads to lower deaggreation efficiency of the 
APIs and is indicated by the decrease in MMAD of the FP upon SX 
conditioning in HFA-134a. 
 
Table 4.11   In vitro aerosolisation performance data for formulations 
manufactured using SX conditioned in-situ with HFA. Results are described by 
the recovered dose (RD), emitted dose (ED), fine particle mass (FPM), fine 
particle fraction (FPF) expressed as a percentage of the emitted dose, mass 
median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) 
 RD (µg) ED (µg) FPM (µg) FPF (%ED) MMAD (µm) GSD (µm) 
SX Binary 
Initial 54.58 ±3.12 32.11 ±2.55 11.69 ±1.01 36.39 ±2.34 1.98 ±0.02 2.71 ±0.02 
HFA 46.54 ±2.38 24.74 ±1.98 6.40 ±0.78 25.87 ±1.31 3.99 ±0.03 2.17 ±0.02 
SX in Combination with FP 
Initial 48.75 ±3.57 28.78 ±2.21 11.90 ±1.27 41.35 ±1.36 3.08 ±0.03 2.00 ±0.02 
HFA 47.50 ±3.61 24.41 ±2.01 6.38 ±0.69 26.14 ±0.99 3.23 ±0.03 1.92 ±0.02 
FP in Combination with SX 
Initial 216.50 ±7.35 139.28 ±4.55 47.26 ±2.45 33.93 ±1.35 3.91 ±0.04 2.00 ±0.02 
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Figure 4.16   Stage by stage deposition profile expressed as the 
percentage of emitted dose per stage for SX in binary formulations 
manufactured using SX conditioned in-situ with HFA 
 
 
4.4 CONCLUSIONS   
The results reported in this study have shown how post-micronisation 
conditioning can expedite the stress relaxation of micronised SX. Whilst 
particle size is largely unaffected by conditioning, other key physical properties 
such as specific surface area and surface roughness are directly influenced 
when SX particles are exposed to elevated temperature or humidity. These 
changes also coincide with a cohesive shift in the interfacial chemical system 
of SX particles. The ability of having a manufacturing process which expedites 
the thermodynamic stability of the drug properties is critical in being able to 
formulate a drug product which remains stable throughout the registered shelf-
life. Whilst conditioning SX drives a cohesive shift in the chemical nature of the 
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SX particles, this shift is more pronounced with respect to FP. Results show 
how conditioning SX has a significant impact on the performance of FP in a 
ternary formulation. Interfacial and surface area stability seem to be achieved 
within the first 30 days of conditioning for SX particles using both conditioning 
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The use of glycopyrrolate bromide (GLY) as an inhaled dosage form was first 
approved in 2012 (European Medicines Agency, 2012) as a once-daily 
maintenance bronchodilator treatment to relieve symptoms in adult patients 
with chronic obstructive pulmonary disease (COPD). It is administered as a 
50µg dose in a capsule based dry powder inhaler. Phase III clinical trial data 
showed how the use of GLY improved lung function and reduced both 
shortness of breath and exacerbations (D’Urzo et al., 2011; Beeh et al., 2011). 
Clinical trials also demonstrated superior bronchodilation effect over tiotropium 
(Kerwin et al., 2012), another maintenance bronchodilator used for the 
treatment of COPD.  
 
For drug delivery to the lungs, GLY crystals need to be reduced to a mean 
particle size of less than 10µm (Jones et al., 2008). This is commonly achieved 
by highly energetic air-jet micronisation, creating high velocity collisions which 
lead to size reduction. This process, as discussed previously, creates new 
surfaces, and may induce mechanical activation which may lead to physical 
and chemical modifications which can influence flow, adhesion and stability 
issues (Shur et al., 2008). It has been widely reported, that while unmicronised 
GLY is stable, the micronisation process appears to lead to instability in terms 
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of handling, due to irreversible particle agglomeration as the hydrophilic GLY 
molecules aggressively absorbing water from the atmosphere (Rich, 2007). 
The tendency to form drug aggregates is synonymous with quaternary 
ammonium compounds (Pandy et al., 2010) and relates to instability in 
physical and chemical properties, leading to a high degree of variation in the 
performance of formulations. It has been reported elsewhere (Morton et al., 
2008) that the introduction of a post-micronisation conditioning step can be 
used to alter the dynamics by which the new surfaces of the drug particles re-
equilibrate to the more stable crystalline state. This study therefore aims at 
assessing the introduction of 2 distinct conditioning steps in such a way as to 
impede the formation of drug aggregation for post-micronised GLY particles, 
and thereby yield GLY particles with desirable and stable physicochemical 
properties.      
 
5.2 MATERIAL & METHODS 
5.2.1 Materials 
Coarse GLY crystals, batch number 0623003, were bought from Sigma-Aldrich 
(St. Louis, MO, United States). GLY is a long-acting muscarinic-agonist 
(LAMA) with a chemical name of 3[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-
dimethyl pyrrolidinium bromide. It is a quaternary ammonium salt with a 
molecular weight of 398.33 and has a chemical formula of C19H28BrNO3. GLY 
has a highly polar nature with a solubility of 21.66 mg/mL. It’s melting point is 
192.5◦C and has a partition coefficient of 0.304 (log10 P = -1.52) in n-
Chapter FIVE                                                                                       204 
 
octanol/water system at ambient temperature. Commercially, GLY is marketed 
as a once daily bronchodilator treatment for COPD. As an anticholinergic 
agent, GLY works by blocking the bronchoconstrictor action of acetylcholine on 
airway smooth muscle cells, consequently dilating the airways. The long 
duration of action can be partly attributed to the sustained concentrations of 
the active substance in the lung as reflected by the prolonged terminal 
elimination half-life of GLY seen in data submitted by the market application 
holder (European Medicines Agency, 2012). 
A milled grade of lactose, ML001, was used throughout this study, supplied by 
DFE Pharma (Vehgel, Netherlands). All solvents used were of HPLC grade 
(Fisher Chemicals, Loughborough, UK). Ultra pure water was produced by 
reverse osmosis (MilliQ, Millipore, Molsheim, France). HFA 134a was supplied 
by Mexichem Fluor (Cheshire, UK) and had a batch number of 003215. 
 
5.2.2 Methods 
5.2.2.1 Micronisation of coarse Glycopyrrolate crystals by air-jet milling  
10 grams of glycopyrrolate bromide were micronised by air-jet milling (McOne, 
Jetpharma, Balerna, Switzerland) under nitrogen using a grinding pressure of 
8 bar and an injection pressure of 12 bar. The feed rate used was of 
approximately 1 gram per minute. These settings yielded just over 6 grams of 
micronised GLY particles with a d90 of 4.20µm which were split into 3 batches 
of 2 grams for post-micronisation conditioning described in table 5.1. 
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Conditions Duration Sample Reference Formulations 
Ambient (25◦C/33 % RH) 7 Days Ambient 0.4% w/w in ML001 
70◦C (33 % RH) 7 Days T70 0.4% w/w in ML001 
HFA (in situ) 7 Days HFA 0.4% w/w in ML001 
  
Table 5.1    Summary of GLY post-micronisation conditioning throughout this 
work 
 
In situ conditioning of the freshly micronised GLY was performed by placing 
the 2 gram sample in 60 grams of HFA. The HFA was directly inserted into a 
pressurised vessel and kept under pressure for 7 days. The vessel was then 
de-pressurised at a rate of 0.1 bar per minute. The HFA conditioned GLY 
sample was left to dry in controlled ambient conditions (25◦C, 33 % RH) for 12 
hours.  
Following the 7 day laagering period, the 3 conditioned GLY samples, ambient, 
T70 and HFA were fully characterised for their physicochemical properties, 
formulated as 0.4 % w/w binary formulations with lactose, and their in vitro 
aerosolization performance measured.   
 
5.2.2.2 Particle Size Analysis  
Particle size distributions of all GLY samples were measured in the wet state 
using a Sympatec HELOS and CUVETTE (Sympatec GmbH, Clausthal-
Zellerfeld, Germany) laser diffraction system using an R3 lens (0.5-175 μm). 
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Approximately 20 mg of GLY particles were suspended in HPLC grade 
cyclohexane containing 0.5 %w/v lecithin (Acros Organics, Geel, Belgium) and 
sonicated for 3 minutes and immediately transferred into a 50 mL cuvette to 
produce an appropriate optical concentration (8-12 %). Each measurement 
was performed in triplicate and particle size analysis was performed using 
WINDOX 5.0 software (Sympatec GmbH, Clausthal-Zellerfeld, Germany).  
 
5.2.2.3 Scanning Electron Microscopy  
Particle morphology of GLY crystals and the 3 conditioned samples was 
investigated using scanning electron microscopy (SEM). Imaging was 
performed using a scanning electron microscope (JEOL JSM6480LV, Tokyo, 
Japan) using 15 kV accelerating voltage. 
 
5.2.2.4 X-ray powder diffraction (XRPD) analysis  
The X-ray powder diffraction (XRPD) patterns of GLY samples were analysed 
on a Bruker Powder Diffractometer (D8; Bruker AXS Inc., Madison, USA) using 
CuKα radiation (λ=1.54 Å). The data were collected over a single 2θ sweep 
with range 2θ = 5 - 30° and a step size of 0.025°/step with a step time of 1.5 s. 
 
5.2.2.5 Differential Scanning Calorimetry  
The thermal properties of all samples were investigated using a differential 
scanning calorimeter (DSC 2920, TA Instruments, Surrey, UK). The sample 
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and reference pan were heated at a rate of 10◦C/min from 30◦C to 250◦C. The 
calorimeter head was continuously flushed with dry nitrogen gas at 0.2 L/min 
during all measurements.  
 
5.2.2.6 Specific Surface Area by BET  
The specific surface area of the GLY crystals and all 3 conditioned samples 
was measured using a Gemini 2360 surface area analyser (Micromeritics 
Instrument Corporation, Norcross, USA).  
 
5.2.2.7 Rugosity Calculation 
Rugosity (Ra) is the qualitative description of the surface roughness of 
particles. It is mathematically described in Equation 6.1 (Joshi et al., 2002). It 
uses the particles’ surface volume result obtained from particle size 
measurement and the specific surface area value achieved from BET analysis. 
The validity of rugosity values for comparative reasons relies on the lack of 
change to macroscopic shape.   
 
 a  =
 easured  ET Surface Area (SSA)
Calculated Surface Area from Particle Size  easurements (Sv)
 
    Equation 6.1 
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5.2.2.8 Methodology of the CAB approach to colloid probe AFM 
5.2.2.8.1 Crystallisation of substrates 
To perform quantitative binary and combination AFM-CAB analysis of 
secondary processed GLY samples, smooth single crystal surfaces of GLY 
and lactose monohydrate were produced. Briefly, saturated solutions of GLY in 
2 ml of acetone were prepared and sonicated prior to filtration via a 0.22-µm 
PTFE membrane filter (Whatman Inc., Clifton, NJ, USA). GLY was crystallised 
using water as the anti-solvent. Briefly, a microscope cover slip (12 mm x 12 
mm) was supported on a vertical post in a crystallisation dish that contained 
the anti-solvent. A droplet of the saturated solution of the API was then placed 
on the coverslip using a syringe attached to the 0.22-µm-membrane filter. The 
system was sealed by inverting a glass lid in the crystallisation dish to allow 
vapour phases of the miscible solvents to come into equilibrium resulting in 
heterogeneous nucleation and crystal growth within the droplet. The glass 
cover slip was then attached to a magnetic AFM stub.  
Lactose was crystallized upon introduction of saturated droplets between two 
glass cover slips. Smooth lactose crystals were generated upon preparing a 
solution of lactose (1 gm-1) in double-distilled water, which was heated to 100 
°C with constant stirring. The heated saturated droplet of the solution was 
filtered through a 0.2 μm PTFE membrane filter (Whatman Inc., Clifton, NJ, 
USA) and placed on to the centre of a clean cover slip, which was then 
sandwiched by placing another cover slip over the droplet. The resulting 
lactose crystals were then isolated upon cleaving the coverslips apart and 
attaching each coverslip to a magnetic AFM stub.  
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5.2.2.8.2 Colloidal probe force measurements 
Prior to colloidal force measurements, individual particles from each GLY were 
attached onto standard V-shaped tipless cantilevers with pre-defined spring 
constants (DNP-020, DI, CA, USA) using an epoxy resin glue (Araldite, 
Cambridge, UK). Five probes were prepared for the as received, ambient, T70 
and HFA conditioned GLY samples. All probes were examined with an optical 
microscope (magnification 50x) to ensure the integrity of the attached particle, 
before allowing the thin layer of glue to cure and dry.  
Single crystal substrates were loaded onto an AFM scanner stage, which was 
enclosed in a custom-built environmental chamber, in which the ambient 
conditions were maintained at a constant temperature of 25 °C (± 1.5 °C) and 
relative humidity of 35 % RH (± 3 %). The interaction forces were measured by 
recording the deflection of the AFM cantilever as a function of the substrate 
displacement (z) by applying Hooke’s Law. Individual force curves (n = 1024) 
were conducted over a 10 µm x 10 µm area at a scan rate of 4 Hz and a 
compressive load of 40 nN.  
A custom-built software was developed to extract data contained within each 
force-volume dataset. These data was analyzed to ensure normal distribution, 
indicating uniform contact area between the drug probe and the smooth 
substrate surfaces. Arithmetic mean and standard deviation were measured to 
produce CAB plots for the interactions of the different samples of GLY with 
lactose monohydrate.  
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5.2.2.9 Preparation of powder formulations 
0.4 % w/w GLY binary formulation blends were manufactured for each of the 3 
conditioned GLY samples. All 3 GLY samples were sieved through a mesh 
size of 200µm prior to formulating. The 4 gram blends were manufactured by 
the sequential addition of the drug to the milled lactose (ML001) followed by 
low shear blending using a T2F Turbula® mixer (Wily A Bachofen AG, Basel, 
Switzerland) for 45 minutes at 46 rpm. 
From each blend, 12.5 ± 0.5 mg were hand filled into size 3 
hydroxypropylmethyl cellulose (HPMC, Shionogi Qualicaps, Madrid, Spain) 
capsules. The loaded dose for the GLY binary formulations was 50 µg of GLY 
per 12.5 mg fill weight. In order to ensure the dissipation of any electrostatic 
charges induced during processing, the capsules were stored at 44 % RH for 
24 hours prior to in vitro testing. 
5.2.2.10 In vitro aerosolisation testing 
A next generation impactor (NGI, Copley Scientific, Nottingham, UK) 
connected to vacuum pumps (GE Motors) was used to test the aersolisation of 
each formulation. The NGI surfaces were coated with 1 % v/v silicone oil in 
hexane to eliminate any particle bounce. For each experiment, two individual 
capsules of the same blend were discharged into the NGI at a flow rate of 60 
L/min for 4 seconds, equivalent to a total volume of 4L, from a Rotahaler® DPI 
device (Cipla, Mumbai, India). A flow meter (DFM 2000, Copley Scientific, 
Nottingham, UK) was used to verify the air flow prior to each test. The amount 
of API deposited on each part of the NGI was determined by high pressure 
liquid chromatography (HPLC) analysis. This testing protocol was repeated 
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three times for each formulation, following which, the mass median 
aerodynamic diameter (MMAD) geometric standard deviation (GSD), fine 
particle mass less than 5.0μm (FP ) and fine particle fraction (FPF) were 
determined.  
5.2.2.10.1 Stability profile assessment for formulations via stress       
testing 
A selection of capsules from each formulation were hermetically sealed in 
aluminium packaging and put into two distinct stability chambers; one set at 
30◦C with a relative humidity of 65 %, and the other at 40◦C and 75 % RH. The 
in vitro performance of these capsules was tested at the pre-defined time 
intervals of 1 and 3 months. Testing for in vitro aerosolisation performance was 
conducted as previously described.    
5.2.2.11 HPLC Methodology for the quantification of GLY 
Detection and quantification of GLY was performed via HPLC analysis. The 
mobile phase consisted of 10 % acetonitrile (Fisher Chemicals, Loughborough, 
UK), 40 % 0.02M sodium dihydrogen phosphate monohydrate (Sigma, 
Gillingham, UK) adjusted to a pH of 6.50 and 50 % methanol (Fisher 
Chemicals, Loughborough, UK). This was pumped (Jasco PU-980, Tokyo, 
Japan) at a flow rate of 1.0 mL/min through a 250 mm long hypersil-BDS 
column of a 4.0 mm inner diameter with silica gel packing with a particle size of 
5 µm (Thermo Scientific, Loughborough, UK). The samples were injected 
using an autosampler (Jasco, Tokyo, Japan) into the column fit into an oven 
(Jasco CO-965, Tokyo, Japan) kept at 30◦C. The eluted drug was detected 
using a Jasco UV-975 detector (Jasco, Tokyo, Japan) set at a wavelength of 
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222nm for GLY. The retention time was of approximately 4.75 minutes. A 
linear regression analysis of GLY standards with known concentrations varying 
between 0.05 and 50 µg/mL was used to validate the method and quantify the 
unknown samples. The limit of detection for this method was found to be 0.01 
µg/mL and the linearity of the method between the validated concentrations of 
0.05 µg/mL and 50 µg/mL had a coefficient of determination of 0.9997.  
5.2.2.12 Statistical analysis 
Statistical analysis between different populations was carried out using one-
way analysis of variance. Comparison of the mean values was performed by 
Tukey’s multiple comparison. Analysis for statistical difference was performed 
using GraphPad Prism software (GraphPad Software Inc, California, USA). 
Error bars in graphical representations of data show ± standard deviation (s.d.) 
in all cases. 
 
5.3 Results and Discussion 
5.3.1 Physicochemical characterisation 
In order to understand the influence of post-micronisation conditioning on the 
structural relaxation of GLY, the physicochemical properties of the conditioned 
samples were studied. The particle size distribution data collected for all the 
conditioned GLY samples are tabulated in table 5.2.  
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 d10 (µm) d50 (µm) d90 (µm) 
Crystals 2.22 ±0.03 36.03 ±0.04 71.54 ±0.29 
Post-Micronisation 0.78 ±0.03 2.04 ±0.03 4.20 ±0.11 
Ambient (7 Days) 2.11 ±0.02 21.58 ±0.04 66.72 ±0.31 
T70 (7 Days) 0.82 ±0.04 2.09 ±0.02 4.35 ±0.17 
HFA (7 Days) 0.77 ±0.02 1.90 ±0.03 3.80 ±0.12 
 
Table 5.2   Particle Size Distribution of GLY samples handled during this study 
as determined by laser diffraction 
 
The particle size data demonstrated a high degree of particle aggregation may 
occur when freshly micronised GLY is exposed to ambient conditions for 7 
days following air-jet micronisation. This particle aggregation process is 
thought to be caused by the aggressive uptake of water by the hydrophilic GLY 
particles as reported elsewhere (Rich, 2007). The particle size distribution of 
this sample exhibited a very significant (p<0.001) increase in the d90 value for 
the ambient GLY sample, suggesting that this sample may not be suitable for 
delivery to the lungs (Jones et al., 2008a). The T70 and HFA GLY particle size 
distribution data suggested that post-micronisation conditioning of GLY 
particles for 7 days using both temperature and in situ conditioning may 
impede the aggregation of the GLY particles. The particle size distributions for 
both these samples suggest that the GLY particles are suitable for delivery to 
the lungs (Jones et al., 2008a).  
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The SEM micrographs for GLY crystals and the three distinct post-
micronisation conditioned GLY particles are shown in figure 5.1. These 
micrographs reaffirm the particle behaviour seen in the particle size distribution 
results, highlighting how the ambient GLY sample (figure 5.1B) aggregates to 
form a coarse cluster of micronised particles (figure 5.1A) following ambient 
storage for 7 days post-micronisation. The GLY particles conditioned as 
described previously in table 5.1 and referred to as T70 and HFA, produce 
SEM micrographs (figure 5.1 C-F) show particles suitable for delivery to the 















Figure 5.1    Scanning Electron Micrographs for GLY crystals (A), 
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Figure 5.2    X-ray powder diffraction profiles for GLY crystals and the 
post-micronised conditioned samples 
 
Figure 5.2 shows the XRPD diffractograms for the GLY crystals, ambient, T70 
and HFA samples. The sharp peaks observed in the diffractograms for all 
samples suggest polymorphic stability upon conditioning, although this was 
expected since only one polymorphic form has been reported for GLY (Baxter, 
2011). The XRPD results also suggest that all GLY samples are predominantly 
crystalline in nature, even though this analytical technique is unable to detect 
amorphous content levels below 10 % (Saleki-Gerhardt et al., 1994). The 
decrease in the peak intensities for the conditioned samples maybe caused by 
the rougher surfaces of the micronised GLY particles, decreasing the efficiency 
with which X-rays are scattered.  
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Figure 5.3   Differential Scanning Calorimetry thermographs for the 
GLY crystals, ambient, T70 and HFA samples 
 
The DSC thermographs are shown in figure 5.3. All thermographs display a 
melting onset at approximately 193◦C, confirming the purity of the known 
polymorphic form for GLY which has a reported melting point of 192.5◦C 
(Baxter, 2011).  The glass transition (Tg) from amorphous to crystalline GLY 
occurs at a temperature of around 65◦C (Baxter, 2011). The absence of any 
calorimetric activity for all samples at this temperature suggests that all 
samples have re-crystallised prior to analysis. The particle size distribution and 
the SEM images suggest that the aggressive intake of water by the GLY 
particles stored at ambient conditions for 7 days acts as a plasticiser, which 
may lead to the structural reconstruction of the process induced structural 
disorder. Whilst this surface-led relaxation process is undesired due to the 
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physical changes previously discussed rendering the GLY particles unsuitable 
for inhalation. 
One notable difference in the thermographs of the GLY samples is the 
magnitude of the endotherms upon melting. Table 5.3 tabulates the 
endothermic enthalpies required in melting the different GLY samples. The 
GLY crystals required an enthalpy of 384.2 J.g-1 for the melting process. This 
value was relatively high compared to the endothermic response of micronised 
GLY samples maybe because the molecular arrangements in crystalline 
regions are generally denser than molecular arrangements found in particles 
containing amorphous pockets (semi-crystalline), requiring more energy to 
break down and cause complete melting. The results in table 5.3 show how 
the energy required for the melting process of the GLY particles stored at 
ambient conditions for 7 days was significantly (p<0.02) lower than the T70 
and HFA samples. The T70 GLY sample also required significantly (p<0.02) 
more energy in order to melt than the HFA GLY sample. This suggests that 
post-micronisation conditioning using an elevated temperature of 70◦C for 7 
days is more efficient at re-crystallising the disordered, micronised GLY 
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 Melting Endotherm (J/g) 
Sv (m
2/cm3) SSA (m2/gram) Ra 
Crystals 384.20 ±26.51 0.89 0.04 ±0.01 0.04 
Ambient 194.95 ±13.69 0.92 4.71 ±0.22 5.11 
T70 309.40 ±14.51 3.62 6.41 ±0.08 1.77 
HFA 272.33 ±13.49 3.91 4.80 ±0.03 1.23 
 
Table 5.3   Melting endotherm (J/g) from DSC analysis, surface area 
per unit volume (Sv), specific surface area per unit mass (SSA), and 
rugosity values (Ra) for GLY crystals and the 3 conditioned 
micronised samples  
 
 
Figure 5.4   Specific Surface Area the conditioned GLY samples 
determined by BET analysis 
 
Figure 5.4 shows the specific surface area (SSA) for the 3 conditioned GLY 
samples determined by BET analysis using gas adsorption. This figure shows 
how the T70 GLY sample had a significantly (p<0.02) higher specific surface 
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per unit mass than the other 2 conditioned samples. There seemed to be no 
significant differences between the specific surface area of the ambient and 
the HFA GLY sample.  The SSA results are tabulated in table 5.3 together with 
the values for the surface area per unit volume obtained from particle size 
analysis. These 2 surface area measurements are used to determine the 
rugosity value of the particles. The rugosity values, tabulated in table 5.3, 
indicate a large difference between the ambient GLY sample and the T70 and 
HFA samples. This high rugosity value for the ambient sample (Ra = 5.11) is 
probably due to the nature of the drug aggregates caused by the fusion of GLY 
particles upon the aggressive uptake of water. The rugosity values also 
suggest a significant difference in the particle roughness of the T70 and HFA 
GLY samples, with T70 having a rugosity value of 1.77 as opposed to the 1.23 
for the HFA sample.  
 
Figure 5.5A   Dynamic Vapour Sorption (DVS) isotherm for the 
ambient GLY conditioned sample 
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Figure 5.5B   Dynamic Vapour Sorption (DVS) isotherm for the T70 
GLY conditioned sample 
 
Figure 5.5C   Dynamic Vapour Sorption (DVS) isotherm for the HFA 
GLY conditioned sample 
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Figures 5.5 (A-C) show the dynamic vapour sorption profiles for the 3 
conditioned GLY samples. The isotherm for the ambient GLY sample shown in 
figure 5.5A seems to show a possible re-crystallisation event occurring 
between 40% and 70 % RH. The sorption profile accelerates between these 2 
humidities suggesting a change is occurring to the molecular arrangement of 
the GLY particles. Figure 5.5B shows the isotherm for the T70 GLY particles. 
This profile shows a significant uptake of water between 0 % and 50 % relative 
humidity. This steep gradient is most probably caused by the rehydration of the 
GLY particles from the anhydrous to the monohydrate state following 
dehydration caused by exposing the particles at 70◦C for 7 days.  Figure 5.5C 
on the other hand shows no particular isothermic activity suggesting that the 
GLY particles conditioned in situ with HFA have a predominantly crystalline 
nature. The moisture uptake can be explained in terms of the hydrophilic 
nature of GLY. 
5.3.2 Interfacial Chemistry Results   
Table 5.4 tabulates the CAB results for the post-micronised conditioned GLY 
particles. The results describe the balance between the cohesive and adhesive 
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 CAB w.r.t Lactose   
Ambient 0.61 ±0.02   
T70 1.19 ±0.03   
HFA 0.69 ±0.01   
 
Table 5.4   Cohesive-Adhesive Balance (CAB) values with respect to Lactose for 
all 3 conditioned GLY samples 
 
The CAB value for the ambient GLY sample describes a powder system which 
is dominated by adhesive forces. A CAB value of 0.61 suggests that drug-
lactose interactions are 1.64 times more frequent than drug-drug interactions, 
as is the affinity between the 2. This highly adhesive interfacial nature 
governing the dynamics of the powder system for the ambient GLY sample, 
suggests that the significant (p<0.02) dominance of the adhesive forces over 
the cohesive forces may impede the efficient aerosolisation of the drug 
particles translating to a poor in vitro performance. Figure 5.6A shows the 
linear regression analysis for the cohesive and adhesive forces of the GLY 
particles conditioned for 7 days at ambient conditions following air-jet 
micronisation.  
The CAB value for the GLY sample conditioned for 7 days at 70◦C  shifts from 
a strongly adhesively-led system to a significant (p<0.02) greater cohesively-
led interfacial powder system. This shift suggests that with a CAB value of 
1.19, the GLY particles for the T70 sample favour drug-drug interactions over 
drug-lactose ones. The dominance of the cohesive forces, seen in the linear 
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regression analysis in figure 5.6B, may suggest that the affinity between drug 
particles will lead to a degree of drug agglomerates formed during formulation. 
The aerosolisation efficiency of these drug particles will be very much 
dependant on the degree cohesiveness governing the formation and 
coalescence of the drug agglomerates. A CAB value of 1.19 suggests that 
whilst cohesively-led, the powder system still contains sporadic 
drug/agglomerates-lactose interactions which enable the drug particles to 
travel out of the capsules and device using the inertial force gathered by the 
larger lactose particles, however, said interactions are weak enough to allow 
the drug agglomerates to detach from on the lactose surface and travel down 
through the impactor.   
The CAB value for the GLY particles following post-micronisation in situ 
conditioning in HFA for 7 days, describes a system dominated by adhesive 
forces as seen in figure 5.6C. This value, which shows a small but significant 
(p<0.05) difference from the interfacial chemistry describing the ambient 
sample, suggests the in situ conditioned particles have a greater affinity 
towards the lactose particles. These preferred drug-lactose interactions may, 
as discussed previously, hinder the aerosolisation of drug particles from on the 
lactose carrier particles, negatively impacting the in vitro performance of GLY.  
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Figure 5.6A    Plot for the cohesion and adhesion forces for the 
ambient GLY particles with respect to lactose 
 
Figure 5.6B    Plot for the cohesion and adhesion forces for the T70 
GLY particles with respect to lactose 
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Figure 5.6C    Plot for the cohesion and adhesion forces for the HFA 
GLY particles with respect to lactose 
 
5.3.3 In vitro performance 
Table 5.5 tabulates the in vitro performance data of 3 distinct binary 
formulations manufactured using the conditioned GLY samples. The results for 
all 3 formulations are consistent with the CAB results discussed previously.  
 RD (µg) ED (µg) FPM (µg) FPF (%ED) MMAD (µm) GSD (µm) 
Ambient 94.77 ±5.27 70.27 ±3.39 11.07 ±0.91 15.76 ±0.70 2.5 ±0.09 2.14 ±0.04 
T70 89.72 ±4.88 69.40 ±2.25 25.58 ±1.71 36.86 ±1.83 3.37 ±0.12 2.33 ±0.04 
HFA 89.22 ±4.71 69.72 ±3.12 15.28 ±1.02 21.92 ±1.21 2.68 ±0.04 2.34 ±0.05 
 
Table 5.5   In vitro aerosolisation performance for GLY formulations produced 
using the conditioned GLY samples; ambient, T70 and HFA. Results are 
described by the recovered dose (RD), emitted dose (ED), fine particle mass 
(FPM), fine particle fraction (FPF) expressed as a percentage of the emitted 
dose, mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) 
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Figure 5.7     Stage by stage deposition profile for the 3 GLY 
formulations expressed as drug deposits in µg 
 
The FPF for the ambient GLY formulation is relatively low at 15.76 %, a value 
that may be attributed to the highly adhesive nature of the GLY particles 
constituting this formulation. As discussed previously, the adhesively-led 
system leads to the impediment of an efficient drug deagglomeration from of 
the lactose carrier particles. A clear characteristic of such a powder system 
can be seen in the stage-by-stage analysis (figure 5.7) where approximately 
50 % of the drug particles is deposited in the pre-separator suggesting 
inefficient deagglomeration from the lactose particle surface.. The relatively low 
MMAD (MMAD = 2.5 µm) for this formulation is also characteristic of an 
adhesively-led system, where the particles are more prone to form drug- 
lactose interactions than form drug agglomerates as shown by  the T70 
formulation (MMAD=3.37 µm). The FPF for the T70 formulation (36.86 %) is 
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significantly (p<0.01) higher to the FPF of both the ambient (15.76 %) and the 
HFA (25.16 %) formulations. Once again, these in vitro data are consistent 
with the CAB results observed for the T70 GLY sample. The T70 drug particles 
preferentially form drug agglomerates, however, the balance in favour of the 
cohesive forces over the adhesive ones is not large enough to hinder these 
drug agglomerates from interacting with the lactose particles, using them as a 
medium to gaining inertial energy in a way to aerosolise form the capsule and 
device. On impact, these drug agglomerates detach from on the lactose 
surface and are free to flow through the impactor. The MMAD for the T70 
formulation (3.37µm) suggests the presence of drug agglomerates significantly 
(p<0.02) larger than those for the ambient (2.5µm) and HFA (2.68) 
formulations. Figure 5.7 shows the significant drop in drug deposits in the pre-
separator discussed previously. There is also a significantly (p<0.05) higher 
amount of drug deposits in the capsules when compared to the drug deposits 
of the other 2 formulations. This is highly likely to be due to the presence of 
some drug agglomerates which failed to have the sufficient inertial energy to 
aerosolise from the capsules probably as a result of segregation from the 
coarse lactose particle. The in situ conditioned formulation also shows in vitro 
data in line with its corresponding interfacial properties. The highly adhesive 
nature of the HFA GLY particles is clearly evidenced in figure 5.7 where the 
low drug deposits in the capsules together with relatively high values in the 
throat and pre-separator are a characteristic footprint of highly adhesive 
systems. Similar to the behaviour of the the ambient formulation, which shares 
a common adhesively-led nature, the significantly (p<0.05) lower (relative to 
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T70) drug values seen in the capsules reflect the high affinity between the drug 
and lactose particles, allowing the drug particles to be effectively entrained 
from the capsule. The significantly (p<0.05) higher values of drug retention in 
the device and pre-separator (relative to T70) are also characteristically 
associated with highly adhesive systems, where the drug particles fail to 
deagglomerate from on the lactose particles as the latter are too large to travel 
further down the NGI apparatus. There is a significant (p<0.05) difference in 
the FPF between the HFA formulation (21.92) and the ambient formulation 
(15.76). This seems to be mainly accounted for in the pre-separator where the 
HFA formulation deposits approximately 13 µg (15 %) of drug less than the 
ambient formulation, and is explained by the slightly more adhesive nature 
exhibited by the ambient GLY particles. 
    
Figure 5.8     Fine particle fraction expressed as a percentage of the 
emitted dose for each GLY formulation plotted against the respective 
CAV value of the conditioned GLY particles 
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Figure 5.8 shows the FPF for each formulation plotted against the respective 
CAB values of the GLY particles. This figure depicts the close relationship 
between the interfacial chemistry of the GLY particles and their respective 
aerosolisation performance. As discussed previously, the slightly cohesive 
nature governing the GLY particles in the T70 formulation yields a significantly 
(p<0.01) higher FPF due to the presence of drug agglomerates which maintain 
a sufficient affinity to lactose to be effectively emitted from the capsules while 
undergoing sufficient deagglomeration upon aerosolisation. On the other hand, 
the highly adhesive forces dominating the formulations for the GLY ambient 
and HFA samples impede the aerosolisation of the GLY particles. Figure 5.8 
summarises this rationale, showing the dependence of in vitro performance on 
the interfacial system governing the drug particles.  
5.3.4 Stability of Formulation Performance  
5.3.4.1 30◦C/65 % RH Stability Profile Results 
Figure 5.9 shows the in vitro performance stability profile for the T70, HFA and 
ambient formulations stored at 30◦C/65 % RH for a period of 3 months. The 
results show that the aerosolisation performance for the T70 and HFA 
formulations remain stable throughout the 3 month profile with no significant 
differences between the different time points. This suggests a high degree of 
chemical stability for GLY particles conditioned at 70◦C and also for those 
particles conditioned in situ with HFA. The statistically similar performances 
together with the lack of differences in the impactor-sized masses (ISM) shown 
in Figure 5.10, advocate that the interactions between the GLY particles and 
the lactose carrier remain unchanged, yielding to a consistent in vitro 
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performance. The ambient formulation, on the other hand, demonstrates a 
significant (p<0.05) downward trend in the aerosolisation performance over the 
3 month period. Whilst there is no statistical significant difference between the 
performance of month 0 (15.76 %) and month 1 (13.91 %), the FPF of the 
Ambient formulation at month 3 (11.54 %) is significantly lower than the 
original timepoint. This downward trend in the FPF for the Ambient formulation 
over the 3 month 30◦C/65 % RH stability profile study is also reflected in the 
ISM values shown in Figure 5.10. These values reflect the instability of the 
adhesive chemical nature of the Ambient GLY particles. The parallel decrease 
in the ISM and FPF shown by the Ambient formulation over the 3 month study 
suggest an unstable chemical system for the GLY particles whereas the 
adhesive nature observed previously changes in magnitude as a function of 
time and stress conditions, leading to instable performance for the formulation.     
 
Figure 5.9    FPF (%) of Ambient, T70 and HFA formulations stored at 
30◦C/65% relative humidity for a 3 month period 
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Figure 5.10    The Impactor-Sized Mass (ISM) for the Ambient, T70 and 
HFA formulations upon testing at the defined stability time intervals 
following storage at 30◦C/65% relative humidity 
 
5.3.4.2 40◦C/75% RH Stability Profile Results 
The FPF results for the T70, HFA and Ambient formulations following a 
40◦C/75 % RH stability study are shown in Figure 5.11.  Whilst confirming the 
stability of the T70 and HFA formulations, this stability study provided further 
evidence of the instability demonstrated by the Ambient GLY formulation. The 
significant difference (p<0.05) between the FPF of month 0 (15.76 %), month 1 
(12.17 %) and month 3 (7.92 %) represent a varying chemical stability 
governing the interactions between the GLY and the lactose particles. The ISM 
values shown in Figure 5.12 confirm the increasing dominance of the adhesive 
forces, impeding the GLY particles from aerosolising away from the larger 
lactose particles and travelling into the impactor. 
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Figure 5.11    FPF (%) of Ambient, T70 and HFA formulations stored at 
40◦C/75% relative humidity for a 3 month period 
 
 
Figure 5.12    The Impactor-Sized Mass (ISM) for the Ambient, T70 and 
HFA formulations upon testing at the defined stability time intervals 
following storage at 40◦C/75% relative humidity 
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These data suggest that the T70 and HFA GLY particles possess increased 
stability translating into stable drug-carrier interactions yielding consistent in 
vitro performances with time and under stress conditions. The unstable nature 
of the Ambient GLY particles highlight the importance of a post-micronisation 
conditioning step to expedite the stress relaxation process that enables the 
attainment of drug particles with a stable chemical properties.   
  
5.4 Conclusions   
This study describes the use of a post-micronisation conditioning step to 
improve the troublesome handling of GLY particles following air-jet 
micronisation. These data confirmed the possible issues with non-conditioned 
GLY particles stored under ambient conditions and its influence on physic-
chemical properties and in vitro performance and formulation stability. This 
study further showed how the introduction of a post-micronisation conditioning 
step may overcome the issues with GLY particles in achieving both physical 
and chemical stability. Whilst post-micronisation conditioning with both an 
elevated temperature and in situ with HFA for 7 days yielded drug particles 
which meet particle size requirements for inhalation, the high temperature 
conditioning appeared to significantly shift the interfacial chemical nature of the 
GLY particles from a highly adhesive system, to a slightly cohesively-led one. 
This chemical shift translated into a significantly higher aerosolisation 
performance, suggesting that the stress relaxation of GLY particles is most 
sensitive to conditioning using elevate temperatures.     
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6 General Conclusions 
6.1 Introduction 
The ever increasing regulatory demands on drug companies for both the 
development and the lifecycle period of a drug product mean that the 
understanding of the inhaled dosage form necessitates from a significant 
increase in published knowledge relating the number of chemical and physical 
transformations involved in the manufacture of aerosol drug products. The 
highly empirical approach, which is still adopted in the manufacturing of dry 
powder inhalers, results in a high failure rate of formulations that are only 
tested for failure post-processing and packaging of the said products. 
Furthermore, the impact of environmental conditions and manufacturing cycle-
times on product performance remains very poorly understood.  
The physicochemical properties of the micronised active pharmaceutical 
ingredients (API) are key to the performance understanding and stability of this 
dosage form. The properties of APIs may change considerably during an 
undefined and unknown period following micronisation. Usage of the API 
within this period is a main source of drug product variability which impacts 
both supply ability of a drug product and also the product’s quality. This work 
aimed at enhancing the understanding of the dynamics with which key 
physicochemical properties change following micronisation, how they related 
to drug aersolisation performance, and how the introduction of a post-
micronisation conditioning step may expedite the stabilising of micronised API 
properties.     
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6.2 Summary        
In chapters 2 and 3, the post-micronisation dynamics of FP were investigated 
with respect to both ambient and targeted conditions. Results reported in 
chapter 2 indicated that whilst the micronised drug remains largely stable in 
terms of particle size distribution, conditioning over a relatively short period 
exhibited differing trends in the interfacial chemistry of the FP particles with 
respect to SX. An adhesive shift was observed for FP samples conditioned 
using elevated humidity a moderately high temperature over a period of 14 
days. On the other hand, drug particles conditioned under ambient relative 
humidity at an elevated temperature of 70°C for a short period of 72 hours 
exhibited a cohesive shift with respect to SX particles. The interfacial chemical 
system with respect to lactose was more stable. In situ conditioning with HFA 
generated conditioned particles which seemed to have stabilised the interfacial 
properties of freshly micronised FP. The aerosolisation trends observed were 
consistent with the changes in the interfacial shifts reported for the micronised 
particles. The same trends were followed by SX particles highlighting the 
relevance of this work to tertiary formulations. Chapter 3 examines the impact 
of post-micronisation conditioning on the stress relaxation of micronised FP 
particles over longer period of times and more specific laagering conditions. 
Whilst the chemical interfacial system with respect to lactose seems to remain 
relatively stable once again over a period of 90 days, the chemical system of 
FP particles conditioned over a period of 90 days experienced a constant 
adhesive drift with respect to SX particles which seemed to be more sensitive 
to time rather than laagering conditions. The shift from a highly cohesive to a 
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highly adhesive chemical system occurred over a period of 90 days. However, 
approximately 85 % of this shift appears to occur within the first 60 days of 
conditioning. Conditioning using an elevated related humidity of 75 % at 
ambient temperature for 90 days produced significant morphological and 
topographical changes to the FP particles with a significant particle 
smoothening event being observed. The impaction performance benefitted 
from the drop in cohesive interactions significantly improving the aerosolisation 
efficiency of the conditioned FP samples.  
Chapter 4 described the kinetics of micronised SX particles upon conditioning. 
The results indicated an expedited stress relaxation when conditioned at 60°C 
over a period of 60 days, manifested in a pronounced drop in the specific 
surface area of the conditioned particles. There was accompanied a generally 
strong cohesive shift with respect to FP particles, whilst the cohesive drift with 
respect to lactose whilst significant, was less pronounced. The impactor results 
were once again consistent with the changing interfacial properties. 
Conditioning SX particles in situ with HFA for 21 days promoted greater 
physical stability and also expedited the cohesive chemical shift observed in 
the SX samples conditioned environmentally over a period of 60 days. 
Chapter 5 highlights the importance of post-micronisation conditioning for 
highly hydrophilic drug compounds such as glycopyrrolate bromide (GLY). 
Whilst storage under ambient conditions producesd particles with physical 
properties that are not suitable for inhalation, conditioning using an elevated 
temperature of 70°C generated particles with physical properties within the 
respirable range and transformed the interfacial chemical system with respect 
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to lactose from a highly adhesive system to a slightly cohesive system. This 
translated into a significantly improved aerosolisation performance. In situ 
conditioning with HFA also allowed for optimum physical properties however, 
failed to influence the highly adhesive interfacial system.  
6.3 General Conclusion 
This work clearly highlights the importance of secondary processing of APIs 
intended for use in dry power inhalers in order to assist development of a well 
understood and stable drug product. Results reported within suggest a clear 
distinction between the processing requirements of hydrophobic and 
hydrophilic drug compounds. FP and SX require a laagering period of around 
60 days during which the stress relaxation coincides with a general adhesive 
drift in the interfacial chemistry with respect to each other, whilst the chemical 
system between the drug compounds and the lactose remains largely 
unchanged. GLY on the other hand, exhibits relatively rapid kinetics with post-
micronisation conditioning that are essential to ensure particles have the 
required physical properties to be suitable for inhalation.  The use of an 
elevated high temperature imposes a surface chemistry shift from a highly 
adhesive system to a slightly cohesive one. The use of HFA as a conditioning 
option seems to promote stable physical properties and generally expedites or 
stabilises interfacial shifts for hydrophobic compounds. The post-micronisation 
kinetics of hydrophobic drug particles have been seen to depend highly on 
time whereas those of hydrophilic compounds are highly reliant on the 
conditions employed.  
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6.4 Future Work 
Whilst data presented in this work clearly highlight the importance of 
conditioning drug compounds intended for use in dry power inhaler 
formulations, the publication of further knowledge is required to add further 
control to this growing therapeutic branch. Chapter 5 underlined the 
importance of understating the stability of formulations manufactured using 
drug particles conditioned following micronisation. Increased knowledge on the 
stability of DPI formulations is essential in identifying a sustainable secondary 
processing methodology. Another important aspect meriting investigating is the 
impurity profile of both the drug compound and formulation as a function of 
time and conditions following micronisation. The hypothesis would be that 
secondary processing alters the degradation of the drug compound. 
Finally, further work should make use of the progress in vibrational 
spectroscopy and its application in the assessment of DPIs. This will allow for 
a better understanding of the chemical composition of the aerosolised drug 
particles further validating the importance of interfacial chemistry in both binary 
and ternary powder formulations.      
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